Understanding the Warburg Phenotype and the Metabolic Plasticity of Proliferative Mammalian Cells Using \u3csup\u3e13\u3c/sup\u3eC Metabolic Flux Analysis by Odenwelder, Daniel
Clemson University
TigerPrints
All Dissertations Dissertations
8-2019
Understanding the Warburg Phenotype and the
Metabolic Plasticity of Proliferative Mammalian
Cells Using 13C Metabolic Flux Analysis
Daniel Odenwelder
Clemson University, dan.odenwelder@gmail.com
Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations
This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by
an authorized administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Odenwelder, Daniel, "Understanding the Warburg Phenotype and the Metabolic Plasticity of Proliferative Mammalian Cells Using
13C Metabolic Flux Analysis" (2019). All Dissertations. 2472.
https://tigerprints.clemson.edu/all_dissertations/2472
  
 
 
 
 
 
 
 
UNDERSTANDING THE WARBURG PHENOTYPE AND THE METABOLIC 
PLASTICITY OF PROLIFERATIVE MAMMALIAN CELLS USING 13C 
METABOLIC FLUX ANALYSIS 
 
 
A Dissertation 
Presented to 
the Graduate School of 
Clemson University 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy 
Bioengineering  
 
 
by 
Daniel C. Odenwelder 
August 2019 
 
 
Accepted by: 
Dr. Sarah W. Harcum, Committee Chair 
Dr. Kim Paul 
Dr. Ying Mei 
Dr. Agneta Simionescu  
 
 ii 
ABSTRACT 
 
Proliferative cells, including many types of cancer and pluripotent stem cells, rely 
primarily on glycolysis and lactate metabolism for energy, regardless of oxygen 
availability. This metabolic phenotype – referred to as the Warburg effect – results in 
wasteful lactate accumulation. Although cancer cells and pluripotent stem cells share this 
central metabolic characteristic, the sensitivities of each of these cell types to lactate stress 
appear contradictory. While lactate accumulation is thought to adversely impact 
pluripotent stem cell proliferation and differentiation capacities, cancer cells have been 
shown to possess bioenergetic plasticity to utilize lactate catabolism for fuel. As a result, 
lactate buildup within the hypoxic tumor microenvironment has been hypothesized to 
promote cancer progression and malignancy, in part by selecting for cancer populations 
capable of catabolizing lactate. Moreover, lactate has been shown to promote “stemness” 
gene expression in cancer, suggesting that lactate plays a functional role in regulating 
pluripotency gene expression. However, an incomplete understanding of the impact of 
lactate on intracellular metabolism for proliferative cells remains. In this work, 13C-
metabolic flux analysis was used to quantify the intracellular metabolic responses of breast 
cancer cells and induced pluripotent stem cells (iPSCs) to high extracellular lactate; in 
particular, to determine the role of lactate as a metabolic substrate. In this research, it was 
demonstrated that both iPSCs and breast cancer cells employ dual consumption of glucose 
and lactate to support growth. In addition, this is the first study to determine and quantify 
intracellular contribution of lactate in proliferative iPSC metabolism. These results provide 
insight into the metabolic flexibility of highly proliferative cells with respect to lactate 
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metabolism and suggest that, much like many types of cancer cells, iPSCs possess the 
capacity to metabolize lactate to promote exponential growth and maintain pluripotency.  
 iv 
DEDICATION 
 
 
 I would like to dedicate this dissertation to my parents – Kathleen and Charles 
Odenwelder Jr. The success of my work is in large part due to their tremendous sacrifices 
and unwavering support throughout my life. I will be forever grateful for the work ethic 
they have instilled in me and for always prioritizing my education above everything else. 
This dissertation would not be possible without their sacrifice and encouragement.  
 
 v 
ACKNOWLEDGMENTS 
 
 Throughout my time as a graduate student, I have received a tremendous amount 
of support. First, I am extremely grateful to my advisor, Dr. Sarah Harcum, for providing 
me with the incredible opportunity to pursue this degree under her supervision and for her 
profound belief in my ability. It has been a pleasure to learn from her over the years during 
my development as a researcher. I would also like to thank my thesis committee for 
providing valuable feedback and guidance to me throughout this project.  
 
I would like to thank all of my current labmates for their friendship and support 
throughout this long journey. Tom Caldwell and Dr. Xiaoming Lu deserve special thanks 
for their assistance with the induced pluripotent stem cell (iPSC) project. I would also like 
to acknowledge my former labmates – Dr. Yogender Gowtham and Dr. Arthur Nathan 
Brodsky – who helped me acclimate to the lab and served as my mentors early on. Arthur 
deserves special thanks for including me in his cancer research project and for introducing 
me to metabolic flux analysis. It was a pleasure to work alongside all of you. Also, many 
thanks to the Clemson University Bioengineering department for the opportunity to pursue 
my doctoral degree.  
 
Special thanks go to Paul Gulde and Serena Smith from Thermo Fisher for donating 
custom media for the iPSC project. Without their generous donation, much of this work 
would not have been possible. Also, thank you to Dr. Stephen A. Duncan at the Medical 
 vi 
University of South Carolina for donating the K3 iPSCs. Additionally, I’d like to recognize 
the Advanced Mammalian Biomanufacturing Innovation Center and my funding sources – 
NSF IPP-1624641 and NSF CBET-1218345 – for financially supporting me and my 
graduate research projects. 
 
Finally, I would like to thank all my friends and family for the immense support, 
and for contributing to my personal growth these past few years. I could not have 
accomplished any of this without their laughter, guidance, and encouragement. 
 vii 
ABBREVIATIONS 
Abbreviations Full Form 
2D Two-dimensional 
3D Three-dimensional 
3PG 3-phosphoglycerate 
AcCoA Acetyl coenzyme A 
ACL ATP citrate lyase 
ACON Aconitase 
AKG a-ketoglutarate 
AKGD a-ketoglutarate dehydrogenase 
Ala Alanine 
ANCOVA Analysis of covariance 
Asp Aspartate 
AT Aminotransferase 
ATP Adenosine triphosphate 
CHO Chinese hamster ovary 
Cit Citrate 
CM Cardiomyocyte 
CO2 Carbon dioxide 
CoA Coenzyme A 
CS Citrate synthase 
CSC Cancer stem cell 
DHAP Dihydroxyacetone phosphate 
DMEM Dulbecco’s modified Eagle medium 
DMFA Dynamic metabolic flux analysis 
DNA Deoxyribonucleic acid 
EMU Elementary metabolite unit 
ESC Embryonic stem cell 
ETA Extracellular Time-Course Analysis 
 viii 
Abbreviations Full Form 
FA Fatty acid 
FAME Fatty acid methyl ester 
FBS Fetal bovine serum 
Fum Fumarate 
FUM Fumarase 
GC-FID Gas chromatography-flame ionization detector 
GC-MS Gas chromatography-mass spectrometry 
GDH Glutamate dehydrogenase 
GLM Generalized linear model 
Gln Glutamine 
Glu Glutamate 
GMP Good manufacturing practices 
H3K4me3 Histone H3 lysine 4 
hESC Human embryonic stem cell 
HIF Hypoxia inducible factor 
HK Hexokinase 
hPSC Human pluripotent stem cell 
HRP Horseradish peroxidase 
HSD Honestly significant difference 
ICM Inner cell mass 
IDH Isocitrate dehydrogenase 
INCA Isotopomer Network Compartmental Analysis 
iPSC Induced pluripotent stem cell 
Lac Lactate 
LC Liquid chromatography 
LDH Lactate dehydrogenase 
Mal Malate 
MCT Monocarboxylate transporter 
 ix 
Abbreviations Full Form 
MDH Malate dehydrogenase 
ME Malic enzyme 
MEF Mouse embryonic fibroblast 
mESC Murine embryonic stem cell 
MFA Metabolic flux analysis 
MID Mass isotopomer distribution 
miPSC Murine induced pluripotent stem cell 
MS Mass spectrometry 
MTBSTFA N-methyl-N-(tert-butyldimethylsilyl)-trifluoroacetamide 
NAD+ Nicotinamide adenine dinucleotide (oxidized) 
NADH Nicotinamide adenine dinucleotide (reduced) 
NADPH Nicotinamide adenine dinucleotide phosphate 
Oct4 Octamer-binding transcription factor 4 
OXPHOS Oxidative phosphorylation 
PBS Phosphate buffered saline 
PC Pyruvate carboxylase 
PDH Pyruvate dehydrogenase 
PDK Pyruvate dehydrogenase kinase 
PFK Phosphofructokinase 
PGK Phosphoglycerate kinase 
PK Pyruvate kinase 
PPP Pentose phosphate pathway 
PSC Pluripotent stem cell 
PVDF Polyvinylidene difluoride 
Pyr Pyruvate 
qRT-PCR Quantitative reverse transcriptase polymerase chain 
reaction 
RNA Ribonucleic acid 
 x 
Abbreviations Full Form 
ROCKi Rho-associated, coiled-coil containing protein kinase 
inhibitor 
ROS Reactive oxygen species 
SAM S-adenosylmethionine 
SCID Severe combined immunodeficient 
SCS Succinyl coenzyme A synthetase 
SDH Succinate dehydrogenase 
SE Standard error 
SEM Standard error of mean 
SIM Single ion mode 
Sox2 Sex determining region Y-box 2 
SSR Sum of squared residuals 
Suc Succinate 
TBS Tris buffered saline 
TBST Tris buffered saline with Tween 
TCA Tricarboxylic acid cycle 
TDH Threonine dehydrogenase 
TOF Time-of-flight 
UCP2 Uncoupling protein 2 
  
 xi 
TABLE OF CONTENTS 
 
 
Page 
 
TITLE PAGE .................................................................................................................... i 
 
ABSTRACT ..................................................................................................................... ii 
 
DEDICATION ................................................................................................................ iv 
 
ACKNOWLEDGMENTS ............................................................................................... v 
 
ABBREVIATIONS ....................................................................................................... vii 
 
LIST OF TABLES ....................................................................................................... xvii 
 
LIST OF FIGURES .................................................................................................... xviii 
 
CHAPTER 
 
 I. INTRODUCTION ......................................................................................... 1 
 
   1.1 Motivation .......................................................................................... 1 
   1.2 Organization ....................................................................................... 3 
 
 II. LITERATURE REVIEW .............................................................................. 5 
 
   2.1 Pluripotent stem cells ......................................................................... 5 
    2.1.1 Embryonic stem cells ............................................................. 5 
    2.1.2 Induced pluripotent stem cells ............................................... 6 
    2.1.3 Pluripotent stem cells and cancer ........................................... 9 
   2.2 Metabolic requirements of pluripotent stem cells ............................ 10 
    2.2.1 Glucose – and essential sugar .............................................. 10 
      2.2.1.1 Glycolysis and the Warburg effect ............................... 12 
      2.2.1.2 Glucose concentration and stem cell metabolism ........ 14 
    2.2.2 Anaplerosis and amino acid metabolism ............................. 16 
    2.2.3 Lactate fermentation and accumulation ............................... 22 
 xii 
Table of Contents (Continued) 
Page 
      2.2.3.1 Lactate metabolism as a result of oxygen tension ........ 22 
      2.2.3.2 Lactate transport across the cell membrane ................. 23 
      2.2.3.3 Lactate as a metabolic substrate (in tissues) ................. 24 
      2.2.3.4 Lactate as a metabolic substrate (cell culture) .............. 25 
      2.2.3.5 Lactate in cancer cell metabolism ................................ 26 
      2.2.3.6 Lactate in iPSC metabolism ......................................... 28 
    2.2.4 Metabolic remodeling during the acquisition and  
      loss of pluripotency .................................................................. 29 
    2.2.5 Metabolic effects from xeno-free conditions ....................... 32 
   2.3. Metabolic flux analysis (MFA) ....................................................... 33 
    2.3.1 History of MFA .................................................................... 36 
    2.3.2 13C-MFA in Chinese hamster ovary cell metabolism .......... 39 
    2.3.3 13C-MFA and cancer metabolism ........................................ 40 
    2.3.4 13C-MFA and stem cell metabolism .................................... 41 
 
 III. HIGH EXTRACELLULAR LACTATE CAUSES REDUCTIVE 
CARBOXYLATION IN BREAST TISSUE CELL LINES GROWN 
UNDER NORMOXIC CONDITIONS ........................................................ 44 
 
   3.1 Abstract ............................................................................................ 44 
   3.2 Introduction ...................................................................................... 45 
   3.3 Materials and Methods ..................................................................... 48 
    3.3.1 Cell line and media formulations ......................................... 48 
    3.3.2 Cell growth and parallel labeling experiments .................... 48 
    3.3.3 Cell numbers, and glucose, and lactate  
      concentrations ........................................................................... 51 
    3.3.4 Preparation of samples for gas chromatography- 
      mass spectrometry analysis ...................................................... 51 
    3.3.5 Extracellular amino acid concentration  
      and intracellular MID measurements ....................................... 51 
    3.3.6 Determination of biomass specific consumption 
 xiii 
Table of Contents (Continued) 
Page 
      and production rates ................................................................. 52 
    3.3.7 Metabolic network model .................................................... 52 
    3.3.8 Metabolic flux analysis ........................................................ 54 
    3.3.9 Statistical analysis ................................................................ 55 
   3.4 Results .............................................................................................. 56 
    3.4.1 Cell growth ........................................................................... 56 
    3.4.2 Glucose, lactate, and amino acid metabolism ...................... 60 
    3.4.3 Lactate tracer uptake ............................................................ 63 
    3.4.3 Intracellular labeling from [1,2-13C] glucose  
      and [U-13C] glutamine .............................................................. 66 
    3.4.5 Metabolic flux analysis ........................................................ 70 
   3.5 Discussion ........................................................................................ 73 
   3.6 Acknowledgements .......................................................................... 78 
 
 IV. EFFECTS OF LOW GLUCOSE AND HIGH LACTATE 
CONCENTRATIONS ON INDUCED PLURIPOTENT  
   STEM CELL METABOLISM .............................................................. 80 
 
   4.1 Abstract ............................................................................................ 80 
   4.2 Introduction ...................................................................................... 81 
   4.3 Materials and Methods ..................................................................... 84 
    4.3.1 Cell culture ........................................................................... 84 
    4.3.2 Cell growth and parallel labeling experiments .................... 87 
    4.3.3 Cell numbers and extracellular metabolite 
      concentrations ........................................................................... 89 
    4.3.4 Derivatization and GC-FID analysis of  
      extracellular amino acids .......................................................... 89 
    4.3.5 Extraction of intracellular metabolites ................................. 90 
    4.3.6 Derivatization and GC-MS analysis of 
      intracellular metabolites ........................................................... 90 
    4.3.7 Determination of biomass specific  
 xiv 
Table of Contents (Continued) 
Page 
      consumption and production rates ............................................ 91 
    4.3.8 Dry cell weight measurements ............................................. 92 
    4.3.9 Metabolic network model .................................................... 92 
    4.3.10 Metabolic flux analysis ...................................................... 93 
    4.3.11 Extended expansion of K3 iPSCs ...................................... 94 
    4.3.12 iPSC embryoid body formation and 
      spontaneous differentiation  ..................................................... 94 
    4.3.13 RNA extraction and qRT-PCR .......................................... 95 
    4.3.14 Western blots ..................................................................... 98 
    4.3.15 Statistical Analysis ............................................................. 99 
   4.4 Results and Discussion .................................................................. 100 
    4.4.1 Cell growth ......................................................................... 100 
    4.4.2 Glucose, lactate, and amino acid metabolism .................... 104 
    4.4.3 Intracellular metabolite labeling dynamics 
      using [1,2-13C] glucose tracer ................................................. 112 
    4.4.4 Intracellular metabolite labeling dynamics 
      from [U-13C] glutamine tracer ................................................ 118 
    4.4.5 Intracellular metabolite labeling dynamics 
      from [U-13C] lactate tracer ..................................................... 124 
    4.4.6 Pluripotency and differentiation potential ......................... 131 
    4.4.7 Metabolic flux analysis ...................................................... 136 
   4.5 Conclusions .................................................................................... 145 
 
 V. CONCLUSIONS AND FUTURE WORK ................................................ 147 
 
   5.1 Conclusions .................................................................................... 147 
   5.2 Future Work ................................................................................... 148 
 
 
APPENDICES ............................................................................................................. 149 
 
 xv 
Table of Contents (Continued) 
Page 
 A: Measured extracellular metabolite concentrations for 
   the three breast cell lines – MCF 10A, MCF7,  
   and MDA-MB-231  .............................................................................. 150 
 B: Metabolic reactions used in the 13C-MFA simulations  
   for the three breast cell lines ................................................................ 153 
 C: Metabolism of labeled lactate through the TCA cycle .............................. 155 
 D: Measured intracellular MIDs from [1,2-13C] glucose,  
   [U-13C] glutamine, and [U-13C] lactate for the three  
   breast cancer cell lines ......................................................................... 156 
 E: Metabolism of labeled lactate through the TCA cycle .............................. 165 
 F: Metabolic flux maps for three breast cell lines grown in  
   control and high-lactate media ............................................................. 167 
 G: Metabolic flux analysis for three breast cell lines grown 
   in control and high-lactate cultures ...................................................... 170 
 H: Measured and simulated MIDs from 13C-MFA simulations 
   for three breast cell lines ...................................................................... 184 
 I: Measured extracellular metabolite concentrations for K3 iPSCs .............. 196 
 J: Measured extracellular amino acid concentration profiles 
   for K3 iPSCs ........................................................................................ 200 
 K: Metabolic flux analysis model description and assumptions  
   for iPSC study ...................................................................................... 202 
 L: Metabolic reactions used in the 13C-MFA simulations for 
   K3 iPSCs .............................................................................................. 204 
 M: GC-MS metabolite mass fragments used for intracellular 
   Isotope quantification for K3 iPSCs .................................................... 206 
 N: Measured intracellular MIDs from [1,2-13C] glucose, 
   [U-13C] glutamine, and [U-13C] lactate for K3 iPSCs .......................... 207 
 O: Metabolite isotope labeling distribution from [1,2-13C] 
   glucose, [U-13C] glutamine, and [U-13C] lactate 
   for K3 iPSCs ........................................................................................ 218 
 P: Metabolic flux analysis results for K3 iPSCs grown in  
   Control, Low Glucose, High Lactate, and Low Glucose + 
   High Lactate cultures ........................................................................... 221 
 xvi 
Table of Contents (Continued) 
Page 
 Q: Measured and simulated MIDs from 13C-MFA 
   simulations for K3 iPSC cultures ......................................................... 229 
 
REFERENCES ............................................................................................................ 233 
 xvii 
LIST OF TABLES 
 
 
Table                                                                                                                               Page 
 
 2.1 List of metabolic flux analysis studies for pluripotent stem cells ................ 43 
 
 3.1 Measured extracellular fluxes for glucose, lactate, and  
   amino acids for the MCF 10A, MCF7, and MDA-MB-231  
   cell lines in the control and high-lactate media ..................................... 62 
 
 4.1 Media formulations for iPSC cultures examined in 13C-MFA 
   studies .................................................................................................... 86 
 
 4.2 PCR primer sequences for analysis of K3 iPSCs ......................................... 97 
 
 4.3 Measured biomass specific uptake and production rates 
   for extracellular metabolites (nmol/106 cells×h) ................................... 110 
 
 xviii 
LIST OF FIGURES 
 
 
Figure                                                                                                                             Page 
 
 2.1 Applications of iPSCs for disease modeling, drug screening,  
   and cell replacement therapy approaches. ............................................... 8 
 
 2.2 Simplified mammalian metabolic pathways through A) 
    glycolysis and B) tricarboxylic acid (TCA) cycle ................................ 11 
 
 2.3 Simplified schematic of amino acid metabolism for  
   mammalian cells .................................................................................... 20 
 
 2.4 Schematic of the fluxome showing the cooperative  
   Regulation between the genome, transcriptome, proteome,  
   and metabolome ..................................................................................... 35 
 
 2.5 Metabolic network using classic MFA and 13C-MFA ................................. 38 
 
 3.1 Experimental setup for the parallel labeling experiments 
   for each of the three breast cell lines ..................................................... 50 
 
 3.2 Growth profiles for MCF10A, MCF7, and MDA-MB-231  
   cultures in control and high-lactate media ............................................. 59 
 
 3.3 Glucose and lactate concentration and glucose, lactate,  
   and glutamine flux profiles for three breast cell line  
   cultures in the control and high-lactate media shown  
   relative to the time of media exchange .................................................. 61 
 
 3.4 Uptake of [U-13C] lactate by the three breast cell lines ............................... 65 
 
 3.5 Mass isotopomer distributions (MIDs) for the TCA  
   metabolites from the [U-13C] glutamine labeling of the  
   MDA-MB-231 cells cultured in the control and high-lactate  
   media ...................................................................................................... 68 
 
 3.6 Evidence of reductive carboxylation of a-ketoglutarate  
   (AKG) to citrate from [U-13C] glutamine labeling ................................ 69 
 
 3.7 Comparison of key metabolic fluxes for MCF 10A (A),  
   MCF7 (B), and MDA-MB-231 (C) ....................................................... 72 
 
 xix 
List of Figures (Continued) 
Page 
 4.1 Parallel isotope labeling and culture replicate setup for 
   each condition ........................................................................................ 88 
 
 4.2 Growth characteristics of K3 iPSC cultures in low and high  
   glucose and lactate containing media .................................................. 103 
 
 4.3 Glucose consumption and lactate production profiles 
   for K3 iPSCs ........................................................................................ 107 
 
 4.4 Glutamine consumption, glutamate production, and 
   ammonia production profiles for K3 iPSCs ......................................... 111 
 
 4.5 Comparison of fractional isotopomer labeling and fractional  
   abundance of MIDs for glycolytic metabolites from  
   [1,2-13C] glucose for K3 iPSCs ............................................................ 114 
 
 4.6 Comparison of fractional abundance of MIDs for TCA 
   metabolites from [1,2-13C] glucose for K3 iPSCs 
   at 24-h .................................................................................................. 117 
 
 4.7 Comparison of fractional abundances of MIDs for TCA 
   metabolites from [U-13C] glutamine for K3 iPSCs  
   at 24-h .................................................................................................. 119 
 
 4.8 Comparison of fractional abundance of reductive 
   carboxylation species from [U-13C] glutamine 
   at 24-h .................................................................................................. 121 
 
 4.9 Intracellular fractional labeling of oxidative glutamine 
   metabolites from [U-13C] glutamine at 24-h ........................................ 123 
 
4.10 Comparison of fractional abundance of MIDs for glycolytic 
   metabolites from [U-13C] lactate labeling for K3 iPSCs ..................... 125 
 
4.11 Carbon atom transitions outlining potential mechanisms 
   for generating M+2 labeled pyruvate from [U-13C] 
   lactate ................................................................................................... 126 
 
4.12 Comparison of fractional abundance of MIDs for TCA 
   Metabolites from [U-13C] lactate labeling for  
   K3 iPSCs at 24-h .................................................................................. 130 
 xx 
List of Figures (Continued) 
Page 
4.13 Comparison of pluripotency gene and protein expression 
   for K3 iPSCs after one and five passages due to glucose 
   and lactate concentration ...................................................................... 134 
 
4.14 Comparison of gene expression for K3 iPSCs after one 
   passage, five passages, and seven days of spontaneous 
   differentiation due to glucose and lactate concentration ...................... 135 
 
4.15 Lactate tracer uptake and production for the network  
   model reaction ...................................................................................... 138 
 
4.16 Metabolic flux maps for K3 iPSCs predicted from the MFA 
   simulations: A) Control and B) High Lactate cultures ........................ 142 
 
4.17 Metabolic flux maps for K3 iPSCs predicted from the MFA 
   simulations: A) Low Glucose and B) Low Glucose + High 
   Lactate cultures .................................................................................... 143 
 
4.18 Comparison of simulated metabolic fluxes from 13C-MFA 
   for K3 iPSCs ........................................................................................ 144 
 
  
 1 
CHAPTER ONE 
 
INTRODUCTION 
 
1.1. Motivation 
Induced pluripotent stem cells (iPSCs) have the potential to drastically improve cell-
based therapies and diagnostics in the near future; however, stem cell applications are 
currently limited by our capability to generate sufficient quantities of undifferentiated stem 
cells that meet Good Manufacturing Practices (GMP). Current technologies are capable of 
generating 106 cells/mL; however current estimates indicate that between 109 and 1010 cells 
will be required per patient (Abecasis et al., 2017; Kehoe et al., 2010; Kropp et al., 2016; 
Kumar et al., 2017). An incomplete understanding of the conditions that cause iPSC 
differentiation is one obstacle preventing further scale-up capabilities. However, since 
culture variability is known to cause differentiation, providing a constant environment is 
favorable for expansion, also called proliferation. To bridge the gap between small-scale 
iPSC culture and controlled bioreactors, it is essential to develop a comprehensive 
understanding of the metabolic responses of iPSCs to environmental factors such as 
glucose, glutamine, and lactate concentrations. This will aid in the development of control 
parameters, thresholds, and set points for future bioreactor processes.  
Highly proliferative cells, including cancer and pluripotent stem cells, rely primarily 
on aerobic glycolysis and lactate fermentation for energy, a process known as the Warburg 
effect (Gaspar et al., 2014; Vander Heiden et al., 2009; Varum et al., 2011; Warburg, 1956). 
While this distinct metabolic trait appears wasteful and energy inefficient, in cancer cells, 
it promotes tumor malignancy and induces a stem cell-like phenotype in certain cancer 
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populations (Bonuccelli et al., 2010; Kennedy and Dewhirst, 2010; Martinez-Outschoorn 
et al., 2011). Additionally, some cancer cell populations catabolize lactate as a carbon 
source, conceivably providing these adaptive cells with a competitive advantage over 
normal cell populations in highly acidic and lactic acid filled tumors (Kennedy and 
Dewhirst, 2010; Kennedy et al., 2013; Martinez-Outschoorn et al., 2011; Pavlides et al., 
2010; Sonveaux et al., 2008). Therefore, this Warburg phenotype has been widely 
investigated as a target for cancer therapies (Doherty and Cleveland, 2013; Sonveaux et al., 
2008). On the other hand, lactate accumulation in in vitro iPSC culture is viewed primarily 
as a wasteful metabolic byproduct that adversely impacts cell proliferation capacity and 
pluripotency (Chen et al., 2010; Olmer et al., 2012; Wang et al., 2013). Yet, an incomplete 
understanding of the impact of lactate on intracellular metabolism of iPSCs remains. In 
order develop cell culture techniques to improve iPSC quality and proliferation capacity, a 
more comprehensive understanding of the impact of lactate accumulation on iPSC 
metabolism and strategies to reduce this lactate accumulation are required. 
 Recent computational techniques have made it possible to quantify intracellular 
metabolic fluxes through complex metabolic pathways (Sa et al., 2015; Stephanopoulos 
et al., 1998). In this dissertation, 13C metabolic flux analysis (13C-MFA) was used to 
quantify intracellular metabolic fluxes through central metabolic pathways for breast 
cancer cells and iPSCs to understand the Warburg phenotype and uncover the roles of 
glucose and lactate in intracellular metabolism for highly proliferative cells. Using 13C-
MFA for this research provided a temporal representation of intracellular metabolic shifts 
in breast cancer and iPSC metabolism due to glucose and lactate perturbations. The 
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findings from this work can improve the understanding of iPSC metabolism and could be 
useful to design/optimize improved iPSC culture processes. The data in this work will 
also add to the current body of work related to cancer and iPS cell metabolism and 
provide further evidence of the metabolic plasticity of highly proliferative cells.  
 
1.2. Organization 
This dissertation is divided into five chapters. Chapter One outlines the motivation 
for this research. Chapter Two contains a literature review of key topics related to breast 
cancer and iPSC metabolism research. This includes a brief history of pluripotent stem 
cells (PSCs), the development of iPSCs, and the similarities between cancer and PSCs. A 
detailed description of the metabolic characteristics of PSCs and cancer, including the roles 
of glycolysis and lactate fermentation, are also included in the literature review. Finally, a 
brief introduction to metabolic flux analysis (MFA), the applications of MFA as a 
computational tool, and a review of previous studies that used MFA to study Chinese 
hamster ovary (CHO), cancer, and PSC metabolism is also provided. Chapter Three 
contains the recently published research paper, titled High extracellular lactate causes 
reductive carboxylation in breast tissue cell lines grown under normoxic conditions. This 
paper examined the effects of elevated extracellular lactate levels on intracellular 
metabolism for three different breast cancer cell lines using 13C-MFA. The authors on this 
paper are Dr. Arthur Nathan Brodsky and Dr. Sarah W. Harcum. Arthur and I shared co-
first authorship (Brodsky et al., 2019). Arthur was responsible for conceptualization of the 
project, methodology, data curation, investigation, formal analysis, and writing the original 
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draft, while I was responsible for methodology, data curation, investigation, formal 
analysis, writing the original draft, responding to reviewer comments and edits, and writing 
the final draft of the publication. Chapter Four describes the effects of glucose and lactate 
concentrations on iPSC metabolism and pluripotency, which was the majority of my 
dissertation research project. It is intended that this chapter will be submitted as a 
manuscript to a peer reviewed journal in the near future, where I am the first author, and 
Dr. Xiaoming Lu and my advisor, Dr. Sarah W Harcum, are co-authors. Dr. Xiaoming Lu 
assisted with gene expression analysis for the iPSC project. Finally, Chapter Five discusses 
conclusions and the future direction of the iPSC work.  
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CHAPTER TWO 
 
LITERATURE REVIEW 
 
 
2.1. Pluripotent stem cells 
 Since James Thompson first isolated human embryonic stem cells from surplus in 
vitro fertilized embryos in 1998, pluripotent stem cells (PSCs) have served as an exciting 
potential resource for cell-based therapies and regenerative medicine (Kimbrel and Lanza, 
2015; Mitalipov and Wolf, 2009; Thomson et al., 1998). Stem cells are considered to be 
pluripotent if capable of 1) indefinite self-renewal and 2) differentiation to cell types from 
each of the three germ layers – the endoderm, ectoderm, and mesoderm (Melton, 2014). 
These two characteristics make pluripotent stem cells ideal tools for regenerative medical 
applications (Avior et al., 2016; Trounson and DeWitt, 2016).  
 
2.1.1. Embryonic stem cells 
Embryonic stem cells (ESCs) are isolated from the inner cell mass (ICM) of 
embryos in the blastocyst stage of development (Mitalipov and Wolf, 2009). ESCs cultured 
in vitro express the same stage specific transcription factors associated with “stemness”, 
including octamer-binding transcription factor 4 (Oct4), SRY (sex determining region Y)-
box 2 (Sox2), and Nanog (Yu and Thomson, 2014). While pluripotent cells found in the 
ICM only transiently express these transcription factors prior to differentiation during 
development, ESCs grown in vitro may be cultured indefinitely while maintaining 
expression of these “stemness” genes and a pluripotent phenotype; because of this, ESCs 
are considered to be immortalized cell lines (Luong and Gerecht, 2008). Given this 
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seemingly limitless in vitro expansion capacity, it is understandable that ESCs have long 
been thought of as the optimal tool for regenerative medicine. However, due to the ethical 
concerns surrounding harvesting cells from the ICM of human embryos, the use of ESCs 
in regenerative therapies has been heavily restricted by US government regulations. Since 
it is currently illegal to destroy an embryo to create any hESC line, researchers in the United 
States are restricted to using hESC lines generated prior to August 9, 2001 (Volarevic et 
al., 2018). Along with these government restrictions, there is also a divide in popular 
opinion over the use of hESCs (Green, 2007). Despite these limitations, a number of ESC 
treatments are undergoing clinical trials for severe heart failure, macular degenerative 
disease, retinitis pigmentosa, and amyotrophic lateral sclerosis (clinicaltrials.gov).  
 
2.1.2. Induced pluripotent stem cells 
The ethical concerns associated with using ESCs as a therapeutic was alleviated 
with the discovery that pluripotency could be “induced” in somatic cells. Induced 
pluripotent stem cells (iPSCs) are pluripotent stem cells derived by nuclear reprogramming 
of adult somatic cells. IPSCs are reprogrammed to a pluripotent state by overexpression of 
transcription factors associated with pluripotency; this was first discovered by Takahashi 
et al. in 2006 through ectopic expression of four transcription factors – Oct4, Sox2, c-Myc, 
and Klf4 – in adult murine fibroblasts (Takahashi and Yamanaka, 2006). This approach 
has since been used to develop both normal and diseased human iPSC lines (Cayo et al., 
2012; Si-Tayeb et al., 2010; Takahashi et al., 2007; Yu et al., 2007). iPSCs share the same 
self-renewal and differentiation capacity as ESCs. In addition, iPSCs exhibit similar colony 
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morphology to ESCs and have been shown to acquire a more ESC-like phenotype with 
prolonged culture in vitro (Panopoulos et al., 2012). Originally, reprogramming of somatic 
cells to iPSCs was performed using retroviruses or lentiviruses; however, these methods 
can result in integration of viral DNA into the host cell genome (Si-Tayeb et al., 2010; 
Takahashi and Yamanaka, 2006). More recently, integration-free approaches, such as 
infection of cells with adenoviruses, synthetic modified mRNAs, and transient transfection 
of plasmid DNA, have been implemented to improve iPSC safety (Si-Tayeb et al., 2010; 
Stadtfeld et al., 2008; Warren et al., 2010). Overall, the end result of nuclear 
reprogramming is a rewiring of iPSC epigenetics towards an embryonic stem cell-like state 
(Mitalipov and Wolf, 2009).  
Since patient-specific human iPSC (hiPSC) lines can be derived for cell therapy 
applications, this reduces the concerns over immune rejection (Shi et al., 2017). With 
proper differentiation, hiPSCs can be used to perform personalized patient cell replacement 
therapies tissue regeneration, and in vitro drug screening studies (Avior et al., 2016; 
Kimbrel and Lanza, 2015; Trounson and DeWitt, 2016; Wu and Hothedlinger, 2011). 
Furthermore, hiPSCs may be used to investigate disease progression of normal and 
pathological human cell development in vitro (Figure 2.1) (Avior et al., 2016; Kimbrel and 
Lanza, 2015; Paes et al., 2017). Currently, a number of iPSC-derived therapies are 
undergoing clinical trials to treat various types of cancers, heart failure, thalassemia, and 
age-related macular degeneration using hiPSC-derived cell therapies (clinicaltrials.gov).   
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Figure 2.1. Applications of iPSCs for disease modeling, drug screening, and cell 
replacement therapy approaches. Patient-derived iPSCs can be used to study disease 
progression in vitro and perform drug screening studies on diseased cells. Patient-specific 
iPSCs may also be genetically modified to correct a mutation, differentiated into the 
desired cell type, and transplanted back into the donor patient (autologous transplant). 
Alternatively, iPSCs can be derived from a healthy donor and differentiated to a desired 
cell type to be used for allogeneic transplantation. Translated with permission from 
[Springer Nature]: [Springer Nature] [Cell Biology and Toxicology] (Bárbara Cristina 
Martins Fernandes Paes, Pablo Diego Moço, Cristiano Gonçalves Pereira et al), 
[COPYRIGHT] (2016). 
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2.1.3. Pluripotent stem cells and cancer 
The extraordinary ability of PSCs to self-renew and differentiate towards each germ 
layer provides therapeutic potential and challenges. While these characteristics make PSCs 
ideal candidates for cell-based therapies, the plasticity of PSCs makes it difficult to control 
differentiation, eliminate undifferentiated cells, and control cellular expansion (Volarevic 
et al., 2018). In addition, both iPSCs and ESCs form teratomas—a benign germ-line tumor 
containing cells from each of the three germ layers—in severe combined immunodeficient 
(SCID) mice (Ben-David and Benvenisty, 2011). Moreover, iPSCs have also been shown 
to form teratocarcinomas—a malignant germ-layer tumor—and be more tumorigenic than 
ESCs (Mayshar et al., 2010; Miura et al., 2009). Given the tumorigenic nature of PSCs and 
the ability of many cancers to repopulate a tumor following treatment, some researchers 
have hypothesized that malignant tumors propagate from a small subset of stem cell-like 
cells, which are commonly referred to as cancer stem cells (CSC) (Hope et al., 2004). To 
this point, some carcinoma cells undergoing epithelial-to-mesenchymal transition—a 
process associated with cancer migration and malignancy—were shown to possess stem 
cell-like characteristics (Chen et al., 2012; Rhim et al., 2012; Yu et al., 2013). Furthermore, 
under elevated lactate exposures similar to that found in metastatic tumors, human 
tumorigenic, luminal breast cells exhibited elevated expression of genes which are 
upregulated in ESCs and are associated with “stemness” (Martinez-Outschoorn et al., 
2011). As a result, there appear to be numerous similarities between cancer and PSCs. In 
order for PSCs to become routinely used cell-based therapy tools, it is paramount to 
determine what makes PSCs and CSCs different from each other. 
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2.2. Metabolic requirements of pluripotent stem cells 
2.2.1. Glucose – an essential sugar 
Glucose is rich in potential energy and serves as the primary metabolic substrate 
for most mammalian cells. In fact, the complete oxidation of glucose to carbon dioxide and 
water generates large amounts of energy in the form of 36 molecules of adenosine 
triphosphate (ATP) (Nelson et al., 2008). Furthermore, proliferating cells must also 
synthesize sufficient macromolecules to support rapid cell growth (Lunt et al., 2011). 
Glucose supports all of these metabolic needs, with glucose-derived carbon contributing to 
the synthesis of nucleotides, lipids, glycogen, and energy production through glycolysis (in 
the cytosol) and the tricarboxylic acid (TCA) cycle and oxidative phosphorylation (in the 
mitochondria) (Lunt et al., 2011).   
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Figure 2.2. Simplified mammalian metabolic pathways through A) glycolysis and B) 
tricarboxylic acid (TCA) cycle. Metabolites are shown in black and enzymes responsible 
for each reaction are shown in blue italics.   
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2.2.1.1. Glycolysis and the Warburg effect 
 Glycolysis is the central pathway responsible for glucose catabolism in the cytosol, 
in which one six-carbon molecule of glucose is converted into two three-carbon molecules 
of pyruvate. Glycolysis is broken down into two parts: a preparatory phase and an energy 
pay-off phase. In the preparatory phase, two ATP are consumed to phosphorylate glucose 
to glucose 6-phosphate (by hexokinase (HK)) and fructose 6-phosphate to fructose 1,6-
bisphosphate (by phosphofructokinase-1 (PFK-1)) (Nelson et al., 2008). Four ATP 
molecules are generated in the pay-off phase of glycolysis from the conversions of 1,3-
biphosphoglycerate to 3-phosphoglycerate (by phosphoglycerate kinase (PGK)) and 
phosphoenolpyruvate to pyruvate (by pyruvate kinase (PK)) (Nelson et al., 2008). Overall, 
metabolism of glucose to pyruvate results in a net gain of energy in the form of two ATP  
molecules and two nicotinamide adenine dinucleotide (NADH) reducing molecules; 
moreover, key intermediate biomass building blocks such as lipids, proteins, and nucleic 
acids are also generated through glycolysis (Hume and Weidemann, 1979; Vander Heiden 
et al., 2009). 
Glucose catabolism for energy production is regulated in normal mammalian cells 
in part by oxygen availability (Semenza et al., 1994). In oxygen rich environments, cells 
can further oxidize pyruvate to CO2 in the TCA cycle and produce large quantities of ATP 
through oxidative phosphorylation (OXPHOS) (Lunt et al., 2011). On the other hand in the 
absence of oxygen, pyruvate is reductively metabolized to lactate through fermentation 
(Vander Heiden et al., 2009). Anaerobic fermentation of pyruvate to lactate by lactate 
dehydrogenase (LDH) generates reducing cofactors required to sustain continuous flux 
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through glycolysis, as described further below (Vander Heiden et al., 2009). However, in 
the 1920’s, Otto Warburg discovered that proliferating cells—including cancer and stem 
cells—primarily rely on glycolysis and lactate fermentation for energy production 
irrespective of oxygen availability; this is commonly referred to as the Warburg Effect 
(Warburg, 1956). This reliance on aerobic glycolysis is now widely accepted as a metabolic 
feature of both cancer and stem cells (Folmes et al., 2012; Folmes et al., 2011; Gaspar et 
al., 2014; Vander Heiden et al., 2009; Varum et al., 2011; Zhang et al., 2011).  
In order for complete oxidation of glucose, pyruvate generated from glycolysis is 
transported into the mitochondria and converted to acetyl-CoA and CO2 by the pyruvate 
dehydrogenase (PDH) enzyme complex. The rate of pyruvate entry into the mitochondria 
is partially dependent on reducing equivalent shuttles, specifically reduced NADH 
transport from the cytosol to mitochondria via either the malate-aspartate shuttle or the 
glycerol 3-phosphate shuttle (Mulukutla et al., 2010). It was previously proposed that the 
high glycolytic flux state of proliferating cells might outpace the maximum PDH activity 
(Curi et al., 1988). Also, pluripotent stem cells exhibited decreased activity of PDH 
compared to somatic cells (Chandel et al., 2016; Teslaa and Teitell, 2015). Furthermore, 
uncoupling protein 2 (UCP2) was shown to regulate hPSC metabolism by blocking glucose 
oxidation in the mitochondria and promoting aerobic glycolysis (Zhang et al., 2011). As a 
result of the factors listed above, the conversion of pyruvate to acetyl-CoA within the 
mitochondria is slow, and PSCs quickly reduce excess cytosolic pyruvate to lactate instead 
(DeBerardinis et al., 2007). 
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As mentioned previously, the incomplete oxidation of glucose to lactate by LDH 
generates oxidized nicotinamide adenine dinucleotide (NAD+) and maintains a cytosolic 
NAD+/NADH ratio necessary to sustain glycolytic activity and promote cell proliferation 
(DeBerardinis et al., 2008). Moreover, NAD+ is required for nucleotide and amino acid 
biosynthesis, which might also contribute to rapid biomass accumulation and proliferation 
(Lunt et al., 2011). Although incomplete oxidation of glucose to lactate is an energy 
inefficient process, with 2 ATP produced as compared to the 36 ATP produced from the 
complete oxidation of glucose through the TCA cycle and OXPHOS, rapidly proliferating 
cells consume glucose at an elevated rate in order to compensate for this inefficient energy 
output (Guppy et al., 1993; Pfeiffer et al., 2001). It also has been suggested that 
proliferating cells rely primarily on glycolysis because of the significant biomass building 
blocks – proteins, lipids, and nucleic acids – required to support cell division (DeBerardinis 
et al., 2008; Vander Heiden et al., 2009; Zhang et al., 2012).  
 
2.2.1.2. Glucose concentration and stem cell metabolism 
Since PSCs rely on glycolysis for growth, commercially available PSC cell culture 
media consists of high glucose concentrations – mTeSR (2.5 g/L) and Essential 8 Flex 
(3.15 g/L) – relative to physiological blood glucose concentrations, which range from 0.6 
to 1.0 g/L (Güemes et al., 2016; Rathjen et al., 2014; Varum et al., 2011; Zhang et al., 
2011). As a result, PSCs grown in vitro have been observed to consume copious amounts 
of glucose and secrete a significant proportion of glucose-derived carbon as lactate (Cliff 
et al., 2017; Folmes et al., 2011; Gaspar et al., 2014; Gu et al., 2016; Moussaieff et al., 
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2015). Although this Warburg phenotype results in wasteful lactate accumulation as well 
as an undesirable drop in pH, few studies have evaluated the effects of glucose 
concentration on PSC growth, extracellular metabolism, and pluripotency (Chen et al., 
2010; Horiguchi et al., 2018; Kim et al., 2009; Mochizuki et al., 2011; Tohyama et al., 
2016; Wang et al., 2006).  
Interestingly, the effect of glucose concentration on establishing ESC lines from mouse 
blastocysts has previously been disputed. Wang et al. 2006 illustrated that culturing mESCs 
in physiological glucose (1 g/L) improved cell proliferation, reduced oxidative stress, and 
overall was more effective for establishing a stable ES cell line when compared to high 
glucose (4.5 g/L) media (Wang et al., 2006). In contrast, Kim et al. 2009 showed that 
culture of mESCs in high glucose containing media resulted in increased expression of 
Oct4, Sox2, and Nanog during early cell line generation from blastocysts. This was 
suggested to be a result of glucose concentration regulating pluripotency gene expression, 
as well as due to DNA methylation and histone acetylation (Kim et al., 2009). The 
discrepancies between these studies partially arose because different basal medias were 
used. As a result, the effect of glucose concentration on mESC proliferation and 
pluripotency could not be deconvoluted from the effects of each unique basal media used. 
In addition, low glucose (1 g/L) did not impact embryoid body formation for mESCs; 
however, glucose concentration influenced differentiation potential; high glucose (4.5 g/L) 
resulted in more efficient cardiomyocyte production, while low glucose caused more 
efficient differentiation towards neural cells (Mochizuki et al., 2011). 
Similar to mESCs, glucose concentration has been shown to have variable effects on 
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hPSC metabolism and pluripotency. For instance, growth of hESCs in low glucose media 
(1.5 g/L) with daily media replacement resulted in a 10% reduction in lactate production 
and a 40% increase in final cell yields when compared with the control glucose (3 g/L) 
feed strategy (Chen et al., 2010). Alternatively, when implementing less frequent media 
changes, high glucose concentrations improved maintenance of PSCs and reduced 
differentiation gene expression (Horiguchi et al., 2018). Interestingly, hESCs also 
previously were shown to survive for up to 24-h in glucose deficient media (Tohyama et 
al., 2016). However, glucose depleted media supplemented with lactate was shown to 
support only cardiomyocyte survival and loss of residual pluripotent stem cell population 
during differentiation and selection process (Tohyama et al., 2013). Similarly, growth of 
PSC-derived cardiomyocytes in glucose-depleted medium supplemented with fatty acid 
and 3,3’,5-Triiodo-L-Thyronine facilitated cardiomyocyte selection and maturation in a 
similar manner to lactate supplemented medium, and also improved mature cell 
functionality (Lin et al., 2017). As a whole, these results suggest that the effect of glucose 
concentration on PSC metabolism and pluripotency is highly dependent on the cell lines 
and media used.  
 
2.2.2. Anaplerosis and amino acid metabolism 
Pluripotent stem cells primarily oxidize pyruvate to acetyl-CoA and depend on 
amino acid anaplerosis to maintain TCA cycle function (Gaspar et al., 2014; Wellen and 
Thompson, 2012). In addition, mammalian cells are composed of ~ 70% protein by dry 
cell weight; this causes a significant amino acid demand on proliferating cells (Bonarius et 
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al., 1996). In particular, since glutamine is the most abundant free amino acid in circulating 
blood, glutamine catabolism is crucial for mammalian cell metabolism (Bergström et al., 
1974; Folmes and Terzic, 2016). Glutamine serves as an important substrate for 
bioenergetics and macromolecule synthesis (Eagle, 1955; Kovacevic and McGivan, 1983). 
For example, glutamine carbons are metabolized to TCA cycle intermediates and used to 
synthesize four nonessential amino acids (aspartate, asparagine, glutamate, and proline) 
(Lunt et al., 2011). Also, glutaminolysis through malic enzyme generates lactate and 
NADPH (DeBerardinis et al., 2007). Proliferating cells require significant amounts of 
reducing cofactors, including NADPH, to fulfill biosynthesis requirements for cell 
replication, including lipid synthesis, and to limit damage related to reactive oxygen 
species (ROS) (DeBerardinis et al., 2008; Folmes et al., 2012; Vander Heiden et al., 2009). 
Furthermore, glutamine has been shown to be reductively metabolized to citrate by 
cytosolic isocitrate dehydrogenase (IDH1) and used for lipid biosynthesis (Metallo et al., 
2012; Yoo et al., 2008). In fact, proliferative cells have been observed to favor reductive 
glutamine metabolism for lipid biosynthesis in hypoxic (1-5% O2) environments (Fan et 
al., 2013; Fendt et al., 2013; Grassian et al., 2014; Jiang et al., 2016; Metallo et al., 2012; 
Metallo et al., 2009; Wise et al., 2011). Thus, glutamine catabolism is integral to cell 
metabolism and proliferation. Furthermore, Tohyama et al. 2016 showed that glutamine 
oxidation was required for hPSC survival, with glutamine depletion resulting in rapid cell 
death within 24-h (Tohyama et al., 2016). This is in part because hPSCs oxidize pyruvate 
poorly (Tohyama et al., 2016; Varum et al., 2011; Zhang et al., 2011). Moreover, glutamine 
consumption and its contribution to succinate, fumarate and malate metabolite pools was 
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observed to increase in glucose-deficient media (Tohyama et al., 2016). In fact, glutamine 
consumption also was observed to modulate hematopoietic cell differentiation; glutamine 
uptake and metabolism drove erythroid development, while glutamine deprivation 
preferentially favored myeloid lineage development instead (Oburoglu 2014). 
Since the essential amino acids—histidine, isoleucine, lysine, leucine, methionine, 
phenylalanine, threonine, tryptophan, and valine—cannot be de novo synthesized by 
mammalian cells, these amino acids must be supplemented to support cell metabolism and 
growth (Figure 2.3). A number of essential amino acids have previously been shown to 
influence pluripotent stem cell metabolism and maintenance of pluripotency (Edgar, 2002; 
Shiraki et al., 2014; Shyh-Chang et al., 2013; Wang et al., 2009). Wang et al. (2009) 
showed that murine ESCs were sensitive to threonine availability and could not proliferate 
in threonine depleted medium (Wang et al., 2009). Murine ESCs were shown to convert 
threonine to acetyl coenzyme A (acetyl-CoA) and glycine via threonine dehydrogenase 
(TDH), which was expressed at high levels in pluripotent mESCs and rapidly decreased in 
expression levels early in differentiation (Wang et al., 2009). Whereas, supplementing 
media with pyruvate and glycine mitigated the effects of threonine depletion on mESCs 
(Shyh-Chang et al., 2013). On the other hand, human PSCs were shown to have an inactive 
TDH enzyme, and therefore were not sensitive to threonine depletion (Edgar, 2002; Shiraki 
et al., 2014). Yet, deprivation of leucine, lysine, methionine, or tryptophan resulted in 
reduced cell growth for human ESCs and iPSCs (Shiraki et al., 2014). Moreover, leucine, 
lysine, and methionine induced apoptosis during prolonged deprivation (Shiraki et al., 
2014). Therefore, while murine and human PSCs possess unique essential amino acid 
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metabolic requirements, amino acid metabolism is crucial for sustaining proliferation and 
preventing differentiation.  
 20 
 
Figure 2.3. Simplified schematic of amino acid metabolism for mammalian cells. 
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Gene expression and chromatin structure are regulated by histone and DNA 
methylation (Cedar and Bergman, 2009). Central to this, methyltransferases utilize S-
adenosylmethionine (SAM) as a methyl donor (Goll and Bestor, 2005; Lu et al., 2008). 
SAM production depends on one-carbon metabolism and is influenced by specific amino 
acid availability (Shiraki et al., 2014; Shyh-Chang et al., 2013). Strikingly, intracellular 
SAM levels were higher in mouse and human PSCs compared to fibroblasts (Deng et al., 
2009; Panopoulos et al., 2012; Shyh-Chang et al., 2013). Furthermore, SAM levels 
increased during the later stages of reprogramming and were elevated in iPSCs compared 
to hESCs; this suggests a causative role in reprogramming and regulation of pluripotency 
(Deng et al., 2009; Panopoulos et al., 2012; Shyh-Chang et al., 2013). In particular, PSCs 
were shown to be sensitive to SAM histone methylation of histone H3 lysine 4 (H3K4me3) 
(Shiraki et al., 2014; Shyh-Chang et al., 2013). In murine ESCs, threonine deprivation or 
knockout of TDH negatively affected SAM production and gene expression (Shyh-Chang 
et al., 2013). In human ESCs and iPSCs, reduction of intracellular SAM led to a decline in 
H3K4me3 methylation and global DNA methylation (Shiraki et al., 2014). Consequently, 
reduction of intracellular SAM resulted in decreased Nanog expression and enhanced 
differentiation towards all 3 germ layers (Shiraki et al., 2014). In this way, threonine and 
methionine seem to affect metabolism and cell fate of murine and human PSCs respectively 
through the same SAM-related mechanism.  
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2.2.3. Lactate fermentation and accumulation 
2.2.3.1. Lactate metabolism as a result of oxygen tension 
Lactate production and accumulation in mammalian cell metabolism was originally 
viewed as an oxygen dependent characteristic, with only oxygen deprived cells 
participating in lactate fermentation (Warburg et al., 1927). Notwithstanding, lactate 
fermentation has also been shown to be a byproduct of aerobic metabolism, and 
accumulates significantly in mammalian cell culture (Eagle et al., 1958). As mentioned 
above, the reliance on glycolysis and lactate fermentation by proliferating cells for 
macromolecule synthesis and energy production irrespective of oxygen level is referred to 
as the Warburg Effect (Warburg, 1956). The rate of lactate accumulation is based on the 
carbohydrate conversion rates to either glucose- or fructose-phosphate (Eagle et al., 1958). 
Until recently, the general consensus has been that pyruvate is the end product of glycolysis 
for well oxygenated systems, and lactate is the glycolytic end product for poorly 
oxygenated systems (Mulukutla et al., 2010; Vander Heiden et al., 2009). However, since 
the LDH reaction is nearly at equilibrium, and because LDH activity has been shown to be 
much higher than important regulatory enzymes for glycolysis and oxidative metabolism, 
lactate has recently been hypothesized to be the true end product of glycolysis, irrespective 
of oxygen availability (Kane, 2014; Rogatzki et al., 2015; Schurr, 2017).  
Hypoxia-inducible factors (HIFs) are transcription factors that regulate oxygen 
homeostasis in response to cellular environment conditions (Semenza, 2012). HIF-1 is a 
heterodimer composed of 2 subunits (HIF-1α and HIF-1β). HIF activity is regulated by O2 
concentrations and is dependent on the stability of the α-subunit (Manalo et al., 2005; Wang 
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and Semenza, 1995); under normoxic conditions HIF-1α is inactivated and degraded, while 
in hypoxic conditions it is stabilized and activated (Berra et al., 2001; Jaakkola et al., 2001). 
Under hypoxic conditions, HIF-1 was shown to activate the transcription of genes encoding 
glucose transporters and glycolytic enzymes (Semenza et al., 1994). In addition, HIF-1 
activation resulted in increased expression of pyruvate dehydrogenase kinase (PDK1), 
which phosphorylated and inactivated the PDH complex and prevented pyruvate from 
entering into the TCA cycle (Papandreou et al., 2006; Semenza, 2012). Therefore, in 
hypoxic conditions, pyruvate is converted to lactate in order to maintain a high carbon flux 
through glycolysis. Interestingly, lactate and pyruvate have also recently been shown to 
cause HIF-1α accumulation and stabilization independent of hypoxia (De Saedeleer et al., 
2012; Lu et al., 2002; Sonveaux et al., 2012). This suggests that lactate also reciprocally 
activates HIF-1 and contributes to the Warburg phenotype (Ferguson et al., 2018).  
 
2.2.3.2. Lactate transport across the cell membrane  
Intracellular lactate homeostasis and transport across the plasma membrane is 
facilitated by monocarboxylate transporters (MCT) (Halestrap, 2012). MCTs are proton-
linked plasma membrane transporters responsible for shuttling lactate, pyruvate, and 
ketone bodies across the cell membrane (Halestrap, 2012). MCT transport is based on the 
presence of H+ and the direction of the metabolite concentration gradient (Halestrap, 2012). 
By coupling transport of protons with lactate, MCTs control intracellular pH and prevent 
toxic levels of intracellular lactate buildup (Doherty and Cleveland, 2013). There are four 
MCTs responsible for lactate transport (MCT 1-4), with MCT1 exhibiting the highest 
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affinity for lactate uptake and MCT4 primarily responsible for lactate secretion 
(Dubouchaud et al., 2000; Halestrap, 2012). For example, within the tumor 
microenvironment, cancer cells which exhibit high MCT1/MCT4 ratios have been shown 
to consume and utilize lactate for energy (Corbet et al., 2014; Kennedy et al., 2013; Perez-
Escuredo et al., 2016; Sonveaux et al., 2012). As a result, MCT1 inhibitors are one of many 
potential anti-cancer treatments. Interestingly, high MCT1 expression levels were also 
associated with a naïve pluripotent cell state for both hESCs and hiPSCs (Gu et al., 2016). 
As MCT1 is associated with lactate uptake, this may suggest that PSCs are capable of 
consuming lactate as a metabolic substrate, while maintaining pluripotency. 
  
2.2.3.3. Lactate as a metabolic substrate (in tissues) 
In anaerobic exercise, contracting skeletal muscle cells secrete lactate. Normal 
blood lactate levels are maintained below 1.0 mM, while during intense exercise, blood 
lactate levels can rise to as high as 11 mM (Ferguson et al., 2018). Originally, circulating 
lactate secreted from muscles was thought to accumulate and act as a dead-end waste 
product (Hill et al., 1924). More recently, however, a cell-to-cell lactate shuttle was 
proposed, which postulates that lactate secreted by contracting muscle cells acts as an 
energy intermediate and can be oxidized, or undergo gluconeogenesis or glycogenesis in 
neighboring tissues (Brooks, 1985). In support of this hypothesized lactate shuttle, during 
exercise, normal human myocardium exhibited elevated exogenous lactate oxidation 
(Gertz et al., 1988). Also, cardiomyocytes preferentially metabolized lactate over glucose 
during fetal heart development (Werner and Sicard, 1987). Notably, neural tissue were also 
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shown to be capable of metabolizing plasma lactate; circulating lactate supported up to 10% 
of oxidative requirements under physiological conditions and was capable of supporting a 
larger fraction of energy requirements as circulating lactate levels rose during exercise 
(Boumezbeur et al., 2010). Moreover, in mice, lactate was shown to feed TCA metabolism 
for all tissues via circulating blood during both fed and starved metabolic states (Hui et al., 
2017). This suggests that lactate is an energy intermediate during resting and active 
metabolic states. 
 
2.2.3.4. Lactate as a metabolic substrate (cell culture) 
Lactate has also been shown to serve as a substrate to numerous types of 
mammalian cells in vitro. In the field of recombinant protein production, mammalian 
cells— including Chinese hamster ovary (CHO), hybridoma, and NS0 cells—have been 
observed to shift from relying on glycolysis and lactate fermentation for rapid growth, 
towards a lactate consumption state during the stationary growth phase of fed-batch 
processes (Altamirano et al., 2006; Mulukutla et al., 2012; Zhou et al., 1997). Lactate 
consumption metabolism was also found to correlate with increased cellular productivity 
for CHO cells, while lactate production and accumulation corresponded to poor processes 
and product qualities (Charaniya et al., 2010; Mulukutla et al., 2012; Mulukutla et al., 
2015). Therefore, the metabolic shift from lactate production to consumption is often 
encouraged in mammalian bioprocessing. In order to reduce lactate accumulation and 
promote lactate oxidation, a number of media formulations and feeding strategies have 
been adopted, including: low initial glucose concentrations, supplementation with 
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galactose, and glutamine limiting feed rates (Altamirano et al., 2006; Chee Furng Wong et 
al., 2005; Lee et al., 2015). Interestingly, lactate has also previously been fed to CHO cells 
to promote lactate consumption, control pH, and reduce ammonia buildup (Li et al., 2012). 
Moreover, cells undergoing lactate oxidation produced up to six times more ATP per mole 
of carbon consumed than cells using glycolysis and lactate production for energy (Martínez 
et al., 2013).  
 
2.2.3.5. Lactate in cancer cell metabolism 
Since the seminal work of Otto Warburg in the 1920s, numerous types of cancer 
have been shown to rely heavily on glycolysis and lactate fermentation to support 
proliferation irrespective of oxygen availability (Cairns et al., 2011; DeBerardinis et al., 
2008; Vander Heiden et al., 2009; Warburg, 1956). Moreover, within the tumor 
microenvironment, select populations of cancer cells can also catabolize lactate, a process 
referred to as the Reverse Warburg Effect (Kennedy and Dewhirst, 2010; Kennedy et al., 
2013; Martinez-Outschoorn et al., 2011; Pavlides et al., 2010; Sonveaux et al., 2008). 
Consequently, the cell-to-cell lactate shuttle has been extended to describe the tumor 
microenvironment, where cancer-associated fibroblasts generated lactate from aerobic 
glycolysis and epithelial cancer cells oxidized lactate for fuel (Kennedy et al., 2013; 
Martinez-Outschoorn et al., 2011; Pavlides et al., 2010; Sonveaux et al., 2008). This 
symbiotic relationship between hypoxic tumor populations generating lactate and oxidative 
tumor cells consuming lactate has been linked to varying expression levels of lactate 
transporters (MCT1 and MCT4); cancer cell lines that preferentially oxidize lactate for 
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energy exhibited elevated expression levels of MCT1, while tumor cells exhibiting the 
Warburg phenotype had elevated expression of MCT4 (Kennedy et al., 2013; Sonveaux et 
al., 2008). 
Lactate oxidation also appears to promote cancer progression. Intratumoral lactate 
injections have been shown to result in increased cancer metastasis in vivo (Bonuccelli et 
al., 2010). Lactic acidosis is also used as a diagnostic indicator in some types of cancer, 
with high intratumoral lactate levels correlating with treatment resistance as well as poor 
patient prognosis (Kennedy and Dewhirst, 2010). One hypothesis is that the Warburg 
phenotype provides cancer cells with a competitive advantage. In this way, lactate secretion 
and tumor acidification have been shown to promote cell invasion and metastasis (Gatenby 
and Gillies, 2004). Furthermore, exposure to lactate in vitro caused an upregulation of 
genes associated with stemness and resulted in a shift towards the “cancer stem cell” 
phenotype (Martinez-Outschoorn et al., 2011). When catabolized, lactate-derived acetyl-
CoA was either used for mitochondrial metabolism or for histone acetylation (Martinez-
Outschoorn et al., 2011). Besides, exposure to extracellular lactate (10 mM) resulted in 
increased histone acetylation for breast cancer cells and promoted increased malignancy 
and stemness gene expression (Martinez-Outschoorn et al., 2011). In addition, HeLa and 
H460 cells metabolized exogenous lactate for lipid synthesis, with lactate derived carbon 
playing a more significant role in lipid synthesis than glucose (Chen et al., 2016). Moreover, 
in an in vivo human lung tumor model, lactate was metabolized and contributed more to 
TCA cycle metabolism than glucose (Faubert et al., 2017). These results suggest that 
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lactate-derived acetyl-CoA serves both a metabolic and regulatory role in cancer 
progression.  
 
2.2.3.6. Lactate in iPSC metabolism 
Lactate accumulates rapidly in iPSC culture as well, and as a result, daily media 
exchanges are routinely performed, in part to prevent lactate stresses (Olmer et al., 2012; 
Wang et al., 2013). Unlike other mammalian cells, PSCs have been shown to be dependent 
on glycolysis and lactate fermentation for growth, with decreased rates of glycolysis and 
lactate productions previously corresponding to increased rates of PSC differentiation; 
therefore, lactate accumulation appears to be a byproduct of healthy PSCs (Folmes et al., 
2011; Gaspar et al., 2014; Gu et al., 2016; Moussaieff et al., 2015; Panopoulos et al., 2012; 
Varum et al., 2011). A number of studies have investigated the effects of lactate 
accumulation on murine and human PSCs and shown variable sensitivities between species. 
For example, murine embryonic stem cells (mESC) efficiently proliferated in 10 mM 
lactate, with lactate concentrations as high as 40 mM not affecting mESC pluripotency 
(Chaudhry et al., 2009; Martinez-Outschoorn et al., 2011). Also, miPSCs cultured in high 
lactate containing media exhibited no changes to cellular proliferation or pluripotency for 
lactate concentrations below 39 mM; although, supplementation of 22 mM lactate or higher 
resulted in a decreased lactate production flux (Gupta et al., 2017). However, these studies 
did not determine whether extracellular lactate was metabolized as a carbon source or if 
lactate production was inhibited.  
Conversely, hESCs grown in media containing lactate above 11 mM exhibited 
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decreased cell growth (Chen et al., 2010). Likewise, lactate accumulation has been 
suggested to be the limiting factor in prolonged hiPSC expansion, with lactate 
accumulation adversely impacting growth rates (Horiguchi et al., 2018). Similar to mESCs, 
lactate production rates decreased for hESCs grown in media with lactate between 22-55 
mM. Additionally, continuous passaging of hESCs in high extracellular lactate (11-22 mM) 
resulted in decreased pluripotency (Chen et al., 2010). Furthermore, elevated lactate 
conditions preferentially induced cardiomyocyte differentiation for iPSCs in glucose 
deficient differentiation media (Tohyama et al., 2013). On the other hand, Wilmes et al. 
2017 showed that iPSCs were extremely sensitive to extracellular acidification, and that 
media acidification contributed to reduced glucose consumption, proliferation, and 
pluripotency (Wilmes et al., 2017). In addition, glycolysis, lactate production, and cell 
growth rates were modulated by media pH (Gupta et al., 2017; Liu et al., 2018; Wilmes et 
al., 2017). This suggests that daily media replacement partially is used for pH control and 
that improved media buffering capacity could alleviate some of these issues. Nonetheless, 
no previous hPSC study has fully characterized the effects of high extracellular lactate on 
intracellular metabolism.  
 
2.2.4. Metabolic remodeling during the acquisition and loss of pluripotency 
Metabolic remodeling appears to directly contribute to cell fate, with glycolysis 
playing a critical functional role in the acquisition and maintenance of pluripotent stem 
cells (DeBerardinis et al., 2008; Folmes et al., 2012; Folmes et al., 2011; Ryall et al., 2015). 
For example, PSCs have been shown to exhibit an increased dependence on glycolysis and 
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lactate production compared to primed and fully differentiated cells; this coincided with an 
elevated glucose contribution to nucleotide production (Folmes et al., 2011; Gaspar et al., 
2014; Gu et al., 2016; Moussaieff et al., 2015; Panopoulos et al., 2012; Varum et al., 2011). 
This dependence on glycolysis was also coupled with an increased uncoupling of 
respiration and energy metabolism (Folmes et al., 2011; Zhang et al., 2011). Stimulation 
of glycolysis also was observed to promote maintenance of stemness for PSCs and 
augmented somatic reprogramming to iPSCs, while inhibition of specific glycolytic 
reactions in turn inhibited reprogramming (Ezashi et al., 2005; Folmes et al., 2011; 
Mohyeldin et al., 2010). Furthermore, somatic cells with elevated glycolytic metabolism 
reprogrammed more efficiently to iPSCs; this suggests a degree of metabolic memory of 
the somatic cells from which iPSCs are derived (Panopoulos et al., 2012). Interestingly, 
the shift towards aerobic glycolysis during somatic cell reprogramming preceded 
pluripotency gene expression (Folmes et al., 2011). Also, acetyl-CoA generated from 
glycolysis contributed to the epigenetic regulation of PSCs through histone acetylation and 
maintenance of an open chromatin structure (Moussaieff et al., 2015). These results 
demonstrate that maintaining a high glycolytic flux is a defining metabolic characteristic 
of PSCs and critical for maintaining stemness. 
In addition to the metabolic shifts which have been observed during reprogramming 
of somatic cells to iPSCs, regulation of glucose metabolism guides cell differentiation 
towards each of the three germ layers—ectoderm, endoderm, and mesoderm (Folmes et al., 
2013; Folmes and Terzic, 2016; Gaspar et al., 2014; Mathieu and Ruohola-Baker, 2017; 
Wanet et al., 2015). Spontaneous differentiation of PSCs is accompanied by a decrease in 
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glycolytic fluxes and increased OXPHOS; this metabolic shift also occurs prior to a loss 
of pluripotency. Furthermore, inhibition of glycolysis has been shown to promote 
spontaneous differentiation, suggesting that metabolism plays a functional role in 
regulating cell self-renewal and differentiation (Gu et al., 2016; Moussaieff et al., 2015; 
Zhang et al., 2011). With the increased OXPHOS and mitochondrial activity associated 
with spontaneous differentiation, mitochondrial structures also shift from the small, 
circular mitochondria found in PSCs to the elongated tubular structures found within 
somatic cells (Varum et al., 2011). And, differentiated cells have more mitochondrial mass 
and mitochondrial DNA (Cho et al., 2006; Prigione et al., 2010; Varum et al., 2011). With 
this, PSCs undergoing differentiation exhibits elevated levels of intracellular ATP and 
decreased lactate production (Cho et al., 2006; Folmes et al., 2011; Prigione et al., 2010; 
Varum et al., 2011). These alterations to the mitochondria support the shift from glycolysis 
to oxidative metabolism for differentiating cells and increases cellular energy production 
required to perform specific cell functions (Gaspar et al., 2014). 
Understanding the dynamics of PSC metabolism is critical to initiate differentiation 
towards specific somatic cell types. As mentioned above, the general assumption has been 
that PSC metabolism shifts away from relying on glycolysis and towards a dependence on 
OXPHOS upon differentiation (Gu et al., 2016; Moussaieff et al., 2015; Varum et al., 2011; 
Zhang et al., 2011). These, previous studies have primarily compared PSC metabolism with 
either fully developed somatic cells or spontaneously differentiated cell populations 
(embryoid bodies), thus were not able to provide sufficient information about the unique 
metabolic remodeling associated with the development of germ layer-specific cells (Gu et 
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al., 2016; Moussaieff et al., 2015; Varum et al., 2011; Yanes et al., 2010; Zhang et al., 
2011). In contrast, it was recently shown that metabolic remodeling during differentiation 
was germ layer-specific, with endodermal and mesodermal differentiation coupled with 
shifts from elevated glycolysis to oxidative phosphorylation, while PSCs undergoing 
ectodermal differentiation maintain elevated glycolytic fluxes (Cliff et al., 2017). Therefore, 
it is important to understand the unique metabolic requirements of each germ layer in order 
to generate fully developed, functional somatic cells, since metabolism contributes to the 
acquisition and loss of pluripotency. 
 
2.2.5. Metabolic effects from xeno-free conditions 
Given that the iPSC phenotype must be tightly controlled in order to develop high 
quality cell sources for cell therapies, the use of chemically defined xeno-free surface 
matrices and medias have become increasingly important to meet regulatory safety 
concerns. In contrast, pluripotent stem cells were first cultured directly on mouse 
embryonic fibroblast feeder cells (MEFs) or on animal-derived matrices (i.e. Matrigel); the 
first PSC media also contained fetal bovine serum (FBS) (Desai et al., 2015). There are 
several issues with using animal-derived components in cell therapies, including: the risk 
of animal pathogens exposure, broad lot-to-lot variability, and ill-defined components 
(Desai et al., 2015; Hughes et al., 2010; Nagaoka et al., 2010).  
In addition to regulatory concerns, surface substrates and media components have both 
previously been shown to affect PSC metabolism in variable manners. HESCs grown on 
Matrigel-coated exhibited higher growth rates and metabolic activity than a number of 
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chemically defined surface matrices (Silva et al., 2015). In addition, PSCs shifted from 
glycolysis to oxidative phosphorylation when grown in 3D aggregates compared to 2D 
monolayers (Kropp et al., 2016; Silva et al., 2015). Interestingly, xeno-free cell culture 
media (Essential 8TM (E8) and mTeSRTM) have been shown to alter lipid metabolism and 
increase ROS generation for iPSCs when compared to knockout serum replacement media 
(Bangalore et al., 2017; Zhang et al., 2016). Moreover, glutamine anaplerosis for both 
iPSCs and hESCs, increases 4-fold in chemically defined E8TM medium compared to 
conditioned medium (Zhang et al., 2016). Besides, the addition of 20% FBS to chemically 
defined mTeSR1TM medium resulted in increased reliance of hESCs on glutamine 
anaplerosis and decreased pluripotency (Rathjen et al., 2014). Transcriptomics and 
metabolomics analysis have shown that stem cell phenotypes converge with tightly 
controlled and reproducible conditions (Silva et al., 2015). Therefore, it is important to 
characterize PSCs in each media to understand the media-dependent growth and metabolic 
characteristics. 
 
2.3. Metabolic flux analysis (MFA)  
Metabolic flux analysis (MFA) is a powerful technique used to determine 
intracellular metabolic pathway fluxes and resolve the contribution of individual metabolic 
pathways to overall cell metabolism (Sa et al., 2015; Stephanopoulos et al., 1998). In MFA, 
intracellular fluxes are determined by coupling extracellular uptake and secretion rates of 
nutrients and waste products with a discrete stoichiometric metabolic network model 
(Stephanopoulos et al., 1998). While metabolomics approaches alone provide a view of the 
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cell potential, coupling concentration changes with a functional network through MFA 
offers a representation of cellular phenotype and pathway interactions (Niklas and Heinzle, 
2011; Sauer, 2006; Stephanopoulos et al., 1998). The fluxome (compilation of intracellular 
metabolic fluxes) represents the interplay between the genome, transcriptome, proteome, 
and metabolome of a cell (Figure 2.4) (Sauer, 2006). As a result, MFA is frequently used 
to examine cell lines and cell culture conditions to compare the degree of engagement of 
individual metabolic pathways under each condition (Niklas and Heinzle, 2011). In 
addition, MFA can be used to determine targets for metabolic engineering and to optimize 
cell culture media and feed strategies based on cellular metabolic capacities (Bonarius et 
al., 1997; Wiechert, 2001).  
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Figure 2.4. Schematic of the fluxome showing the cooperative regulation between 
the genome, transcriptome, proteome, and metabolome. Image from (Sa et al., 2015). 
Translated with permission from [Springer Nature]: [Springer Nature] [Springer eBook] 
(João V. Sá, Tiago M. Duarte, Manuel J. T. Carrondo et al.), [COPYRIGHT] (2015). 
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2.3.1. History of MFA 
In classic MFA, extracellular consumption and production fluxes are coupled with 
a metabolic network model and a mass balance is performed to determine intracellular 
metabolic fluxes (Sa et al., 2015; Stephanopoulos et al., 1998). Also, in classic MFA, a 
pseudo steady-state hypothesis is assumed while cells are in exponential growth. The 
pseudo steady-state hypothesis implies that changes to metabolite pools due to small 
perturbations are rapid in comparison to cell growth and the intracellular pool sizes remain 
constant during an experiment (Stephanopoulos et al., 1998; Wiechert, 2001). One 
limitation to classical MFA is that complex intracellular pathways—bidirectional reactions, 
parallel pathways (glycolysis vs. pentose phosphate pathway), and cyclic fluxes (TCA 
cycle)—cannot be resolved well if only extracellular data is used (Sa et al., 2015; 
Stephanopoulos et al., 1998). In addition, classic MFA is limited by the number of accurate 
metabolite measurements used to constrain the metabolic model to physiologically feasible 
solutions (Sa et al., 2015). 
More recently, MFA using stable isotopes has been used to uniquely determine 
complex intracellular fluxes, including cyclic pathways and bidirectional fluxes; these 
fluxes cannot be quantified reliably using unlabeled MFA approaches (Hiller and Metallo, 
2013; Metallo et al., 2009; Nicolae et al., 2014; Sauer, 2006). Asymmetries of metabolite 
labeling which arise from branchpoint reactions allow for intermediate reaction fluxes to 
be determined (Figure 2.5A and B) (Stephanopoulos and Stafford, 2002). While the classic 
MFA approach is a relatively straightforward metabolite balance, with measured 
extracellular fluxes serving as the model constraints, 13C-MFA is more computationally 
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challenging; the use of intracellular isotopomer measurements results in a nonlinear least 
squares problem (Niklas and Heinzle, 2011). Similar to classic MFA, 13C-MFA also relies 
on the pseudo steady-state assumption of cell metabolism (Sa et al., 2015). Further, in 13C-
MFA, isotopically labeled intracellular metabolite pools are assumed to be at an isotopic 
steady-state (Kelleher, 2001). This means that the fractional isotope labeling of any given 
metabolite remains constant for the simulation timepoint; the distribution of labeling for a 
metabolite may fluctuate but the ratio of labeled-to-unlabeled metabolite does not change 
(Sa et al., 2015). Since current isotope measurement techniques cannot detect individual 
compartmental metabolite labeling (mitochondrial vs. cytosolic), a single pooled labeling 
approach is most often used for 13C-MFA (Metallo et al., 2012; Zamboni, 2011).  
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Figure 2.5. Metabolic network using classic MFA and 13C-MFA. A) Bidirectional 
pathway using classic MFA. The substrate A and metabolite E can be measured 
extracellularly, but metabolites B, C, and D cannot be measured. It is impossible to 
calculate the intracellular fluxes v2, v3, v4, and v5, because the system is underdetermined 
(i.e. multiple solutions satisfy the observed measurements); B) Bidirectional pathway using 
13C-MFA. Measuring the isotope profile of metabolites C and D provide a unique solution 
to the intracellular fluxes. In addition, the ratio of labeled vs. unlabeled metabolites 
provides the degree of exchange occurring. C) Flow chart of 13C-MFA process. Image 
adapted from (Duckwall et al., 2013).  
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Given the relatively slow growth rates of mammalian cells and the long-time frame 
to reach isotopic steady-state, new MFA methods have shifted towards isotopically 
nonstationary MFA – INST-MFA (Jazmin and Young, 2013) or dynamic MFA (DMFA) 
(Leighty and Antoniewicz, 2011). Isotopic nonstationary MFA is ideal for systems where 
isotope labeling is slowly incorporated. Nonstationary MFA can be used to identify 
bottlenecks in cell metabolism for extended processes or due to environmental 
perturbations, and allow for modeling more dynamic bioprocessing systems, such as fed-
batch cultures (Ahn and Antoniewicz, 2012; Leighty and Antoniewicz, 2011). In isotopic 
nonstationary MFA, a complete set of extracellular metabolite and intracellular mass 
isotopomer distribution (MID) time-series measurements are fit simultaneously to a 
metabolic model; this provides the metabolic transients throughout an entire cell culture 
process (Leighty and Antoniewicz, 2011).   
 
2.3.2. 13C-MFA in Chinese hamster cell culture 
13C-MFA has previously been used to characterize various mammalian cell systems for 
bioprocess development and metabolic engineering approaches (Altamirano et al., 2006; 
Ivarsson et al., 2015; Templeton et al., 2017b). As CHO cells serve as the primary 
mammalian host used for industrial manufacturing of therapeutic proteins, these cells were 
the focus of most mammalian cell bioprocess MFA studies (Wurm, 2004). Previously, 13C-
MFA has been used to evaluate the effects of growth phases (exponential vs. stationary), 
carbon sources, and pH on metabolism and protein production (Ahn and Antoniewicz, 
2011; Ahn and Antoniewicz, 2013; Altamirano et al., 2006; Bonarius et al., 2001; Duarte 
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et al., 2014; Ivarsson et al., 2015; Lee et al., 2015; Sengupta et al., 2011; Templeton et al., 
2013; Templeton et al., 2017b). In addition, 13C-MFA has been used to determine the 
metabolic phenotypes of high productivity CHO cell lines to improve cell line engineering 
and clonal selection (Templeton et al., 2017a). Overall, the use of 13C-MFA to understand 
CHO cell metabolism has resulted in improved bioprocessing conditions, higher peak cell 
densities, and higher product yields. 
  
2.3.3. 13C-MFA and cancer metabolism 
Metabolic alterations have been suggested to play a functional role in cancer 
progression (Cairns et al., 2011). Therefore, MFA approaches have been used to establish 
the baseline metabolic states of various types of cancer. In addition, 13C-MFA has been 
used to determine the response of cancer cells to different cell culture conditions, such as 
glucose and O2 concentrations (Gaglio et al., 2011; Jiang et al., 2016; Metallo et al., 2012), 
and to investigate the effects of genetic mutations on cancer cell metabolism and 
invasiveness (Grassian et al., 2014; Jiang et al., 2017; Parker et al., 2017). In particular, 
hypoxia was shown to rewire TCA metabolism in cancer cells, which resulted in reductive 
carboxylation of glutamine to citrate via isocitrate dehydrogenase (IDH) for lipogenesis 
(Metallo et al., 2012; Wise et al., 2011). This metabolic flexibility was hypothesized to 
provide an adaptive advantage for cancer cells within the hypoxic tumor microenvironment 
(Mullen et al., 2012). Recently, reductive carboxylation has also been suggested to be a 
metabolic response to stress, including reactive oxygen species generation and lactate 
accumulation (Brodsky et al., 2019; Fendt et al., 2013; Jiang et al., 2016). Furthermore, 
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Pancreatic ductal adenocarcinoma was shown to consume more glucose and secrete more 
lactate when undergoing epithelial-mesenchymal transition (Liu et al., 2016). Recently, 
13C-MFA was used to elucidate the in vivo metabolism of non-small cell lung cancer 
(NSCLC), where Faubert et al. 2017 found that lactate was metabolized and contributed a 
greater fraction of carbon to the TCA cycle than glucose (Faubert et al., 2017; Hensley et 
al., 2016). In this way, MFA has been used to investigate the metabolic wiring of various 
types of cancer and uncover pathways for therapeutic targeting.  
 
2.3.4. 13C-MFA and stem cell metabolism 
As mentioned previously, PSCs exhibit unique metabolic phenotypes during 
different stages of growth and differentiation (Gu et al., 2016; Moussaieff et al., 2015; 
Varum et al., 2011; Zhang et al., 2011). However, unlike with CHO and cancer cells, only 
a few studies have used MFA approaches to determine the fluxome of pluripotent stem cell 
metabolism. Instead, most studies to date have performed isotope tracer experiments and 
measured extracellular metabolite profiles, but have not perform 13C-MFA or constructed 
a metabolic flux model (Carey et al., 2015; Gaspar et al., 2014; Gu et al., 2016; Moussaieff 
et al., 2015; Varum et al., 2011). Extracellular metabolism and intracellular pathway 
activity could be assessed, but the relative rates of intracellular reactions could not be 
determined. For MFA studies that have been performed in PSCs, these studies have focused 
primarily on the effects of cell culture conditions (oxygen and media), and metabolic shifts 
associated with differentiation (Table 2.1) (Badur et al., 2015; Correia et al., 2018; Sa et 
al., 2017; Sepúlveda et al., 2010; Turner et al., 2014; Zhang et al., 2016). In Turner et al. 
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(2014), a Warburg phenotype was observed for hESCs grown either in 20% or in 2% 
oxygen, with a stoichiometric conversion of glucose to lactate (Turner et al., 2014). MFA 
was performed using only extracellular metabolite measurements to constrain the 
metabolic model, which resulted in overlapping and broad flux determination between 
conditions and limited intracellular flux resolution (Turner et al., 2014). In Zhang et al. 
(2016) and Badur et al. (2015), a metabolic model of fatty acid metabolism was constructed 
for hESC and iPSC using 13C-MFA to determine the effects of chemically defined media 
and enzymatic passaging, respectively; however, a general metabolic flux model for central 
carbon metabolism was not reported (Badur et al., 2015; Zhang et al., 2016). On the other 
hand, Sà et al. 2017 and Correia et al 2018 each used 13C-MFA to construct detailed 
metabolic flux models for central carbon metabolism to describe the metabolic shifts 
associated with targeted differentiation of ESC and iPSC (Correia et al., 2018; Sa et al., 
2017). A detailed metabolic flux model of central carbon metabolism has not been 
constructed using 13C-MFA to elucidate the metabolic plasticity of PSCs during self-
renewal. Hopefully in the future, understanding the metabolic regulations for iPSCs under 
cell culture relevant conditions will help to understand the metabolic features of stem cells 
and aid in the development of robust cell culture processes. Utilizing MFA to predict the 
phenotype of a cell population will be integral to understand the cellular response to cell 
culture processes and to generate high quality cell-based therapies.
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Table 2.1 List of metabolic flux analysis studies for pluripotent stem cells.  
 
Cell Types Flux 
Analysis 
Method 
Isotopes Used Major Observations Reference 
mESC MFA None 
 
- Analyzed the metabolic shifts between three different differentiation 
protocols: embryoid body formation, matrigel surface coating, and gelatin 
surface coating. 
- Observed differences in lactate metabolism between the embryoid body 
samples compared to the matrigel and gelatin samples. This difference 
was attributed to differences in oxygen availability between conditions. 
(Sepúlveda 
et al., 2010) 
hESC MFA None - Compared metabolism in 20% and 2% oxygen. 
- Observed the Warburg phenotype in both conditions, with a 
stoichiometric conversion of glucose to lactate. 
- No changes to fluxome due to oxygen concentration. 
(Turner et 
al., 2014) 
hESC 13C-MFA [U-13C] glucose - Enzymatic passaging of hESCs caused reduction in glucose 
consumption, TCA metabolism, and de novo lipogenesis. Enzymatic 
passaging may have a lasting metabolic effect on hESCs. 
(Badur et 
al., 2015) 
hESC & hiPSC 13C-MFA [1,2-13C] glucose, 
[U-13C] glucose 
[U-13C] glutamine 
[1-13C] glutamine 
- hPSCs were capable of utilizing either glycolysis or oxidative 
phosphorylation for growth. 
- Metabolic phenotype of hPSCs was dependent on nutrient availability. 
(Zhang et 
al., 2016) 
mESCs & 
astrocytes 
13C-MFA 
(INST-MFA) 
[1-13C] glucose 
[U-13C] glutamine 
- Observed a reduction in central carbon metabolism in the astrocytes and 
a slower incorporation of isotope labeling. 
- mESC consumed glutamine and utilized reductive carboxylation for 
lipogenesis, while astrocytes produced glutamine. 
(Sa et al., 
2017) 
hESC and hiPSC 13C-MFA [1,2-13C] glucose - Compared hPSC metabolism to hPSC- derived cardiomyocytes (ESC 
and iPSC-CM). 
- Observed a shift from glycolysis to oxidative phosphorylation in hPSC-
CMs cultured as 3D aggregates 
(Correia et 
al., 2018) 
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CHAPTER THREE 
 
HIGH EXTRACELLULAR LACTATE CAUSES REDUCTIVE 
CARBOXYLATION IN BREAST TISSUE CELL LINES GROWN UNDER 
NORMOXIC CONDITIONS 
 
3.1. Abstract 
In cancer tumors, lactate accumulation was initially attributed to high glucose 
consumption associated with the Warburg Effect. Now it is evident that lactate can also 
serve as an energy source in cancer cell metabolism. Additionally, lactate has been shown 
to promote metastasis, generate gene expression patterns in cancer cells consistent with 
“cancer stem cell” phenotypes, and result in treatment resistant tumors. Therefore, the goal 
of this work was to quantify the impact of lactate on metabolism in three breast cell lines 
(one normal and two breast cancer cell lines – MCF 10A, MCF7, and MDA-MB-231), in 
order to better understand the role lactate may have in different disease cell types.  Parallel 
labeling metabolic flux analysis (13C-MFA) was used to quantify the intracellular fluxes 
under normal and high extracellular lactate culture conditions. Additionally, high 
extracellular lactate cultures were labelled in parallel with [U-13C] lactate, which provided 
qualitative information regarding the lactate uptake and metabolism. The 13C-MFA model, 
which incorporated the measured extracellular fluxes and the parallel labeling mass 
isotopomer distributions (MIDs) for five glycolysis, four tricarboxylic acid cycle (TCA), 
and three intracellular amino acid metabolites, predicted lower glycolysis fluxes in the high 
lactate cultures. All three cell lines experienced reductive carboxylation of glutamine to 
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citrate in the TCA cycle as a result of high extracellular lactate. Reductive carboxylation 
previously has been observed under hypoxia and other mitochondrial stresses, whereas 
these cultures were grown aerobically. In addition, this is the first study to investigate the 
intracellular metabolic responses of different stages of breast cancer progression to high 
lactate exposure. These results provide insight into the role lactate accumulation has on 
metabolic reaction distributions in the different disease cell types while the cells are still 
proliferating in lactate concentrations that do not significantly decrease exponential growth 
rates.  
 
3.2. Introduction 
Since the 1920s, many types of cancers have been shown to rely heavily on glycolysis 
and lactate fermentation to produce energy rather than the more energy efficient complete 
oxidation of glucose in the mitochondria, even in the presence of sufficient oxygen. This 
metabolic state is called the Warburg Effect (Cairns et al., 2011; DeBerardinis et al., 2008; 
Heiden et al., 2009; Warburg, 1956). In addition, lactate can be utilized by cancer cells in 
the presence of glucose, a process known as the Reverse Warburg Effect (Kennedy and 
Dewhirst, 2010; Kennedy et al., 2013; Martinez-Outschoorn et al., 2011; Pavlides et al., 
2010; Sonveaux et al., 2008). Not only does this capability to use lactate provide cancer 
cells a metabolic advantage in vivo, it seems to favor cancer progression. For example, 
when lactate was injected into mice with xenografts of the human breast cancer cell line 
MDA-MB-231, metastasis increased ten-fold (Bonuccelli et al., 2010). When the human 
breast cancer cell line MCF7 was exposed to lactate in vitro, genes associated with 
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“stemness” were upregulated and gene expression patterns consistent with the “cancer stem 
cell” phenotype were observed (Martinez-Outschoorn et al., 2011). In several other types 
of cancers, intratumoral lactate levels – which can rise to as high as 40 mM – correlated 
with treatment resistance as well as poor patient prognosis (Kennedy and Dewhirst, 2010). 
Further, it has been shown in xenotransplants and mouse cancer models that inhibiting the 
ability of cancer cells to utilize lactate can force the cells to become glycolytic and retard 
tumor growth through glucose starvation, while rendering the remaining cells more 
susceptible to radiation treatments (Sonveaux et al., 2008). Since lactate accumulation and 
its subsequent utilization by surrounding cancer cells appears to negatively affect cancer 
patient outcomes, deciphering the role of lactate at the metabolic level within central 
carbon metabolism is crucial.  
 Metabolic flux analysis (MFA) is a computational tool that is used to quantify the 
intracellular metabolic fluxes of individual metabolic pathways (Bonarius et al., 1997; 
Stephanopoulos, 1999). MFA can be used to compare changes in metabolic activity due to 
particular factors (Bonarius et al., 2001; Munger et al., 2008). Classical MFA uses 
extracellular uptake and secretion rates of nutrients and waste products, and a discrete 
metabolic network model of the relevant metabolic reactions (Hiller and Metallo, 2013; 
Nicolae et al., 2014). The use of stable isotopic tracers, typically 13C-labeled nutrients, and 
the resulting mass isotopomer distribution (MID) data increases the resolution of individual 
fluxes within the defined metabolic reaction network (Metallo et al., 2009; Sauer, 2006; 
Tang et al., 2009). Several mammalian systems have been characterized including Chinese 
hamster ovary (CHO) cells at both stationary and exponential growth phases (Ahn and 
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Antoniewicz, 2011; Ahn and Antoniewicz, 2013; Templeton et al., 2013), MDA-MB-231 
cells under various nutrient conditions (Gaglio et al., 2011), and several other cancer cell 
lines under hypoxia (Jiang et al., 2016; Metallo et al., 2012). There are several software 
tools available to assist researchers with resolving the intracellular fluxes including Metran, 
OpenFLUX, 13CFlux2, INCA and FiatFlux (Ahn and Antoniewicz, 2011; Quek et al., 
2009; Weitzel et al., 2013; Young, 2014; Zamboni et al., 2009). All of these software tools 
rely upon regression analysis to solve the system of linear equations specified by the 
metabolic network.  
 The aim of this study was to determine the role of extracellular lactate on the 
metabolism of three different proliferating breast cell lines (one non-tumorigenic epithelial 
breast cell line and two breast cancer cell lines). Each cell line was grown in a low glucose 
control (e.g., normal or typical laboratory) media or in a high-lactate media, where sodium 
lactate was added to the control medium to make the high-lactate medium. The high-lactate 
concentration was selected for each cell line such that equivalent exponential growth rates 
for the control and high-lactate cultures were maintained. These equivalent exponential 
growth rates were important for the modeling assumptions for two reasons: 1) the quasi-
steady state assumption was met equally well by both conditions, and 2) it allowed for 
normalizations of fluxes between the conditions for the same cell line based on biomass 
generation. Parallel labeling experiments were conducted with [1,2-13C] glucose, [U-13C] 
L-glutamine, and [U-13C] sodium lactate, where the control cultures were only labeled with 
[1,2-13C] glucose and [U-13C] L-glutamine. The lactate labeling data for the high-lactate 
cultures provided uptake and direct intermediate tricarboxylic acid (TCA) cycle labeling 
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information. The intracellular metabolic fluxes were predicted for each cell line and each 
condition from the glucose and glutamine labeling data.  
 
3.3. Materials and Methods 
3.3.1. Cell lines and media formulations 
MCF 10A (ATCC® CRL-10317TM), MCF7 (ATCC® HTB-22TM) and MDA-MB-
231 (ATCC® HTB-26TM) cells were from the American Tissue Culture Collection (ATCC). 
MCF 10A cells are a non-tumorigenic breast cell line, MCF7 cells are a tumorigenic, 
luminal breast cancer cell line, and MDA-MB-231 cells are a metastatic, basal breast 
cancer cell line (Zancan et al., 2010). Dulbecco’s modified Eagle medium (DMEM) 
without glucose, glutamine, sodium pyruvate, and phenol red (Life Technologies) was used 
as the growth media. The growth media was supplemented to contain 5 mM glucose 
(Thermo Fisher), 3 mM glutamine (Life Technologies), 10% dialyzed fetal bovine serum 
(dFBS, Life Technologies), 100 U/mL penicillin, and 100  g/mL streptomycin (100X 
Penicillin-Streptomycin solution, Life Technologies). High-lactate cultures were 
supplemented with 10 mM sodium L-lactate (Sigma) for the MCF 10A cultures and 20 
mM for the MCF7 and MDA-MB-231 cultures. The isotopic tracers were [1,2-13C] glucose, 
[U-13C] L-glutamine, and [U-13C] sodium lactate, all purchased from Sigma-Aldrich. 
 
3.3.2. Cell growth and parallel labeling experiments 
All cell lines were seeded at 2 x 104 cells/cm2 into either 6-well plates or T-25 flasks 
in the control growth media. Cells were cultured at 37°C in a 5% CO2 humidified incubator. 
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After 24-h, the media for the MDA-MB-231 cultures was exchanged and the experimental 
conditions were introduced. The media exchange time is used to set time 0 for all cell lines. 
For MCF 10A and MCF7 cell lines the lag phase was longer, so the media was replenished 
at 24-h post seeding. The media was exchanged 48-h post seeding for MCF10A and MCF 
7 to introduce the experimental conditions. For clarity, the full experimental setup is shown 
in Figure 3.1. Cell numbers and extracellular metabolite concentrations were measured as 
shown in Figure 3.1, where all times are relative to the isotope media exchange. Cell 
numbers and glucose and lactate concentrations were obtained from the six-well plates, 
while the amino acid concentrations were obtained from the T-25 flasks. Cells for 
intracellular metabolite analysis were obtained from the T-25 flasks 24-h after the media 
exchange, since 24-h has previously been shown to provide sufficient amount of time for 
isotopic steady state to be achieved for intracellular glycolytic metabolites in CHO cells 
(Ahn and Antoniewicz, 2013). Parallel cultures of glucose (95% molar enriched [1,2-13C] 
glucose) and glutamine tracers (95% molar enriched [U-13C] L-glutamine) were performed 
for the control cultures, whereas the high-lactate cultures also had parallel replicates for 
the lactate tracer (50% molar enriched [U-13C] sodium L-lactate). Six-well plates (Nunc) 
were used to obtain cell numbers and glucose and lactate concentrations with six replicates 
for each time point. T-25 flasks were used to obtain extracellular amino acid concentrations 
and intracellular MID measurements in triplicate. 
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Figure 3.1. Experimental setup for the parallel labeling experiments for each of the 
three breast cell lines. The four or five six-well plates and 15 T-25 flasks were seeded 
simultaneously for each cell line examined. The times shown indicate when the plates or 
flasks were harvested for analysis relative to the isotope media exchange. Isotopic labeling 
is graphically shown by shading (white – no isotope, black – glucose, dark grey – glutamine, 
and light grey – lactate).  The six-well plates did not contain isotopically-labeled media. 
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3.3.3. Cell numbers, and glucose and lactate concentrations 
Cell numbers were obtained using the Scepter 2.0 Handheld Automated Cell 
Counter (Millipore). Glucose and lactate concentrations were measured using a YSI 2700 
Bioanalyzer. 
 
3.3.4. Preparation of samples for gas chromatography-mass spectrometry analysis 
Intracellular and extracellular metabolites and specific metabolite fragments used 
for identification were extracted and derivatized according to the protocol outlined by Ahn 
and Antoniewicz (Ahn and Antoniewicz, 2011), with a few minor changes. Samples were 
incubated and derivatized for 60 min, and the final sample volumes were increased to 1 
mL after derivatization by adding additional pyridine. The injection volumes were 3 µL 
and samples were injected in splitless mode. Amino acid standards were used to calculate 
amino acid concentrations in the [U–13C] algal amino acid solution, which were then used 
to quantify the amino acid concentrations in the extracellular medium.  
 
3.3.5. Extracellular amino acid concentration and intracellular MID measurements 
GC-MS analysis was performed using a Hewlett Packard 7683 GC equipped with 
an HP-5 (30 m x 0.32 mm i.d. x 0.25 µm; J&W Scientific) capillary column, interfaced 
with a Hewlett Packard 5973 MS operating under ionization by electron impact as 70 eV 
and 200°C ion source temperature. The injection port and interface temperatures were both 
250°C while helium flow was maintained at 1 mL/min. Mass spectra were recorded in full 
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scan mode for amino acid quantification and in single ion mode (SIM) for MIDs as well as 
internal standards and standardization curves. MIDs were obtained by integration of single 
ion chromatograms and corrected for natural isotope abundances using the Metran software 
(Fernandez et al., 1996; Yoo et al., 2008). 
 
3.3.6. Determination of biomass specific consumption and production rates 
Specific consumption and production rates for nutrients and waste metabolites in 
the extracellular medium were determined based on cell growth rate and nutrient time 
profiles, where the times are relative to media exchange and not to seeding (Meadows et 
al., 2008). For each sample calculation, statistical analysis of the amino acid concentration 
data was conducted using JMP 10.0.0 (SAS Institute, Inc.). The generalized linear model 
was used where cell line, condition, and time were examined as effectors of the amino acid 
concentration (p £ 0.05). All amino acid concentrations were determined to be significantly 
affected by time (p £ 0.05). Several amino acid concentrations were not significantly 
affected by cell line, condition, or both (p > 0.05). The spontaneous glutamine degradation 
rate was accounted for in the glutamine flux calculation, with a degradation rate of 0.0019 
h-1 (Meadows et al., 2008).  
 
3.3.7. Metabolic network model 
To model central carbon metabolism for the three breast cell lines, a general 
mammalian cell model was used. This generalized mammalian cell model was adapted 
from the previously developed framework by Ahn and Antoniewicz (2013). Major 
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reactions for glycolysis, the pentose phosphate pathway (PPP), the TCA cycle, amino acid 
metabolism, lactate metabolism, and fatty acid metabolism were included in the 
mammalian cell model. Carbon flux to cellular biomass was broken down into two separate 
compartments – the Biomass pool, which included proteins, nucleotides, and carbohydrates, 
and the Lipid Biomass pool, which included lipids and phospholipid (Ahn and Antoniewicz, 
2013; Bonarius et al., 1996; Metallo et al., 2012). The Biomass and Lipid Biomass fractions 
were based on cell mass compositions from literature for hybridoma and MCF7 cells 
(Bonarius et al., 1996; Meadows et al., 2008; Sheikh et al., 2005), and the reported dry cell 
weight for hybridoma (470 pg per cell) (Bonarius et al., 1996). These values were used for 
all three cell lines. The dry cell weights were used to convert the measured growth rates to 
biomass-specific fluxes (Bonarius et al., 1996). In order to reduce the complexity of the 
model to align with the number and detail of measurements taken, only citrate and acetyl-
CoA were modeled with both cytosolic and mitochondrial compartments (Ahn and 
Antoniewicz, 2013; Metallo et al., 2012; Metallo et al., 2009). A lactate exchange reaction 
was included to account for dilution of the intracellular labeled lactate pool by uptake of 
exogenous lactate (v38 in Table B1 in Appendix B). This type of exchange reaction has 
previously been used to account for the dilution of carbon dioxide labeling and does not 
influence the intracellular carbon balance (Leighty and Antoniewicz, 2012). Carbon 
dioxide was treated as an unbalanced metabolite and was not measured. Oxygen uptake 
was excluded from the model and was also not measured. Cofactor balances, such as 
NADH and NADPH were not included in the model, as different isozymes have varying 
cofactor requirements and the inclusion of these assumptions can skew subsequent analysis 
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(Ahn and Antoniewicz, 2011). The breast cell metabolic flux model has 38 reactions. The 
full breast cell metabolic flux model with atom transitions is included in Table B1 in 
Appendix B.  
 
3.3.8. Metabolic flux analysis 
13C-Metabolic flux analysis was performed using the software package Metran (Yoo et 
al., 2008), which utilizes the elementary metabolite unit (EMU) framework (Antoniewicz 
et al., 2007b). Metabolic fluxes were estimated using experimentally measured-values for 
extracellular consumption and production rates and from MIDs obtained for intracellular 
metabolites. In Metran, the intracellular and extracellular metabolic flux predictions were 
based on quantities that minimized the variance-weighted sum of squared residuals (SSRes) 
between the measured values input into the model and the simulated values. Metran can 
process MID data from parallel labeling experiments to predict the metabolic fluxes, a 
capability that has been validated using both E. coli and CHO cells experimental data (Ahn 
and Antoniewicz, 2013; Leighty and Antoniewicz, 2012). In this study, random initial 
fluxes were used, and the MID error was calculated from the biological replicates. 
Additionally, a minimum MID error threshold of 0.6 mol% was applied if the biological 
error was less than 0.6 mol%; this falls within the standard error range that has been used 
in previous MFA studies (Ahn and Antoniewicz, 2013; Metallo et al., 2009). Most of the 
standard errors observed in this study for the biological replicates were higher than the 0.6 
mol% machine error used previously when replicates were not available (Ahn and 
Antoniewicz, 2013). The MIDs metabolites labeled by [1,2-13C] glucose included in the 
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MFA simulations were 3-phosphoglycerate (3PG), dihydroxyacetone phosphate (DHAP), 
pyruvate, lactate, and alanine. The MIDs metabolites labeled by [U-13C] glutamine 
included in the MFA simulations were succinate, malate, a-ketoglutarate (AKG), 
glutamate, citrate, glutamine, and pyruvate. The MIDs of metabolites labeled by [U-13C] 
lactate were not included in the MFA simulations.  
The extracellular flux for each metabolite was calculated as described in Meadows et 
al. (2008) (Meadows et al., 2008), and adapted to the media exchange time as: 
!"#$ % &'("10+	-.""/ ∙ ℎ	2 = 1045(789 − 7;8)=;8(.>? − 1) 							(Eq. 1) 
where, 5	is	the	growth	rate	(ℎMN) . 789  and 	7;8	 are the individual metabolite 
concentrations (mM) at 48 and 24 hours after the media exchange, respectively. =;8 is the 
cell concentration (cells/mL) at 24 hours after the media exchange. In Meadows et al. 
(2008) (Meadows et al., 2008), only the term X0 was used in the flux equation instead of 
X24, as their flux calculation included the initial time, time 0.  In the current study, the flux 
calculation only includes the time points 24-h and 48-h, thus the cell concentration uses 
the 24-h time point as the reference point for the cell concentration.  The value for the term 
t is 24 hours for all of the current flux calculations. 
 
3.3.9. Statistical Analysis 
Statistical analysis was performed using the software JMP pro 10 (SAS Institute, 
Cary, NC). The generalized linear model (GLM) procedure (p ≤ 0.05) and least squares 
method (LS mean) with Tukey HSD (honestly significant difference) were used to 
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determine if growth rates, cell numbers 24-h after the medium exchange, glucose, lactate, 
and amino acid concentrations were affected by the cell line and/or condition. To estimate 
the standard deviation for each metabolite flux, Monte Carlo simulations were conducted 
using 1,000,000 iterations of the flux equation, where the standard deviation for each input 5, (789 − 7;8),	and	=;8	 was applied. For Metran, metabolic flux simulations were 
determined to have converged when a global solution was achieved that satisfied the 
accepted SSRes criteria, unless otherwise specified. This was determined from analyzing 
the simulated fit results via a chi-square statistical test to measure goodness-of-fit 
(Antoniewicz et al., 2006; Antoniewicz et al., 2007a). After convergence, 95% confidence 
intervals were generated for all parameters based on the SSRes parameter (Antoniewicz et 
al., 2006). 
 
3.4. Results 
3.4.1. Cell growth 
To determine the effects of high extracellular lactate on breast cancer metabolism, three 
human breast cell lines, MCF 10A, MCF7, and MDA-MB-231, were grown under both 
control and high-lactate conditions. MCF 10A is a non-tumorigenic epithelial cell line, and 
MCF7 and MDA-MB-231 are two different stages of breast cancer (tumorigenic, luminal 
and metastatic, basal respectively). Sodium lactate was used for the high-lactate conditions 
to reduce the initial media pH shift and prevent shocking the cells due to the lactate addition. 
For MCF7 and MDA-MB-231, the high-lactate culture media consisted of the control 
media supplemented with 20 mM sodium lactate. For MCF 10A, the high-lactate culture 
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media consisted of the control media supplemented with 10 mM sodium lactate. MCF 10A 
cells were unable to grow under the 20 mM lactate stress; however, MCF 10A could grow 
at equal growth rates to the control culture in 10 mM lactate-supplemented media. Both 10 
mM and 20 mM lactate represent normal physiological concentration ranges (Kennedy and 
Dewhirst, 2010; Kennedy et al., 2013; Martinez-Outschoorn et al., 2011). Regrettably, the 
MCF 10A high-lactate cultures had to be cultured at a lower lactate concentration than the 
MCF7 and MDA-MB-231 high-lactate cultures, which prevented direct comparisons 
across all three cell lines. Yet, maintaining equal growth rates between the control and 
high-lactate conditions within each cell line was central to the experimental design. This 
allowed for any observed metabolic changes to be attributed to media condition alone and 
not to a shift in growth rate. 
The control media was composed of Dulbecco’s modified Eagle medium (DMEM) 
with a lower initial glucose concentration (5 mM) than standard DMEM (25 mM), in order 
to be more representative of physiological glucose concentrations, where 5 mM is equal to 
0.90 g/L or 90 mg/dL.  To minimize the interference of other carbon sources on the labeling 
of the intracellular metabolites, other potential carbon sources in the media were reduced 
or eliminated.  For example, sodium pyruvate was eliminated from the standard DMEM 
formulation, and dialyzed fetal bovine serum (FBS) was used to eliminate glucose and 
glutamine carryover and reduce the unquantified amino acids from FBS.  These 
modifications to the media allowed for the labeling studies to be conducted with 95% 
labeled glucose and glutamine.   
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To characterize cell growth, cell counts were taken every 24-h; growth profiles for the 
three cell lines are shown in Figure 3.2. All three cell lines exhibited significant 
reproducible lag phases when passaged in the control media, likely due to either the lower 
than normal glucose concentration and/or the lack of pyruvate in the media, despite 
previously being adapted to this media formulation for over three passages. The lag phases 
were 48-h for MCF 10A and MCF7 and 24-h for MDA-MB-231. After the lag phases, the 
culture media was exchanged to either fresh control media or the high-lactate media, as 
indicated at time 0 in Figure 3.2. For the labeling studies, 13C isotopes replaced the 
unlabeled glucose, glutamine, or lactate in the parallel cultures, at the same concentrations. 
After the lag phase and media exchange, cells from all culture conditions maintained 
exponential growth for 48-h, confirming that the high-lactate media did not significantly 
affect the growth rates of any cell line (p > 0.05). The exponential growth rates were 0.017 
h-1, 0.018 h-1, and 0.021 h-1 for the MCF 10A, MCF7, and MDA-MB-231 cell lines, 
respectively. Previously, 24-h was shown to be sufficient amount of time for isotopic 
steady-state to be reached for glycolysis and PPP metabolites from glucose labeling, while 
TCA metabolites also approach isotopic steady state from glutamine labeling within 24-h 
for mammalian cells (Ahn and Antoniewicz, 2013; Metallo et al., 2009). Therefore, in these 
studies, samples for intracellular MID analysis were taken 24-h after 13C-labeled media 
addition, indicated by the black boxes. The experiments were designed such that all 
cultures were in the mid-exponential phase at the time of harvest for intracellular MID 
analysis (Figure 3.2); this represents a pseudo-steady state, a condition consistent with the 
MFA assumptions (Stephanopoulos, 1999).  
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Figure 3.2. Growth profiles for MCF 10A, MCF7, and MDA-MB-231 cultures in control and 
high-lactate media.  The isotope media exchange occurred at 0-h and samples for MID analysis 
were taken at 24-h. Control media – u¢; high-lactate media – ¯¡£. A) MCF 10A – u¯; B) 
MCF7 – ¡; and C) MDA-MB-231 – ¢£.  Error bars represent standard deviations.  
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3.4.2. Glucose, lactate, and amino acid metabolism 
The control and high-lactate conditions exhibited equal growth rates within each 
cell line; however, high extracellular lactate resulted in reduced glucose utilization and 
reduced lactate accumulation for each cell line (p £ 0.05). Figure 3.3 shows the glucose 
and lactate concentration time profiles for each cell line and condition. The average glucose 
and lactate concentrations for all the 24-h and 48-h samples are listed with the standard 
deviations in Tables A1-A3 in Appendix A. Glucose and lactate fluxes were calculated 
using concentrations measured at 24-h and 48-h with the cell number at 24-h and the 
growth rates as per Eq.1 and are listed with standard deviations in Table 3.1. The standard 
deviations for the glucose and lactate fluxes were determine using Monte Carlo simulations 
due to sample independence (Forbes et al., 2006). The three control cultures exhibited 
higher glycolytic efficiencies compared to the high lactate cultures. Specifically, the 
glycolytic efficiencies for the control conditions were 1.7, 1.5, and 1.8 moles lactate 
produced per mole glucose consumed, respectively, for the MCF 10A, MCF7, and MDA-
MB-231 cell lines. The glycolytic efficiencies for the high-lactate conditions were 1.4, 0.8 
and 1.3 moles lactate produced per mole glucose consumed, respectively, for MCF 10A, 
MCF7, and MDA-MB-231 cell lines. In comparison, the theoretical maximum glycolytic 
efficiency is 2.0 moles lactate produced per mole glucose consumed (Zancan et al., 2010).   
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Figure 3.3. Glucose and lactate concentration and glucose, lactate, and glutamine flux 
profiles for the three breast cell line cultures in the control and high-lactate media 
shown relative to the time of the media exchange. A) Glucose concentrations; B) Change 
in lactate concentrations. Control media – u¢; high-lactate (HL) media – ¯¡£. MCF 
10A – u¯, MCF7 – ¡, and MDA-MB-231 – ¢£. C) Glucose, lactate, and glutamine 
fluxes. Control media – ¢;  high-lactate media – ¢. All error bars represent standard 
deviations
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Table 3.1. Measured extracellular fluxes for glucose, lactate, and amino acids for the MCF 10A MCF7, and MDA-MB-
23 cell lines in the control and high-lactate media. Standard deviations were determined using Monte Carlo simulations of the 
flux equation due to sample independence (Zancan et al., 2010). Negative values represent consumption rates and positive values 
represent production rates. 
Flux (nmol/106 cells×h) 
Cell line MCF 10A MCF7 MDA-MB-231 
Condition Control High-Lactate Control 
High-
Lactate Control 
High-
Lactate 
Metabolite Flux SD Flux SD Flux SD Flux SD Flux SD Flux SD 
Glucose 
(N=6) -222 51 -182 48 -208 44 -158 42 -337 65 -267 67 
Lactate (N=6) 379 56 254 55 318 54 131 32 603 108 342 87 
Glutamine 
(N=3) -48 18 -55 19 -53 19 -63 18 -44 21 -55 21 
Amino Acid (N=3)            
Alanine 11 1.5 11 1.9 14 2.3 12 2.3 10 1.8 8.2 2.0 
Aspartate 4.9 0.8 3.7 0.7 6.5 1.3 5.4 1.1 3.5 0.7 4.5 1.1 
Glutamate 12 1.9 10 1.8 11 2.0 12 2.3 8.5 1.6 10 2.5 
Glycine 6.2 1.6 5.7 3.1 9.6 3.0 9.4 3.2 7.8 2.1 7.0 2.6 
Isoleucine -8.3 2.3 -8.4 2.0 -9.5 2.0 -9.2 2.3 -4.7 1.6 -8.4 2.4 
Leucine -6.6 2.1 -7.5 2.7 -8.3 2.7 -7.5 2.2 -4.7 2.1 -8.8 2.4 
Methionine -2.6 1.0 -1.5 0.8 -3.1 1.1 -2.2 0.8 -1.4 0.5 -2.2 1.0 
Phenylalanine -4.7 1.9 -4.4 1.5 -3.8 1.3 -3.8 1.5 -3.4 0.9 -4.0 2.0 
Proline 1.5 0.3 1.3 0.3 2.8 0.5 2.3 0.5 0.8 0.2 1.3 0.3 
Serine -19 2.9 -20 4.0 -20 4.0 -23 5.2 -16 3.4 -20 5.0 
Threonine -1.9 1.1 -1.9 0.9 -1.2 0.5 -1.2 0.6 -1.2 0.6 -1.6 0.9 
Tyrosine -3.6 1.5 -3.7 1.9 -4.0 1.2 -3.8 1.5 -3.5 1.6 -3.8 1.8 
Valine -5.8 1.7 -6.2 1.6 -9.4 2.0 -10 3.3 -6.3 1.7 -9.1 2.3 
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Amino acid metabolism plays an important role in protein and nucleotide synthesis, 
and anaplerosis for mammalian cells. Extracellular amino acid concentrations were 
measured at 24-h and 48-h after the media exchange to quantify amino acid fluxes. Prior 
to calculating the amino acid fluxes, statistical analysis was conducted for the amino acid 
concentrations with respect to culture condition, cell line, and time. All the amino acid 
concentrations were statistical different with respect to time (p £ 0.05), such that fluxes 
could be calculated; however, many of the amino acid concentrations were not statistically 
different between the cell lines or culture condition (p > 0.05). For example, glutamine 
(Figure 3.3C), methionine, phenylalanine, and tyrosine concentrations were not 
significantly different between cell lines or between the culture conditions (p > 0.05). 
Whereas, aspartate, glutamate, glycine, and threonine concentrations were significantly 
different between cell lines (p £ 0.05), but were not significantly different within the same 
cell line between the control and high-lactate conditions (p > 0.05). In addition, leucine 
concentrations were not significantly different between cell lines (p > 0.05), but were 
significantly different between the control and high-lactate conditions (p £ 0.05). Table 3.1 
lists the calculated amino acid fluxes with the standard deviations determined using Monte 
Carlo simulations due to sample independence (Forbes et al., 2006). The average amino 
acid concentrations for all the 24-h and 48-h samples with the standard deviations are 
shown in Tables A1-A3 in Appendix A. 
 
3.4.3. Lactate tracer update 
To further understand the role of lactate as a metabolic substrate, cells were grown with 
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13C-labeled lactate for the high extracellular lactate conditions. This allowed for 
intracellular metabolite labeling due to lactate uptake and metabolism. Labeled 
intracellular metabolites measured included: lactate, pyruvate, alanine, citrate, AKG, 
glutamate, succinate, fumarate, malate, and aspartate (Figure 3.4A).  The intracellular 
lactate MIDs from [U-13C] lactate labeling of the MCF 10A, MCF7, and MDA-MB-231 
cultures exposed to 10 mM, 20 mM, and 20 mM extracellular lactate, respectively, are 
shown in Figure 3.4B.  MCF7 cells had the highest intracellular lactate isotopomer labeling. 
The TCA metabolites had low levels of labeling, which was primarily M1, for all cell lines. 
These results indicate that extracellular lactate was consumed by the cells even in the 
presence of glucose. For completeness, Figure C1 in Appendix C illustrates the 
intermediate TCA metabolite labeling from [U-13C] lactate, as the primary carbon source, 
as well as the TCA carbon labeling from unlabeled pyruvate and dilution of the labeled 
metabolite pools. All raw uncorrected lactate-derived MIDs for the three cell lines and for 
both conditions are provided in Tables D1-D3 in Appendix D.  
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Figure 3.4. Uptake of [U-13C] lactate by the three breast cell lines. A) Percent carbon 
labeling for intracellular metabolites due to extracellular [U-13C] lactate in the media. MCF 
10A – ¢; MCF7 – ¢; and MDA-MB-231 – ¢. B) Lactate intracellular mass isotopomer 
distributions (MIDs) due to extracellular [U-13C] lactate. Control media – ¢;  high-lactate 
media – ¢.  Error bars represent standard deviations.  
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3.4.4. Intracellular labeling from [1,2-13C] glucose and [U-13C] glutamine 
 [1,2-13C] glucose and [U-13C] glutamine isotopes were used for the parallel labeling 
studies to characterize the relative metabolic contribution of each substrate and estimate 
intracellular metabolic fluxes for glycolysis, the PPP, and the TCA cycle. These isotopes 
have previously been shown to be suitable tracers for characterizing fluxes for mammalian 
cells through glycolysis and the PPP ([1,2-13C] glucose) and the TCA cycle ([U-13C] 
glutamine) pathways (Metallo et al., 2009). The percent isotopomer labeling (100% - M0) 
was calculated for each metabolite using MIDs corrected for natural abundance (Ahn and 
Antoniewicz, 2013; Fernandez et al., 1996). Using [1,2-13C] glucose, the percent isotope 
labeling for DHAP, 3PG, pyruvate, alanine, and lactate were 40% or higher for all three 
cell lines. No significant differences were observed for MIDs from glycolytic metabolites 
(DHAP, 3PG, pyruvate, alanine, and lactate) between the three cell lines and between the 
control and high-lactate conditions. These results reflect the consistently high flux through 
glycolysis for each of the three cell lines and the equivalent growth rates between 
conditions within a given cell line. These results also confirm that the 24-h labeling time 
was sufficient to reach isotopic steady state for [1,2-13C] glucose. The intracellular MID 
profiles for all three cell lines are included in Figure E1 in Appendix E. All raw uncorrected 
MIDs for each cell line and condition are provided in Tables D1-D3 in Appendix D. 
Additionally, all the measured MIDs, corrected for natural isotope abundance, are shown 
in Figures E1 and E2 in Appendix E. 
For the three cell lines and both conditions, glutamine, AKG, and glutamate were 
highly labeled from [U-13C] glutamine. Using [U-13C] glutamine, the observed isotopomer 
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labeling for intracellular glutamine, AKG and glutamate was over 70%. Figure 3.5 shows 
the control and high lactate intracellular MID profiles for MDA-MB-231 from [U-13C] 
glutamine, as an example, for the TCA metabolites. Pyruvate and lactate were minimally 
enriched from the glutamine isotope across the cell lines and both conditions, where Figure 
3.5 shows the MDA-MB-231 data. All the MID profiles for the three cells lines for both 
conditions are shown in Figure E2 in Appendix E. For MCF 10A and MDA-MB-231, the 
high-lactate condition resulted in a higher percent isotope labeling of pyruvate and lactate 
as compared to the control condition. For MCF7, the trend was reversed – the percent 
isotope labeling of pyruvate and lactate were lower in high-lactate condition compared to 
the control condition. 
The TCA metabolites succinate, fumarate, malate, and citrate were all significantly 
labeled by the [U-13C] glutamine tracer. The MID profiles for these metabolites were 
similar for all three cell lines; however, citrate MIDs were significantly different between 
the control and high-lactate cultures within a cell line, indicating the effect of lactate was 
significant. More specifically, a significant increase in M5 citrate labeling was observed in 
the high-lactate conditions for all three cell lines (Figure 3.6A). Increased M5 labeling also 
corresponded with decreased unlabeled citrate and increased percent isotopomer labeling. 
Succinate, fumarate, and malate were mostly M2 and M4 labeled from 13C-glutamine 
labeling, as shown in Figure 3.5 for MDA-MB-23. Figure E2 in Appendix E shows the 
labeling for the other two cell lines.   
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Figure 3.5. Mass isotope distributions (MIDs) for the TCA metabolites from the [U-
13C] glutamine labeling of the MDA-MB-231 cells cultured in the control and high-
lactate media. A) Control media; B) High-lactate media.  
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Figure 3.6. Evidence of reductive carboxylation of a-ketoglutarate (AKG) to citrate 
from [U-13C] glutamine labeling. A) Fractional abundance of M5 labeled citrate for MCF 
10A, MCF7, and MDA-MB-231 cells from the control (¢) and high-lactate media (¢). 
Error bars represent standard deviations. The asterisk (*) indicates the fractional 
abundances were significantly different between the control and high-lactate media per cell 
line (p £ 0.01). B) Carbon atom transition for TCA metabolites from [U-13C] glutamine. 
The black lines depict oxidative glutamine metabolism that results in M4 citrate. The 
dashed red lines depict reductive glutamine metabolism that results in M5 citrate. For 
clarity, some reaction pathways were condensed.  
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3.4.5. Metabolic flux analysis 
To quantify the metabolic activity, Metran was used to predict the intracellular 
metabolite fluxes for each of the three cell lines under both conditions, six simulations in 
total. The experimental procedure section describes in detail the intracellular MIDs and 
extracellular fluxes used for the simulations. Each of the Metran model simulations 
converged to acceptable SSRes except for the MCF7 control condition, which slightly 
overfit. This overfitting was traced back to the high standard error for the glutamine MIDs 
from the biological replicates, where Tables D1 and D3 in Appendix D contain all the raw 
MID values for the three cell lines. This particular MID had a higher standard error than 
typically observed. Review of the data could not identify an experimental error, nor did 
this point meet outlier exclusion test criteria.  Thus, this data point could not be discarded. 
Nevertheless, the effect of excluding this point on the model was examined to determine 
the effect this one data point had on the simulated flux values. When the Metran model 
simulation was conducted for the MCF7 control condition with only this metabolite MID 
standard error value replaced with the 0.6 mol% minimum machine error, the Metran 
simulation converged to an acceptable SSRes value. More importantly, there was no 
significant difference obtained for the simulated flux values. As the flux values are the 
critical outcome, the Metran simulations were conducted using the biological replicate 
MIDs (with the slight overfit SSRes) for the comparisons. The metabolic flux maps were 
generated for the three cell lines under each of the culture conditions, six in total using the 
actual biological replicates, as the flux outcomes were not significantly effected, even 
though the SSRes was overfit for MCF7. The flux maps are shown with standard deviations 
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for the cell lines and conditions in Figures F1-F3 in Appendix F. The list of metabolic 
fluxes for all Metran simulations are provided in Tables G1-G7 in Appendix G, including 
the MCF7 simulation with the 0.6 mol% standard error for the single biological replicate.  
As a part of the validation step, measured MIDs from the parallel glucose and glutamine 
tracer labeling experiments and extracellular flux measurements were compared to the 
simulated results from the model to further investigate the effects of lactate on metabolism 
and to determine cell line specific effects (Ahn and Antoniewicz, 2013; Leighty and 
Antoniewicz, 2012). The simulated fluxes for major pathway reactions for each cell line 
and condition are shown in Figure 3.7. As expected, glycolytic reactions exhibited the 
highest fluxes in both the control and high-lactate cultures. In all three cell lines, the 
glucose consumption and lactate production rates decreased due to high-lactate exposure. 
In addition, MFA simulations predicted slightly decreased PPP fluxes for all three cell lines 
due to high-lactate. As mentioned previously, increased M3 labeling of pyruvate and 
lactate from glutamine was observed for MCF 10A and MDA-MB-231 under high lactate, 
while MCF7 under high lactate resulted in a slight decrease in M3 labeling. This was 
reflected in the MFA simulations as increased malic enzyme fluxes, conversion of malate 
to pyruvate, for the MCF 10A and MDA-MB-231 cell lines under high lactate and a 
decreased malic enzyme flux for the MCF7 under high lactate. Furthermore, MDA-MB-
231 cells exhibited elevated anaplerotic and TCA cycle fluxes – pyruvate carboxylase (PC), 
glutamate dehydrogenase (GDH), pyruvate dehydrogenase (PDH), and citrate synthase 
(CS) – under high lactate, while MCF 10A and MCF7 cells exhibited similar anaplerotic 
and TCA cycle fluxes between conditions (Figure 3.7).  
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Figure 3.7. Comparison of key metabolic fluxes for MCF 10A (A), MCF7 (B), and 
MDA-MB-231 (C). Abbreviations: PPP, pentose phosphate pathway; PDH, pyruvate 
dehydrogenase; CS, citrate synthase; PC, pyruvate carboxylase; GDH/AT, glutamate 
dehydrogenase/aminotransferase; ME, malic enzyme. Error bars represent standard 
deviations. The asterisk (*) indicates the simulated fluxes were significantly different 
between the control and high-lactate conditions (p £ 0.05).  
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3.5. Discussion 
In this study, the metabolic responses of three breast cell lines – MCF 10A, MCF7, and 
MDA-MB-231 – to high-lactate were examined using 13C-MFA. MCF 10A is a non-
tumorous epithelial breast cell line, MCF7 is a tumorigenic, luminal breast cancer cell line, 
and MDA-MB-231 is a metastatic, basal breast cancer cell line. 13C-glucose, 13C-glutamine, 
and 13C-lactate tracers were used in parallel experiments to determine the relative 
contribution of each substrate to intracellular metabolism. [1,2-13C] glucose and [U-13C] 
glutamine were selected as tracers, since both have previously been shown to be suitable 
for characterizing fluxes through glycolysis, the PPP, and TCA cycle pathways for 
mammalian cells (Ahn and Antoniewicz, 2013; Crown et al., 2012; Crown and 
Antoniewicz, 2012; Metallo et al., 2009). In addition, the [U-13C] lactate tracer was used 
to determine the metabolic contribution of lactate to breast cancer cell metabolism. For 
metabolic flux analysis, a detailed metabolic network model was constructed for breast 
cancer cells based a CHO cell metabolic network model (Ahn and Antoniewicz, 2013). 
The intracellular MIDs from parallel labeling experiments and extracellular flux 
measurements were paired with a mammalian metabolic network model to develop 
intracellular metabolic flux maps for each cell line under the control and high-lactate 
conditions.  
As expected, the high-lactate condition caused a reduction in glucose consumption and 
lactate production for all cell lines examined (Figure 3.3). This is consistent with previous 
findings that accumulated lactate acts as a glycolytic signaling molecule and can down-
regulate phosphofructokinase activity, a key glycolytic regulatory enzyme, resulting in 
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decreased rates of glucose consumption (Leite et al., 2007). In addition, lactate 
consumption was observed in the high-lactate condition, as illustrated by the [U-13C] 
lactate tracer uptake in each cell line (Figure 3.4). Metabolic flexibility appears to play an 
important role in enabling cancer to thrive and survive in harsh environments, including 
inflammation, oxidative stress, and extreme nutrient and oxygen fluctuations (Dayem et al., 
2010; Pavlides et al., 2010; Reuter et al., 2010). As a result, the ability to metabolize higher 
levels of lactate offers potential advantages to cancer cells. The higher fractional abundance 
of intracellular M3 lactate labeling for MCF7 compared to MCF 10A and MDA-MB-231 
in this study (Figure 3.4B) is consistent with previous finding that MCF7 display higher 
expression of monocarboxylate transporter 1 (MCT1), the lactate transporter associated 
with increased transport of lactate into the cell (Kennedy et al., 2013; Sonveaux et al., 
2008). Furthermore, since TCA metabolites were only observed to be minimally labeled 
by lactate, this suggests that lactate was not a major source of acetyl-CoA. Also, labeled 
TCA metabolite pools were diluted by the metabolism of unlabeled pyruvate. Nevertheless, 
the intracellular MIDs from the high-lactate cultures demonstrated that each cell line 
consumed and metabolized a significant amount of labeled lactate, most likely to 
compensate for the decreased carbon flux through glycolysis due to decreased glucose 
consumption. 
Intracellular metabolite labeling from [U-13C] glutamine was similar for the control and 
high lactate conditions for each cell line, with over 50% isotope labeling of all TCA cycle 
metabolites. Figure 3.5 shows the labeling for the MDA-MB-231 cells, where Figure E2 
in Appendix E shows the labeling for all three cell lines. Conversely, a slight increase in 
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pyruvate and lactate labeling from glutamine was observed in MCF 10A and MDA-MB-
231 due to high-lactate. This suggests that glutamine anaplerosis was enhanced to provide 
energy via oxidative phosphorylation, and then secreted as alanine and lactate in response 
to decreased glucose consumption and decreased energy generation via glycolysis. 
Interestingly, high-lactate also caused an increase in M5 citrate labeling for each cell line 
(Figure 3.6). The increased M5 citrate labeling in the high-lactate conditions suggests the 
presence of reductive carboxylation of glutamine via the isocitrate dehydrogenase (IDH) 
reaction, as shown as a dashed red line in Figure 3.6B. Also, the decrease in M0 citrate 
indicates an increase in glutamine catabolism through the TCA cycle. Figure 3.5 shows the 
labeling for the MDA-MB-231 cells, where Figure E2 in Appendix E shows the labeling 
for all three cell lines. Furthermore, production of citrate from AKG via the IDH reaction 
– characterized by the exchange flux between AKG and citrate – increased for each cell 
line due to high-lactate. These results suggest that the IDH reaction is highly reversible for 
each breast cell line examined. The MFA simulations also suggested cell line specific TCA 
cycle metabolic responses due to high-lactate, with major anaplerotic and TCA fluxes 
remaining relatively unchanged for MCF 10A cells and MCF7 cells, while increasing for 
MDA-MB-231 cells (Figure 3.7). In particular, the MFA model predicted increased fluxes 
through pyruvate dehydrogenase (PDH) and citrate synthase (CS) for MDA-MB-231 in 
high lactate; this suggests a more active oxidative mitochondrial metabolism for MDA-
MB-231 cells under high lactate, and is consistent with previous work showing that lactate 
promotes a metastatic phenotype (Bonuccelli et al., 2010; Martinez-Outschoorn et al., 
2011). 
 76 
Increases in fumarate, malate, and aspartate M3 labeling have also previously been 
observed with increased reductive carboxylation to support lipid synthesis in cancer cells 
grown under hypoxic conditions (Fan et al., 2013; Fendt et al., 2013; Grassian et al., 2014; 
Jiang et al., 2016; Metallo et al., 2012; Metallo et al., 2009; Wise et al., 2011). This would 
result from [U-13C] glutamine serving as the main source of citrate via reductive 
carboxylation. Yet, M3 labeling of fumarate, malate, and aspartate did not significantly 
increase in this study. In this study, however, fumarate, malate, and aspartate were 
primarily M2 and M4 labeled, as shown in Figure 3.5 for the MDA-MB-231 cell line and 
shown in Figure E2 in Appendix E for all three cell lines. This indicates that the TCA 
metabolites were mainly derived from the glucose-derived pyruvate via oxidative 
metabolism rather than reductive glutamine metabolism. This implies that glutamine via 
reductive carboxylation was not the major carbon source for citrate synthesis in either 
condition. These observations agree with previous studies in which reductive carboxylation 
was observed for cancer cells without shifting the net IDH flux from oxidative to reductive 
glutamine metabolism in the TCA cycle (Fan et al., 2013; Jiang et al., 2016). Jiang et al. 
2016 also previously showed that increases in M5 citrate labeling without accompanied 
changes to M3 fumarate and malate labeling is indicative of reductive carboxylation for 
citrate and AKG shuttling rather than for lipid synthesis. By shuttling AKG and citrate 
from the mitochondria to the cytosol and back, cells can shuffle redox equivalents to 
maintain a net-oxidative TCA metabolism (Jiang et al., 2016). This might suggest that in 
high-lactate conditions, cancer cells utilize the reversible NADPH-depended IDH reactions 
(1 and 2) rather than the NAD+-dependent reaction (IDH3) to compensate for the loss in 
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NAD+ generation as a result of decreased lactate production (Jiang et al., 2016). Recall, 
the two more aggressive breast cancer cell lines examined in this study maintained 
equivalent exponential growth rates to the control cultures at 20 mM lactate, while the 
MCF 10A cell line (a non-tumorigenic epithelial cell line) failed to grow in the 20 mM 
lactate condition, but could maintain equivalent exponential growth rates with the control 
cultures at 10 mM lactate.  
Mammalian cells, including several cancer cell lines, have been observed to rely on 
reductive carboxylation of glutamine for lipid synthesis under hypoxia (Metallo et al., 2009; 
Wise et al., 2011). Reductive carboxylation has also been suggested to be a cellular 
response to environmental stresses, such as reactive oxygen species (ROS) regulation 
(Fendt et al., 2013; Jiang et al., 2016). These previous studies differ with the current work 
in several ways. Mainly, the breast cell lines in this work were cultured in normoxia and in 
an experimental setup which maintained similar growth rates even under stress. This meant 
that the high-lactate MCF 10A cultures contained 10 mM lactate initially, whereas the 
high-lactate MCF7 and MDA-MB-231 contained 20 mM lactate initially. In contrast to our 
results, Fendt et al. 2013 observed a net consumption of lactate for a lung carcinoma cell 
line (A549) grown under normoxia in 25 mM supplemented media (Fendt et al., 2013). In 
addition, Fendt et al. 2013 observed a decreased contribution of reductive glutamine 
metabolism to citrate synthesis; however, there was no mention if the growth rates were 
matched between the control and lactate stress conditions (Fendt et al., 2013). Different 
growth rates could alter the observed metabolic fluxes as there is not a standardized 
normalization method for fluxes.  The non-growth inhibitory lactate concentrations used 
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in this study may very well have different effects on metabolism than lactate concentrations 
that have inhibitory growth effects. This work is the first to observe reductive glutamine 
metabolism due to high extracellular lactate in normoxia, but it may be a common 
phenomenon, as there are many non-inhibitory levels of waste products within an organism. 
While cancer cells have long been known to produce high levels of lactate, especially 
in hypoxic tumor regions, cancer cells can also consume and metabolize lactate as a 
substrate (Kennedy et al., 2013; Pavlides et al., 2009; Sonveaux et al., 2008). The findings 
in this study highlight that high extracellular lactate induces a response mechanism in both 
non-cancer and cancer cells, which is similar to hypoxia or other mitochondrial stresses, 
even in the presence of sufficient oxygen. In addition, lactate supplementation resulted in 
elevated oxidative mitochondrial metabolism activity for MDA-MB-231 cells, as shown 
from the 13C-MFA simulations, and is consistent with previous work showing that lactate 
promotes a metastatic phenotype (Bonuccelli et al., 2010; Martinez-Outschoorn et al., 
2011). These results suggest that modulation of mitochondrial metabolism and reductive 
carboxylation are cellular metabolic responses to stress, including high extracellular lactate 
and hypoxia. The observed response could also contribute to the metabolic flexibility of 
cancer cells and allow for adaptation to high-lactate exposure. Additionally, the response 
observed is lactate dependent and cell line independent, under growth conditions where the 
cells can maintain exponential growth under the lactate stress.  
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CHAPTER FOUR 
EFFECTS OF LOW GLUCOSE AND HIGH LACTATE CONCENTRATIONS 
ON INDUCED PLURIPOTENT STEM CELL METABOLISM 
 
4.1. Abstract 
Human induced pluripotent stem cells (iPSCs) have the potential to dramatically 
improve cell-based therapies in the near future. Yet, to meet rising demands and become 
clinically impactful, sufficient quantities of high quality iPSCs must be generated, a task 
that exceeds current capabilities. To meet these needs, a comprehensive understanding of 
the metabolic and phenotypic responses of iPSCs to different environmental conditions is 
essential. iPSCs rely primarily on aerobic glycolysis to support rapid proliferation in vitro. 
Previous studies have suggested that lactate accumulation is solely a wasteful and 
inhibitory metabolic process for iPSCs. However, the potential impact of lactate 
accumulation on intracellular iPSC metabolism has not been determined. Therefore, the 
goals of this work were to 1) understand the role of lactate as a potential metabolic substrate 
to support iPSC proliferation, and 2) determine whether lactate production could be 
modulated by low glucose feeding strategies. The culture media concentrations represent 
stages of stem cell bioprocessing; the control and low glucose conditions represent a range 
of initial media concentrations during the batch phase, and the two high lactate conditions 
represent media concentrations during fed-batch culture prior to and after bolus glucose 
feed. These concentration ranges are also representative of glucose and lactate conditions 
that cells would encounter at various locations within 3D cell aggregates when cultured in 
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suspension. Parallel labeling metabolic flux analysis (13C-MFA) was used to quantify 
intracellular fluxes for K3 iPSCs under normal glucose, low glucose, and two high 
extracellular lactate culture conditions. In addition, [U-13C] lactate was used as an isotopic 
tracer for the high extracellular lactate cultures to provide information regarding lactate 
catabolism. High extracellular lactate resulted in decreased glucose consumption and 
lactate production, while glucose concentration alone did not affect rates of aerobic 
glycolysis. Moreover, for the high lactate cultures, lactate significantly contributed as a 
metabolic substrate to support oxidative mitochondrial metabolism for iPSCs. These 
results demonstrate that iPSCs can employ dual consumption of glucose and lactate to 
support growth. In addition, this is the first study to determine the intracellular contribution 
of lactate to proliferative iPSC metabolism. These results provide insight into the metabolic 
flexibility of iPSCs with respect to lactate metabolism and suggest that iPSCs possess the 
capacity to metabolize lactate to support exponential growth. Also, as iPSC cultures move 
towards pH-controlled bioreactors, these results suggest that lactate accumulation alone 
does not adversely impact iPSC proliferation at the concentrations examined in this study.  
 
4.2. Introduction 
Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) 
are considered to be dependent on aerobic glycolysis and lactate fermentation for energy 
production (Gu et al., 2016; Varum et al., 2011; Zhang et al., 2011). In addition, during 
somatic cell nuclear reprogramming, iPSCs have been shown to shift from oxidative 
phosphorylation to aerobic glycolysis upon the acquisition of pluripotency (DeBerardinis 
 82 
et al., 2008; Folmes et al., 2012; Folmes et al., 2011; Ryall et al., 2015). Stimulation of 
glycolysis also was observed to promote maintenance of stemness for pluripotent stem cells 
(PSCs) and augmented somatic reprogramming to iPSCs, while inhibition of specific 
glycolytic reactions in turn inhibited reprogramming (Ezashi et al., 2005; Folmes et al., 
2011; Mohyeldin et al., 2010). On the other hand, inhibition of glycolysis was shown to 
promote spontaneous differentiation, suggesting that metabolism plays a functional role in 
regulating cell self-renewal and differentiation (Gu et al., 2016; Moussaieff et al., 2015; 
Zhang et al., 2011). This reliance on glycolysis over oxidative phosphorylation in well- 
oxygenated systems is a metabolic phenotype called the Warburg effect, and is also a 
characteristic of cancer cell metabolism (Cairns et al., 2011; DeBerardinis et al., 2008; 
Vander Heiden et al., 2009; Warburg, 1956). However, unlike cancer cells, which can 
catabolize lactate for energy, PSCs are hypothesized to be highly sensitive to lactate 
accumulation (Chen et al., 2010; Kennedy and Dewhirst, 2010; Kennedy et al., 2013; 
Martinez-Outschoorn et al., 2011; Nath et al., 2017; Ouyang et al., 2007; Pavlides et al., 
2010; Sonveaux et al., 2008). Specifically, hESCs exhibited decreased pluripotency after 
serial passage in 11 mM lactate-containing media (Chen et al., 2010). Moreover, elevated 
lactate and glucose-depleted media has previously been shown to preferentially induce 
cardiomyocyte differentiation for iPSCs (Tohyama et al., 2013). Therefore, PSC culture 
techniques require frequent media exchange to alleviate lactate stresses (Olmer et al., 2012; 
Wang et al., 2013). Since lactate accumulation appears to be an unavoidable byproduct of 
iPSC metabolism, deciphering the role of accumulated extracellular lactate on intracellular 
iPSC metabolism and understanding the regulatory role of glucose concentration to 
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modulate lactate production are crucial.  
Metabolic flux analysis (MFA) is a powerful computational technique used to 
determine intracellular metabolic pathway fluxes (Bonarius et al., 1997; Stephanopoulos, 
1999). In MFA, intracellular fluxes are determined by coupling extracellular metabolite 
uptake and secretion rates with a discrete stoichiometric metabolic network model 
(Stephanopoulos et al., 1998). This technique is frequently used to compare metabolism of 
different cell lines and cell culture conditions to assess the activity of individual pathways 
under each condition (Niklas and Heinzle, 2011). There are two primary MFA approaches: 
stoichiometric MFA, which uses mass balance to determine intracellular metabolic fluxes 
from extracellular consumption and production fluxes, and 13C-MFA, in which stable 
isotope tracers are used to provide intracellular measurements to resolve fluxes through 
more complex metabolic pathways (Sa et al., 2015; Sauer, 2006; Stephanopoulos et al., 
1998). 
The aims of this study were to determine the metabolic contribution of glucose and 
extracellular lactate to iPSC metabolism, and in particular, to determine 1) whether lactate 
can serve as a metabolic substrate in support of iPSC proliferation and 2) if glucose 
concentration can modulate lactate production. K3 iPSCs were grown in both low and 
normal glucose-containing media and with and without extracellular lactate additions. The 
low glucose and high lactate concentrations were selected such that exponential growth 
rates for the cultures were maintained across the four conditions, as would be desired in 
large-scale cultivation. The pluripotency and differentiation capacity of the iPSCs were 
assessed from each culture condition to determine if glucose or lactate concentration 
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impacted these phenotypes. Parallel labeling experiments were conducted with [1,2-13C] 
glucose, [U-13C] L-glutamine, and [U-13C] sodium L-lactate, while the control and low 
glucose cultures were labeled with [1,2-13C] glucose and [U-13C] L-glutamine only, since 
lactate was not added to these cultures. Metabolic flux maps were generated for each 
condition to compare the resulting flux distributions from culturing iPSCs in low glucose 
and high lactate culture media. To our knowledge, this is the first 13C-MFA study to 
investigate the metabolic flexibility of iPSCs respect to lactate catabolism. The 
implications of these results to iPSC bioprocessing will be discussed. 
 
4.3. Materials and Methods 
4.3.1. Cell culture 
K3 iPSCs were donated by Dr. Stephen A. Duncan at the Medical University of South 
Carolina. The K3 iPSCs were generated by transient transfection of human foreskin 
fibroblast cells (ATCC CRL2097) using plasmids coding for Oct4, Sox2, Nanog, and 
Lin28 (Si-Tayeb et al., 2010). In this study, K3 iPSCs were grown on non-tissue culture 
treated 6-well plates and 60 mm cell culture dishes (Corning Inc., Corning, NY) coated 
with 10 µg/mL StemAdhereTM (Primorigen, Cat. no. S2071-500UG) per manufacturer 
instructions. StemAdhereTM is a fully defined recombinant surface matrix composed of a 
fusion protein consisting of E-cadherin and the Fc domain of IgG; this surface matrix has 
previously been shown to be an effective method for culturing human iPSCs (hiPSCs) 
(Nagaoka et al., 2010). Cultures were incubated at 37°C and in a humidified 5% CO2 
incubator in Essential 8 FlexTM (E8 Flex) media (Thermo Fisher Scientific, Waltham, MA). 
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The working volume of media was 3 mL per well in the 6-well plates and 6.5 mL for the 
60 mm cell culture dishes. Cells were maintained by passaging every three days at 1:6 and 
1:12 depending on confluency. To passage cells, the cells were detached from the surface 
with Accutase (Sigma-Aldrich, St. Louis, MO) for 2 min at 37°C and washed with 
phosphate buffered saline (PBS) without calcium or magnesium (Corning Inc., Corning, 
NY). Cells were centrifuged at 500 x g for 5 min and resuspended in fresh E8 Flex 
supplemented with 10 µM Y-27632 – rho-associated, coiled-coil containing protein kinase 
inhibitor (ROCKi) (Stem Cell Technologies, Vancouver, Canada). After 24-h, the media 
was replaced with E8 Flex without ROCKi. For the cell growth and parallel labeling 
experiments, E8 Flex medium without glucose and glutamine was used. The initial media 
concentrations are listed in Table 4.1 for the four culture conditions. The control growth 
media represents standard E8 Flex media concentrations. D-glucose (Fisher Scientific, 
Hampton, NH), L-glutamine (Corning Inc., Corning, NY), sodium L-lactate (Sigma-
Aldrich, St. Louis, MO), and sodium chloride (Fisher Scientific, Hampton, NH) were 
added to unlabeled experiments at concentrations as indicated in Table 4.1. [1,2-13C] D-
glucose (99% enrichment), [U-13C] L-glutamine (99% enrichment), and [U-13C] sodium 
L-lactate (98% enrichment) isotope tracers were used for the parallel labeling experiments 
(Cambridge Isotope Laboratories, Tewksbury, MA), and added to the labeled experiments 
at concentrations matching E8 Flex or as indicated.  
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Table 4.1. Media formulations for iPSC cultures examined in 13C-MFA studies. The 
initial glucose, glutamine, sodium L-lactate, and added sodium chloride concentrations are 
listed for the time corresponding to the isotope labeling (media exchange) addition. Sodium 
chloride was added to balance osmolarity in cultures without sodium lactate.  
 
 13C-MFA Growth Media 
 
Control High Lactate Low Glucose Low Glucose + High Lactate 
Component Concentrations (mM) 
Glucose 18.3  18.3 5.6 5.6 
L-glutamine 2.75 2.75 2.75 2.75 
Sodium L-lactate - 20.0 - 20.0 
Added Sodium chloride + 20.0 - + 20.0 - 
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4.3.2. Cell growth and parallel labeling experiments 
For the growth and isotope labeling studies, K3 iPSCs were initially seeded at 1.0 x 104 
cells/cm2 in E8 Flex with ROCKi to allow for cell attachment and reduce apoptosis 
associated with single cell detachment and passaging (Watanabe et al., 2007). After 24-h, 
a media exchange was performed, and the growth media was introduced to the parallel 6-
well plates and 60 mm cell culture dishes (indicated as Time 0-h in Figure 4.1). For clarity, 
a schematic of the full experimental setup is shown in Figure 4.1. In all, six 6-well plates 
and eighteen 60 mm cell culture dishes were used per high lactate and low glucose + high 
lactate conditions, and six 6-well plates and twelve 60 mm dishes were used per control 
and low glucose conditions. The control growth media represented standard E8 Flex media 
concentrations. Inoculum were used across multiple conditions, such that no condition had 
only a single inoculum. To limit media carryover, cells were washed with PBS for 5 min 
at room temperature prior to adding the growth media. Cell numbers and extracellular 
metabolite concentrations were measured at five time points: 0, 12, 24, 36, and 48-h after 
the media exchange. Cell numbers, glucose, lactate, pyruvate, ammonia, and amino acid 
extracellular measurements were obtained from the 6-well plates. The intracellular mass 
isotope distributions (MIDs) were obtained from 60 mm cell culture dishes at 24-h and 48-
h. The control and low glucose cultures had parallel labeling with [1,2-13C] glucose and 
[U-13C] L-glutamine, whereas the high lactate and low glucose + high lactate cultures had 
parallel labeling with [1,2-13C] glucose, [U-13C] L-glutamine, and [U-13C] sodium L-
lactate.  
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Figure 4.1. Parallel isotope labeling and culture replicate setup for each condition. All 
6-well plates and 60 mm cell culture dishes were seeded in parallel 24 hours prior to the 
media exchange (Time 0-h). The times shown indicate when the plates or dishes were 
harvested for analysis relative to the isotope media exchange. Isotopic labeling is 
graphically shown by shading (clear – no isotope, blue – [1,2-13C] glucose, orange – [U-
13C] L-glutamine, and red – [U-13C] sodium lactate). The 60 mm cell culture dishes 
contained isotopically labeled media. Six wells of a 6-well plate were used to measure cell 
number, glucose, lactate, pyruvate, and amino acid concentrations. The 60 mm cell culture 
dishes were harvested for intracellular isotope MID values.  
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4.3.3. Cell numbers and extracellular metabolite concentrations 
 Cell numbers were obtained using the Vi-Cell XR cell viability analyzer (Beckman 
Coulter, Brea, CA). Extracellular glucose, lactate, pyruvate, glutamine, glutamate, and 
ammonia concentrations were measured using a Cedex Bio (Roche Diagnostics, 
Mannheim, Germany).  
 
4.3.4. Derivatization and GC-FID analysis of extracellular amino acids 
Extracellular amino acid concentrations were measured from the cell culture 
supernatant by derivatization using the EZ:faastTM amino acid analysis kit (Phenomenex, 
Torrance, CA). Standard solutions were prepared for amino acids – alanine, asparagine, 
aspartic acid, glycine, histidine, isoleucine, leucine, lysine, phenylalanine, proline, serine, 
threonine, tryptophan, tyrosine, and valine – to a final concentration of 10 mM in water 
and pH adjusted to below pH 7.0. Samples were prepared by combining 150 µL of cell 
culture supernatant and 50 µL of an internal standard (200 µM norvaline). Sample 
derivatization was performed as per manufacturer instructions (Badawy et al., 2008). 
Standard curves were generated for each amino acid. 
 Derivatized samples were analyzed using a gas chromatography-flame ionization 
detector (GC-FID) instrument (Agilent Technologies, 7890A GC system) equipped with 
an autosampler (Agilent Technologies, 7683B Series Injector). A Zebron ZB-AAA 10 m 
x 0.25 mm capillary GC column was used. The initial column temperature was 60°C and 
increased by 32°C/min to a final temperature of 320°C. The FID detector temperature was 
held at 320°C and 2 µL of sample was injected at an injection temperature of 250°C and a 
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split ratio of 1:15 using a 10 µL syringe (Agilent Technologies, Part # 5181-1267). Helium 
was used as the carrier gas at 1.5 mL/min constant flow.   
 
4.3.5. Extraction of intracellular metabolites 
At 24- and 48-h, the culture media was removed from the 60 mm cell culture dishes to 
remove debris and detached cells. The attached cells were washed with 3 mL of cold PBS 
(4°C) for 5 min. Then, 1 mL of cold methanol (-20°C, LC/MS grade) was added and 
incubated on ice for 5 min. Adherent cells were removed from the dishes using a cell 
scraper. The collected cell suspensions from the dishes were then transferred to 15 mL 
glass centrifuge tubes (with Teflon-sealed caps) which contained 1 mL of chloroform. The 
chloroform, methanol, and cell mixtures were vortexed vigorously for 10 s. Next, 1 mL of 
water was added to each tube, and samples were vortexed vigorously for 1 min. All sample 
tubes were stored overnight at 4°C. After overnight storage, all tubes were centrifuged at 
4000 x g at 4°C for 20 min to fully separate the aqueous and organic phases. The upper 
aqueous phase (methanol and water) contained the polar intracellular metabolites and the 
lower organic phase (chloroform) contained the non-polar metabolites (fatty acids). Each 
phase was transferred to separate GC vials for further analysis. The metabolism quenching 
and separation procedure was adapted from Ahn and Antoniewicz (2013). 
 
4.3.6. Derivatization and GC-MS analysis of intracellular metabolites 
The aqueous phases were evaporated to dryness using a CentriVap (Labconco, Kansas, 
MO). Dried samples were then dissolved in 10 μL of methoxyamine hydrochloride (Sigma-
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Aldrich, St. Louis, MO) and incubated with shaking at 30°C and 1000 rpm for 90 min in 
an EchoThermTM SC20 Orbital Mixing Dry Bath (Torrey Pines Scientific, Inc., Carlsbad 
CA). Next, 90 μL of N-methyl-N-(tert-butyldimethylsilyl)-trifluoroacetamide (MTBSTFA) 
(Sigma-Aldrich, St. Louis, MO) was added to samples to initiate trimethylsilylation. The 
trimethylsilylation reaction was incubated with shaking at 37°C and 1000 rpm for 60 min. 
MTBSTFA containing C8–C30 fatty acid methyl esters (FAMEs) was used as a set of 
internal standards to determine retention times. Derivatized samples were submitted to a 
Leco Pegasus IV time-of-flight (TOF) MS (Leco Corporation) with electron ionization 
mode at −70 eV. A Rtx-5Sil MS column (30 m x 0.25 mm, 0.25 μm) was used. The initial 
temperature was 50°C and held for 1 min, ramped up to 330°C at 20°C/min, then held for 
5 min. The flow rate was set to 1.0 mL/min and 0.5 μL of sample was injected. Mass 
spectrometry detector voltage was 1525 V. Data was acquired at 17 spectra/s with scan 
range from 85 to 600 Da. Ion source temperature was 250°C and transfer line temperature 
was 280°C. Standard mixture and blank samples were injected at the beginning of the 
analysis and every ten samples throughout the analysis for quality control. The GC-MS 
analysis was conducted at the West Coast Metabolomics Center at the University of 
California, Davis. 
 
4.3.7. Determination of biomass specific consumption and production rates 
Extracellular metabolite fluxes were calculated using the Extracellular Time-Course 
Analysis (ETA) software package available for Matlab (Murphy and Young, 2013). The 
ETA software uses a Gaussian error propagation approach to calculate fluxes and standard 
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errors from averaged time series data (Murphy and Young, 2013). This software was used 
to assess the goodness-of-fit of measured experimental data to a linear regression model. 
The glutamine decomposition rate constant (k) was determined for E8-Flex media to be 
0.00178 h-1 using media without cells held at 37°C for 72-h. First-order glutamine 
degradation was accounted for to determine glutamine consumption fluxes in ETA 
(Murphy and Young, 2013). 
 
4.3.8. Dry cell weight measurements 
K3 iPSCs were cultured in E8 Flex media representative of the control growth 
media and harvested from six 100 mm non tissue culture treated dishes at ~ 90% confluence. 
Cells were washed with 5 mL PBS for 5 min, then detached using Accutase for 2 min at 
37°C. Cells from two 100 mm culture dishes were combined for each cell count and 
corresponding dry cell weight. Cells were pelleted by centrifuging at 5000 x g for 5 min. 
Following centrifugation, the supernatant was removed, and cells were resuspended in 10 
mL of water by briefly vortexing. Next, cells were centrifuged again at 5000 x g for 5 min. 
Finally, the water was removed, and the cell pellets were resuspended in 1-2 mL of water, 
vortexed, and transferred to aluminum drying pans. The tubes were rinsed with water and 
the contents were added to the aluminum drying pans. Cell pellets were dried in ambient 
air at 95°C for two days before dry cell weights were obtained. The dry cell weights were 
determined in triplicate. 
 
4.3.9. Metabolic network model 
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A generalized mammalian cell model focused on central carbon metabolism was 
used to model iPSC metabolism. This model was adapted from several previously 
published metabolic frameworks (Ahn and Antoniewicz, 2013; Jiang et al., 2016; Metallo 
et al., 2012). The iPSC model contained the major reactions for glucose consumption, the 
TCA cycle, amino acid metabolism, lactate metabolism, and fatty acid metabolism. Early 
glycolysis and the pentose phosphate pathway (PPP) reactions were not included in the 
iPSC model since the intracellular MIDs for these metabolites were poorly resolved 
experimentally. This approach to simplify glycolysis and PPP is similar to the approach 
used in Jiang et al. 2016. The carbon flux to the biomass was divided into two 
compartments – termed the biomass pool and the “lipid biomass” pool (Ahn and 
Antoniewicz, 2013; Bonarius et al., 1996; Brodsky et al., 2019; Metallo et al., 2012). The 
biomass fraction contains nucleotides, proteins and carbohydrates, and lipid biomass 
fractions contains acetyl-CoA. The relative weight fraction of the biomass and lipid 
biomass pools are 0.9 and 0.1, respectively, based on cell mass composition of hybridoma 
cells (Sheikh et al., 2005) and the experimentally measured dry cell weight for K3 iPSCs. 
The measured K3 iPSC dry cell weight was converted to biomass and lipid biomass fluxes 
using the experimentally determined iPSC growth rates (Bonarius et al., 1996). A full 
description of the metabolic model development and assumptions can be found in 
Appendix K. The full list metabolic reactions including the atom carbon transitions is 
included in Appendix L.  
 
4.3.10. Metabolic flux analysis 
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13C-Metabolic flux analysis was conducted using the Isotopomer Network 
Compartmental Analysis (INCA) software package (Young, 2014). INCA utilizes the 
elementary metabolite unit framework to perform MID simulations, and is capable of 
performing both isotopic steady-state and isotopic non-stationary MFA (Antoniewicz et al., 
2007b; Young et al., 2008). For this work, isotopic steady-state MFA was conducted to 
estimate intracellular metabolic fluxes, where extracellular uptake and secretion fluxes, 
coupled with intracellular MIDs from the 24-h samples were used. In this study, INCA 
software was used to complete the 13C-MFA on the data from the parallel labeling 
experiments, a process that has been shown to improve flux resolution throughout 
intracellular metabolism (Leighty and Antoniewicz, 2012; Leighty and Antoniewicz, 2013). 
Flux estimations were performed for 100 restarts from initial random guesses. This 
increases the likeliness that a global solution will be obtained (Templeton et al., 2013).  
 
4.3.11. Extended expansion of K3 iPSCs 
K3 iPSCs were cultured for five passages in each of the four culture media to assess 
the effects of glucose and lactate on iPSC proliferation and pluripotency. The cell culture 
and passage procedures were as described in sections 4.3.2 and 4.3.3. After five passages, 
cell pellets were obtained and stored at -80°C for gene and protein expression analysis via 
real-time quantitative reverse transcriptase PCR and western blot, respectively. 
Additionally, cells from five passages were used for differentiation studies. 
 
4.3.12. iPSC embryoid body formation and spontaneous differentiation 
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The capacity of K3 iPSCs to spontaneously differentiate towards cell types from each 
germ layer – ectoderm, endoderm, and mesoderm – was assessed using cells that had been 
cultured for five passages in the four culture media. For spontaneous differentiation, K3 
iPSCs were inoculated into uncoated non-tissue culture treated 60 mm cell culture dishes 
at 3x105 cells/mL in E8 Flex with ROCKi. The iPSCs had formed cell aggregates 
(embryoid bodies) in static suspension culture after 24-h. After 24-h, the media was 
removed and replaced with Essential 6TM (E6) spontaneous differentiation media (Thermo 
Fisher Scientific, Waltham, MA). Embryoid bodies were cultured in E6 media for seven 
days, where the media was replaced every other day. After seven days in E6 media, the 
embryoid bodies were harvested for gene and protein expression analysis to determine loss 
of pluripotency and onset of differentiation.  
 
4.3.13. RNA extraction and qRT-PCR 
Total mRNA was isolated from K3 iPSCs at 48-h and from embryoid bodies at day 
7 using a RNeasy® Plus Mini Kit (Qiagen Inc., Valencia, CA) and QIAshredder (Qiagen 
Inc., Valencia, CA) according to the manufacturer’s instructions. Isolated RNA sample 
quality assessment and quantification was performed using a NanoDropTM 8000 
Spectrophotometer (Thermo Fisher Scientific, Waltham, MA). Real-time quantitative 
reverse transcriptase polymerase chain reaction (qRT-PCR) was performed using the 
iTaqTM Univeral SYBR® Green One-Step Kit (Bio-Rad Laboratories, Inc., Hercules, CA). 
qRT-PCR was carried out using the iQTM5 cycler (Bio-Rad Laboratories, Inc., Hercules, 
CA) with the following program: reverse transcription for 10 min at 50°C; polymerase 
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activation and DNA denaturation for 1 min at 95°C; 40 cycles at 95°C for 10 sec, 58.6°C 
for 15 sec, and 72°C for 15 sec. Relative expression was determined using the DDCT method 
with Gapdh used as an internal standard (Livak and Schmittgen, 2001). Primer sequences 
are listed in Table 4.2. Gapdh, Oct4, Sox2, and Nanog primers were purchased from 
Integrated DNA Technologies (IDT, Coralville, IA), while Pax6, Sox17, and Gata2 were 
purchased from Invitrogen (Life Technologies, Carlsbad, CA). 
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Table 4.2. PCR primer sequences for analysis of K3 iPSCs. Primer sequences used for 
qPCR analysis of pluripotency and germ-layer differentiation for K3 iPSCs. 
 
Gene Forward primer sequence (5’à3’) Reverse primer sequence (5’à3’) 
Gapdh CTGGGCTACACTGAGCACC AAGTGGTCGTTGAGGGCAATG 
Gata2 CTGTCTGCAACGCCTGTG GTTCCGAGTCTGGATCCCTT 
Oct4 CTTGAATCCCGAATGGAAAGGG CCTTCCCAAATAGAACCCCCA 
Nanog TTTGTGGGCCTGAAGAAAACT AGGGCTGTCCTGAATAAGCAG 
Pax6 TGTCCAACGGATGTGTGAGT TTTCCCAAGCAAAGATGGAC 
Sox2 GCCGAGTGGAAACTTTTGTCG GGCAGCGTGTACTTATCCTTCT 
Sox17 GTGGACCGCACGGAATTTG GGAGATTCACACCGGAGTCA 
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4.3.14. Western blots  
Whole cell and embryoid body lysates were prepared using 1X Cell Lysis Buffer (Cell 
Signaling Technology, Danvers, MA) containing 1X HaltTM Protease and Phosphatase 
Inhibitor C (Thermo Fisher Scientific, Waltham, MA). The cell lysate protein 
concentration was quantified using the PierceTM BCA Protein Assay Kit (Thermo Fisher 
Scientific, Waltham, MA). Prior to protein separation by electrophoresis, samples were 
mixed with 4X Laemmli buffer (Bio-Rad Laboratories, Inc., Hercules, CA) to a final 
concentration of 1X with 5% b-mercaptoethanol and boiled for 5 min at 95°C. Samples 
were loaded at a concentration of 5 µg of total protein per well. Protein separation was 
performed on 4-15% Mini-PROTEAN® TGXTM Precast Gels (Bio-Rad Laboratories, Inc., 
Hercules, CA) and run on a PowerPacTM 1000 (Bio-Rad Laboratories, Inc., Hercules, CA) 
power supply at 200V for 30 min with running buffer (15 g Tris Base, 72 g glycine, and 5 
g SDS per L ultrapure water). Following electrophoresis, the gel was soaked in cold 
transfer buffer for 30 min. The transfer buffer (20% (v/v) methanol, with 3.03 g Tris Base, 
and 14.4 g glycine per L) was chilled overnight prior to transfer. Protein transfer was 
performed using Immun-Blot® PVDF (polyvinylidene difluoride) membranes and extra 
thick blot paper filter paper (Bio-Rad Laboratories, Inc., Hercules, CA). The PVDF 
membrane and filter pads were soaked in cold transfer buffer prior to the transfer. The 
transfer was conducted at 90 V for 1-h. Non-specific protein binding to the PVDF 
membrane was blocked using 5% non-fat dried milk in Tris buffered saline (TBS) at room 
temperature on an orbital shaker for 1-h. After blocking, the membrane was washed three 
times for 5 min each in cold TBS with 0.5% Tween (Bio-Rad Laboratories, Inc., Hercules, 
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CA) (TBST). Overnight primary antibody incubation was performed at 4°C. Each primary 
antibody was diluted at 1:1000 in TBST – b-actin (Fisher Scientific, Hampton, NH) and 
Oct4 (Novus Biologicals, Centennial, CO). Following the overnight primary antibody 
incubation, the membrane was washed three times for 5 min in TBST to remove unbound 
primary antibody. The secondary antibody incubations were conducted for 1-h at room 
temperature at a 1:1000 dilution in TBST using a goat anti-rabbit IgG HRP-linked antibody 
for b-actin and a goat anti-mouse IgG HRP-linked antibody for Oct4 (Bio-Rad 
Laboratories, Inc., Hercules, CA). Protein detection was obtained using the Vector® VIP 
peroxidase substrate kit (Vector Laboratories, Burlingame, CA) and quantified by 
densitometry using Image Studio Lite (Licor).  
 
Statistical Analysis 
Statistical analysis was performed using JMP Pro 14 software (SAS Institute, Cary, 
NC). The generalized linear model (GLM) procedure (p £ 0.05) and least squares method 
with Tukey HSD (honest significant difference) were used to determine if cell number, 
extracellular metabolite concentrations, gene expression, and protein expression were 
significantly different between conditions (p £ 0.05). An ANCOVA (analysis of covariance) 
was also used to determine if metabolite consumption and production profile slopes were 
significantly different between conditions (p £ 0.05). Student’s two-tailed t-tests were used 
to determine if the extracellular fluxes and intracellular MIDs were significantly different 
between conditions (p £ 0.05). For 13C-MFA model convergence in INCA, an acceptable 
simulation fit was determined to occur when a global solution was reached that satisfied 
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the accepted weighted sum of squared residuals (SSR) criteria between the input 
measurements and simulated measurement outputs. A chi-squared statistical test and 
sensitivity analysis were performed to determine goodness-of-fit and 95% confidence 
intervals for each predicted flux, respectively (Antoniewicz et al., 2006; Antoniewicz et al., 
2007a). 
 
4.4. Results and Discussion 
4.4.1. Cell growth 
To determine the effects of low glucose and high extracellular lactate 
concentrations on iPSC metabolism, K3 iPSCs were grown in media containing either 
typical glucose concentrations (18.3 mM) or low glucose concentrations (5.6 mM). Also, 
cultures were either exposed to high extracellular lactate (20 mM) or not exposed to high 
extracellular lactate. Table 4.1 outlines the media concentrations used, including the 
glucose, lactate, and glutamine concentrations and the supplemented sodium chloride 
concentration. The E8 Flex was provided without glucose and glutamine, such that labeled 
glucose and glutamine could be used for the 13C-MFA studies. An initial screening study 
was performed to determine the minimum glucose concentration that did not result in 
glucose depletion prior to 48-h. Not depleting glucose was important to ensure that glucose 
was not a limiting substrate during exponential growth in order to assume pseudo steady-
state. Recently, media acidosis was shown to negatively impact hPSC, with low pH 
resulting in decreased glucose consumption, cell cycle arrest, and cell death (Liu et al., 
2018). Therefore, sodium L-lactate was used as the lactate source to avoid pH shifts due to 
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the lactate addition and to decouple the effects of pH and lactate on K3 iPSC phenotype. 
An equal molar concentration of sodium chloride was added to the non-lactate cultures to 
balance osmolarity. A screening study was performed to determine the maximum sodium 
lactate concentration that did not inhibit iPSC growth rates and was representative of lactate 
concentrations reported to occur in cell culture (Chen et al., 2010; Nath et al., 2017; Ouyang 
et al., 2007). A major objective was to have equivalent growth rates between the cultures 
across all four conditions; this allowed for any observed metabolic flux differences to be 
attributed to the media differences and not differences in biomass accumulation.  
To characterize cell growth, cell counts were taken every 12-h; growth profiles 
from each condition are shown in Figure 4.2A. Cells were first grown in the control 
medium supplemented with 10 µM ROCKi for 24-h to promote cell attachment and reduce 
apoptosis associated with single cell detachment and passaging (Watanabe et al., 2007). 
Following this 24-h period of attachment, the culture media was removed and the media to 
be examined was added and referenced to as a media exchange. The media exchange is 
indicated by time 0-h in Figure 4.2A. For the parallel labeling experiments, 13C isotopes 
replaced the unlabeled glucose, glutamine, or lactate in the culture media at the same 
concentration. To determine the biomass specific flux associated with cell growth, dry cell 
weight measurements were taken as described in section 4.3.9. The dry cell weight for K3 
iPSC was  263 ± 15 pg/cell (mean ± SEM); this measured dry cell weight is similar to those 
previously reported for two hESC lines cultured in Essential 8 medium – HUES 9 hESC 
(250 pg/cell) and H9 hESC (200 pg/cell) (Zhang et al., 2016). Exponential growth was 
observed for all culture conditions for 48-h. Growth rates were calculated from 0 to 36 
 102 
hours and were similar between conditions (p > 0.05). The similar growth rates shown in 
Figure 4.2B confirm that the glucose and lactate concentrations did not significantly affect 
the growth rates of K3 iPSCs. Previously, murine PSCs have been shown to proliferate in 
up to 40 mM lactate, while growth rates for human PSCs decreased in 11 mM lactate 
containing media (Chaudhry et al., 2009; Chen et al., 2010; Gupta et al., 2017; Nath et al., 
2017). However, low glucose and high lactate culture concentrations did not inhibit growth 
for K3 iPSCs.  
  
 103 
 
Figure 4.2. Growth characteristics of K3 iPSC cultures in low and high glucose and 
lactate containing media. A) Growth profiles. The isotope media exchange occurred at 0-
h and samples for MID analysis were taken at 24-h and 48-h. Control media – ¢; Low 
Glucose media – £; High Lactate media – u; and Low Glucose + High Lactate – ¯. B) 
Growth rates for the times 0 to 36 hours. Error bars represent standard errors. 
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4.4.2. Glucose, lactate, and amino acid metabolism 
PSCs are dependent on glucose catabolism and lactate production to support cell  
growth (Gu et al., 2016; Varum et al., 2011; Zhang et al., 2011). To characterize glucose 
consumption and lactate production for K3 iPSCs, extracellular glucose and lactate 
concentrations were measured at 0, 12, 24, 36, and 48-h after the media exchange. Figure 
4.3 shows the change in glucose and lactate concentrations with time for each culture. The 
data were normalized to show change in concentration since the initial media 
concentrations of glucose and lactate had greater differences than the changes observed 
due to K3 iPSC metabolism in each culture. K3 iPSCs exhibited equal growth rates for 
each condition (Figure 4.2); however, high extracellular lactate resulted in decreased 
glucose consumption and reduced lactate accumulation for both high lactate condition (p 
£ 0.05). Low glucose alone did not significantly impact glucose consumption or lactate 
production (p > 0.05). The average glucose and lactate concentrations for all the 0, 12, 24, 
36, and 48-h samples are listed with standard error in Appendix I, Tables I1-I4. 
Extracellular glucose, lactate, and pyruvate fluxes were calculated using concentrations 
measured at 12, 24, and 36-h and growth profiles from 0-h through 36-h using the 
Extracellular Time-Course Analysis (ETA) software (Figure 4.3D) (Murphy and Young, 
2013). Additionally, Figure 4.3 shows the pyruvate uptake flux for 0 to 36-h. Both high 
lactate cultures had decreased pyruvate consumption fluxes (p £ 0.05), whereas the glucose 
concentration did not have a significant effect on the pyruvate flux (p > 0.05). The pyruvate 
concentration in E8 Flex basal media is only 0.4 mM, and it was observed to be depleted 
between 36 and 48-h. 
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Initially, each high lactate culture exhibited a decreased glycolytic efficiency for the 
first 12-h of culture (Figure 4.3C). Then, from 12 to 48 hours, the glycolytic efficiencies 
were similar across the four conditions. Glycolytic efficiency is defined as the moles of 
lactate produced per mole of glucose consumed, with the theoretical maximum glycolytic 
efficiency being 2.0 moles of lactate produced per mole of glucose consumed. The initial 
difference in glycolytic efficiencies between the high lactate cultures and the control and 
low glucose cultures potentially illustrates an initial shift in glucose to lactate metabolism 
or more likely a lactate shock. This also suggests that iPSCs in the high lactate cultures 
may not have been at a metabolic steady-state through the first 12-h of growth; therefore, 
concentration changes during the first 12-h of growth were excluded from flux calculations. 
Specifically, the low initial glycolytic efficiencies observed immediately following the 
media exchange (between 0-h and 12-h) for each high lactate culture may be the result of 
a high initial lactate exchange across the cell membrane (Figure 4.3C), since lactate is 
transported across the cell membrane through facilitated diffusion by proton-linked 
monocarboxylate transporters (MCTs) (Halestrap, 2012; Huckabee, 1956). Similarly, 
pyruvate transport across the plasma membrane is also facilitated by MCTs (Halestrap, 
2012). Therefore, the decreased pyruvate consumption in both high lactate culture 
conditions could be a result of more favorable lactate transport kinetics (Draoui and Feron, 
2011). Also, since the glycolytic efficiency observed was always less than 2.0, glucose was 
not stoichiometrically converted to lactate, as has previously been reported for hESC 
(Folmes et al., 2011; Turner et al., 2014). However, the similar glycolytic efficiencies 
between 12-h to 48-h suggest that the same proportion of glucose was catabolized to lactate 
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in each condition, and only the net glucose consumed decreased for the cells grown in high 
lactate.  
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Figure 4.3. Glucose consumption and lactate production profiles for K3 iPSCs. A) Net 
glucose consumption. B) Net lactate production. C) Glycolytic efficiencies. Control media 
– ¢; Low Glucose media – £; High Lactate media – u; and Low Glucose + High Lactate 
– ¯. Error bars represent standard errors. D) Calculated glucose consumption, pyruvate 
consumption, and lactate production fluxes for concentration measurements from 12-h to 
36-h for Control (¢), Low Glucose (¢), High Lactate (¢), and Low Glucose + High 
Lactate (¢) culture conditions. The asterisk (*) indicates the calculated flux was 
significantly different from the control condition (p £ 0.05). The pound (#) indicates the 
calculated flux was significantly different from the low glucose condition (p £ 0.05).  
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Proliferating cells require significant protein and nucleotide synthesis to maintain 
rapid growth (Bonarius et al., 1996). As a result, amino acid catabolism plays a critical 
anaplerotic role in pluripotent stem cell metabolism (Gaspar et al., 2014). Extracellular 
amino acid concentrations were measured at 0, 12, 24, 36, and 48-h after the media 
exchange. Statistical analysis was performed to determine if amino acid concentrations 
were significantly different over time and between the conditions. Asparagine, glycine, 
lysine, proline, tryptophan, and tyrosine concentrations did not significantly change with 
respect to time (p > 0.05). Therefore, extracellular fluxes were not calculated for these 
amino acids. All other amino acid concentrations varied significantly with time; thus, 
fluxes were determined for these amino acids. Serine concentrations did not vary between 
the culture conditions (p > 0.05). However, alanine, aspartate, glutamine, glutamate, 
histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, and valine 
concentrations varied between culture conditions (p £ 0.05). Table 4.3 lists the calculated 
amino acid fluxes with standard error determined using the ETA software, where a 
Gaussian error propagation approach was implemented (Murphy and Young, 2013). The 
average amino acid concentrations for all the 0, 12, 24, 36, and 48-h samples are listed with 
standard error in Appendix I, Tables I1-I4. Amino acid concentration time profiles are 
included in Appendix J. 
High extracellular lactate also caused reduced glutamine consumption, glutamate 
production, and ammonia accumulation for both high lactate conditions (p £ 0.05). 
However, the moles of ammonia produced per moles of glutamine consumed remained 
relatively constant for each of the four culture conditions. Figure 4.4 shows the change in 
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glutamine, glutamate, and ammonia concentrations with time for each culture. Lactate has 
previously been suggested to inhibit ammonia secretion in a number of mammalian cell 
lines (Glacken et al., 1988; Hassell et al., 1991). Two potential mechanisms for this are 1) 
the metabolic conversion of lactate to pyruvate also promotes alanine production and 
reduces ammonia accumulation, or 2) lactate inhibits glutaminase activity – the enzyme 
responsible for converting glutamine to glutamate (Glacken et al., 1988; Hassell et al., 
1991). While alanine production did not increase due to high lactate, glutamine 
consumption decreased for both high lactate cultures. These results suggest that high 
extracellular lactate inhibits glutamine consumption and ammonia production.  
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Table 4.3. Experimentally determined biomass specific uptake and production rates 
for extracellular metabolite (nmol/106 cells×h). Fluxes and standard errors were 
calculated using ETA software using the measured cell growth rates and the metabolite 
concentrations from 12 to 36 hours (Murphy and Young, 2013). Negative values 
represent consumption rates and positive values represent production rates. 
 
 Control Low Glucose High Lactate Low Glucose + High Lactate 
Metabolite Flux SE Flux SE Flux SE Flux SE 
Glucose -1164 97.0 -1176 55.1 -897 90.8 -937 43.5 
Lactate 2013 113 1861 72.4 1692 73.4 1537 76.2 
Pyruvate -67.6 2.6 -75.3 2.0 -38.6 3.6 -36.5 2.6 
Ammonia 135 5.1 125 5.7 105 8.4 107 5.5 
Alanine 33.3 2.1 32.2 1.5 28.8 3.5 27.7 3.1 
Aspartate -0.4 0.5 -3.5 0.2 0.3 0.4 -1.8 1.0 
Glutamate 36.1 1.7 32.3 1.2 28.3 1.4 29.4 1.6 
Glutamine -141 16.9 -155 9.0 -107 9.6 -119 9.5 
Histidine 1.1 3.2 -14.7 1.9 -0.6 2.2 0.0 1.4 
Isoleucine -56.7 10.0 -39.3 5.6 -24.7 6.9 -45.4 8.4 
Leucine -41.8 7.0 -31.3 2.6 -9.8 4.2 -20.9 4.8 
Methionine -7.4 1.6 -4.4 1.1 -0.4 1.5 -0.5 1.9 
Phenylalanine -7.6 4.3 -7.7 2.2 7.8 1.2 8.9 2.4 
Serine -33.5 5.2 -23.8 3.7 -28.0 4.0 -46.3 11.1 
Threonine -9.2 3.8 -2.2 2.0 8.4 2.2 -2.2 2.0 
Valine -15.6 3.6 -15.4 2.2 -4.4 3.2 -6.0 4.4 
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Figure 4.4. Glutamine consumption, glutamate production, and ammonia production 
profiles for K3 iPSCs. A) Net glutamine consumption. B) Net glutamate production. C) 
Net ammonia production. Control media – ¢; Low Glucose media – £; High Lactate 
media – u; and Low Glucose + High Lactate – ¯. Error bars represent standard errors. D) 
Calculated glutamine consumption, glutamate production, and ammonia production fluxes 
for concentration measurements from 12-h to 36-h for Control (¢), Low Glucose (¢), 
High Lactate (¢), and Low Glucose + High Lactate (¢) culture conditions. The asterisk 
(*) indicates the calculated flux was significantly different from the control condition (p £ 
0.05). The pound (#) indicates the calculated flux was significantly different from the low 
glucose condition (p £ 0.05).  
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4.4.3. Intracellular metabolite labeling dynamics using [1,2-13C] glucose tracer 
To resolve glucose metabolism in the iPSC cultures, [1,2-13C] glucose was used. 
This tracer has been previously identified as an excellent glucose tracer for resolving 
metabolic fluxes through glycolysis and the pentose phosphate pathway for mammalian 
cells (Metallo et al., 2009). Intracellular MIDs were measured for pyruvate, alanine, and 
lactate from glucose tracer. In this study, poor resolution of the glycolytic metabolites – 
dihydroxyacetone phosphate, 3-phosphoglycerate, and phosphoenolpyruvate – were 
obtained; thus, these MIDs were not used in the subsequent model. Steady-state isotope 
labeling has previously been shown to occur within 24-h for mammalian cells with similar 
growth rates (Ahn and Antoniewicz, 2013; Metallo et al., 2009). The steady-state fractional 
labeling for pyruvate, alanine and lactate are shown in Figure 4.5A. The fractional labeling 
for pyruvate, alanine, and lactate from glucose were lower for the high lactate cultures 
compared to cultures without added lactate. These results suggest that less glucose-derived 
carbon was metabolized to pyruvate, lactate, and alanine when lactate levels were high (p 
£ 0.05). In contrast, the glucose concentration did not significantly affect the fractional 
labeling for these three species (p > 0.05). The fractional labeled species in glycolysis and 
measured glucose consumption fluxes are consistent with respect to the effects of the 
lactate concentration and glucose concentration (Figure 4.3D). 
In addition to providing overall metabolite enrichment, [1,2-13C] glucose was used 
to determine the distribution of mass isotopomers for intracellular metabolites. The MIDs 
for pyruvate, alanine and lactate from [1,2-13C] glucose tracer at 24-h and 48-h for each 
culture condition are shown in Figure 4.5B-E. Each metabolite was primarily unlabeled 
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(M+0) and M+2 labeled. The predominant presence of M+2 labeling, compared to M+1 
and M+3, suggests that glycolysis was highly active in all four culture conditions. Also, 
the small fractional abundance of M1 labeling (>2 % in each condition) suggests that the 
oxidative pentose phosphate pathway was relatively inactive during exponential growth for 
each culture condition.  
  
 114 
 
Figure 4.5. Comparison of fractional isotopomer labeling and fractional abundance 
of MIDs for glycolytic metabolites from [1,2-13C] glucose for K3 iPSCs. A) Percent 
isotopomer labeling. Control (¢), Low Glucose (¢), High Lactate (¢), and Low Glucose 
+ High Lactate (¢) culture conditions. Fractional abundance of MIDs for B) Control media; 
C) Low glucose media; D) High lactate media; E) Low glucose + high lactate media. 
Glycolytic metabolites shown are pyruvate (Pyr), alanine (Ala), and lactate (Lac). The mass 
isotopomer distributions were corrected for natural abundances. The asterisk (*) indicates 
the calculated flux was significantly different from the control condition (p £ 0.05). The 
pound (#) indicates the calculated flux was significantly different from the low glucose 
condition (p £ 0.05).  
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The fractional labeling of TCA metabolites from [1,2-13C] glucose at 24-h are shown 
in Figure 4.6. The fractional labeling of citrate was lower for the high lactate cultures, as 
shown by the higher M+0 fractional abundance. Additionally, the a-ketoglutarate (AKG) 
labeling from [1,2-13C] glucose was also lower for the high lactate cultures. Together with 
the overall labeling, fractional abundance of M+2 labeled citrate was lower for the high 
lactate cultures. These results indicate that glucose-derived carbon entered the TCA cycle 
either as 13C-labeled acetyl-CoA via the enzyme pyruvate dehydrogenase (PDH) or as 13C-
labeled oxaloacetate via the enzyme pyruvate carboxylase (PC). Moreover, the decreased 
overall labeling, in particular M+2 labeled TCA metabolites, suggests that glucose either 
served less as a carbon source for mitochondrial metabolism for both of the high lactate 
cultures, or glucose-derived 13C labeling was diluted by catabolism of another unlabeled 
carbon substrate.  
Lactate accumulation has previously been reported to reduce glycolytic activity by 
inhibiting hexokinase (HK) and phosphofructokinase (PFK) activity in mammalian cells, 
where lactate acts as a signaling molecule to down-regulate PFK activity (Ivarsson et al., 
2015; Leite et al., 2007; Mulukutla et al., 2012; Mulukutla et al., 2015). In addition, lactate 
supplementation and conversion to pyruvate impairs NAD+ generation and promotes 
pyruvate conversion to acetyl-CoA and entry into the TCA cycle; this also results in 
repressed glycolytic fluxes due to an increase in NADH/NAD+ ratio (Fendt et al., 2013; 
Huckabee, 1956; Mintun et al., 2004). The presence of 13C-labeled TCA metabolites from 
the [1,2-13C] glucose tracer confirm that some glucose-derived carbon supported oxidative 
mitochondrial metabolism rather than being used to generate lactate. Furthermore, the 
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detection of significant intracellular citrate labeling from [1,2-13C] glucose and the low 
AKG fractional labeling relative to citrate denotes that glucose catabolism supported 
acetyl-CoA synthesis (Figure 4.6). These results are consistent with recent findings which 
determined that PSCs relied on a modified Warburg effect, where glucose can be converted 
to lactate and acetyl-CoA for PSC proliferation (Moussaieff et al., 2015; Zhang et al., 2016).  
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Figure 4.6. Comparison of fractional abundance of MIDs for TCA metabolites from 
[1,2-13C] glucose for K3 iPSCs at 24-h. TCA metabolites represented are citrate (Cit), a-
ketoglutarate (AKG), glutamate (Glu), succinate (Suc), fumarate (Fum), malate (Mal), and 
aspartate (Asp). The mass isotopomer distributions were corrected for natural abundances.  
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4.4.4. Intracellular metabolite labeling dynamics from [U-13C] glutamine tracer 
To resolve metabolism through the TCA cycle, [U-13C] glutamine was used in 
parallel with the glucose tracer. The [U-13C] glutamine has previously been shown to be 
the optimal glutamine tracer for rapidly labeling TCA cycle metabolites and for resolving 
metabolic fluxes through the TCA cycle for mammalian cells (Metallo et al., 2009). Figure 
4.7 shows the fractional labeling of TCA cycle metabolites from [U-13C] glutamine at 24-
h. [U-13C] glutamine significantly labeled intracellular TCA cycle intermediate metabolites 
for all four culture conditions, with over 50% isotope labeling for all measured species 
(Figure 4.7 and Appendix O, Figure O2). In contrast, pyruvate, alanine, and lactate were 
minimally labeled from [U-13C] glutamine (data in Appendix N, Table N2). The results 
suggest that glutamine is not a major carbon source for pyruvate and its byproducts. The 
overall intracellular metabolite labeling from [U-13C] glutamine was similar for all four 
conditions; however, there were differences in fractional labeling of TCA metabolites. 
Overall, these results indicate that for iPSCs, glutamine serves integral anaplerotic role in 
TCA cycle metabolism, but has little role in pyruvate synthesis, regardless of the 
extracellular glucose and lactate concentrations investigated in this study (Figure 4.7). 
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Figure 4.7. Comparison of fractional abundance of MIDs for TCA metabolites from 
[U-13C] glutamine for K3 iPSCs at 24-h. TCA metabolites represented are glutamine 
(Gln), glutamate (Glu), a-ketoglutarate (AKG), succinate (Suc), fumarate (Fum), malate 
(Mal), aspartate (Asp), and citrate (Cit). The metabolites are listed according to the order 
of oxidative TCA cycle. The mass isotopomer distributions were corrected for natural 
abundances.  
 120 
K3 iPSCs utilized reductive glutamine metabolism, irrespective of the glucose or 
lactate media concentration, as illustrated by the presence of M+5 labeled citrate, along 
with M+3 malate, fumarate, and aspartate (Figure 4.8A). Figure 4.8B outlines the reaction 
pathway for reductive carboxylation, including the labeling patterns. These results indicate 
that the reductive carboxylation appears to be slightly lower for the high lactate cultures; 
however, this observation is only significant when compared to the low glucose cultures (p 
£ 0.05). These results demonstrate that glutamine was reductively metabolized through 
isocitrate dehydrogenase (IDH) and ATP-citrate lyase (ACL) for lipid production in each 
culture. Reductive carboxylation of glutamine for lipid synthesis has previously been 
observed in cancer cells grown under hypoxic conditions (£ 5% O2) (Fan et al., 2013; Fendt 
et al., 2013; Grassian et al., 2014; Jiang et al., 2016; Metallo et al., 2012; Metallo et al., 
2009; Wise et al., 2011). However, recently it has also been shown that mammalian cells 
employed reductive carboxylation in response to cell culture stress and due to various 
media formulations (Brodsky et al., 2019; Jiang et al., 2016). Further, hESCs have been 
shown to utilize glutamine-mediated reductive carboxylation in chemically defined media 
– E8 media (Zhang et al., 2016). Similarly, the results from this study indicate that iPSCs 
used reductive glutamine metabolism to support proliferation in chemically defined media 
under normoxic (20% O2) conditions.  
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Figure 4.8. Comparison of fractional abundance of reductive carboxylation species 
from [U-13C] glutamine at 24-h. A) Fractional abundance of M+5 citrate (Cit) and M+3 
fumarate (Fum), malate (Mal), and aspartate (Asp) from the Control (¢), Low Glucose 
(¢), High Lactate (¢), and Low Glucose + High Lactate (¢) cultures. MIDs were 
corrected for natural abundances. The asterisk (*) indicates the fractional labeling was 
significantly different from the Control cultures (p £ 0.05). The pound (#) indicates the 
fractional label was significantly different from the Low Glucose cultures (p £ 0.05). B) 
Carbon atom transition for TCA metabolites from [U-13C] glutamine. Red circles represent 
13C and white 12C. The black lines depict oxidative glutamine metabolism. Red lines depict 
reductive glutamine metabolism that results in M+5 citrate (Cit) and M+3 oxaloacetate 
(OAA), malate (Mal), fumarate (Fum), and aspartate (Asp).   
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Interestingly, high lactate in the media also resulted in significantly higher M+4 
citrate, M+3 AKG and glutamate, and M+2 succinate, fumarate, malate, and aspartate 
labeling from [U-13C] glutamine (p £ 0.05) as shown in Figure 4.9A. These changes in 
intracellular TCA cycle metabolite labeling suggest elevated oxidative glutamine 
metabolism and retention of glutamine-derived carbon from multiple turns through the 
TCA cycle for the two high lactate culture conditions (Figure 4.9B). Interestingly, while 
glutamine consumption diminished for both of the high lactate culture conditions, it 
appears that the cells compensated for this by retaining more glutamine-derived carbon 
through multiple rounds of oxidative TCA cycle metabolism. Glutamine oxidation has 
previously been shown to be indispensable to hPSC metabolism and survival (Tohyama et 
al., 2016). Also, elevated oxidative glutamine metabolism has previously been shown to 
occur for PSCs cultured in chemically defined media (Zhang et al., 2016). Similarly, lung 
carcinoma cells (A549) and osteosarcoma cells (143B) demonstrated increased oxidative 
glutamine metabolism in response to of 25 mM lactate supplementation, as seen by 
elevated M+3 AKG and decreased reductive glutamine contribution to citrate (Fendt et al., 
2013). Overall, in this study, K3 iPSCs relied primarily on oxidative glutamine metabolism 
to support proliferation, where the high lactate cultures had higher retention of glutamine-
derived carbon through multiple rounds of oxidative TCA cycle metabolism. 
  
 123 
 
 
Figure 4.9. Intracellular fractional labeling of oxidative glutamine metabolites from 
[U-13C] glutamine at 24-h. A) Fractional labeling of TCA cycle metabolites from the 
Control (¢), Low Glucose (¢), High Lactate (¢), and Low Glucose + High Lactate (¢) 
cultures. B) Potential mechanisms which would result in changes to fractional labeling of 
TCA cycle metabolites. MIDs were corrected for natural abundances. The asterisk (*) 
indicates the fractional labeling was significantly different from the control condition (p £ 
0.05). The pound (#) indicates the fractional label was significantly different from the low 
glucose condition (p £ 0.05). Carbon atom transition for TCA metabolites from [U-13C] 
glutamine. Red circles represent 13C and white 12C. The black lines depict oxidative 
glutamine metabolism, which results in M+4 citrate (Cit), M+3 a-ketoglutarate (AKG) and 
glutamate (Glu), and M+2 succinate (Suc), fumarate (Fum), malate (Mal), and aspartate 
(Asp).  
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4.4.5. Intracellular metabolite labeling dynamics from [U-13C] lactate tracer 
To further understand the role of lactate as a potential metabolic substrate in iPSC 
metabolism, iPSCs were cultured with high extracellular lactate. [U-13C] lactate was used 
to allow detection of lactate transport into the cell and metabolic conversion within the cell 
via MIDs of intracellular species. The amount of time required to reach isotopic steady-
state from [U-13C] lactate has not previously been reported for mammalian cells in glucose 
containing media, so the 24-h and 48-h timepoints were used to evaluate the intracellular 
lactate labeling dynamics throughout this experiment. Labeled intracellular metabolites [U-
13C] lactate included: lactate, pyruvate, alanine, citrate, AKG, succinate, fumarate, malate, 
and aspartate. For both high lactate culture conditions, the fraction of labeled intracellular 
pyruvate, alanine and lactate from [U-13C] lactate was observed to be relatively constant 
between the 24-h and 48-h samples (Figure 4.10A and B). The pyruvate, alanine, and 
lactate were primarily M+3 labeled. As shown in Figure 4.10C, [U-13C] lactate transport 
across the cell membrane and direct conversion to pyruvate and alanine results in M+3 
labeling. There was also observed M+2 labeling of pyruvate after 24-h, which requires 
TCA cycle metabolism and conversion to pyruvate via malic enzyme (ME) activity. Figure 
4.11A and B illustrate the mechanisms to generate M+2 pyruvate.   
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Figure 4.10. Comparison of fractional abundance of MIDs for glycolytic metabolites 
from [U-13C] lactate labeling for K3 iPSCs. A) High Lactate media; B) Low Glucose + 
High Lactate media; Pyruvate (Pyr), alanine (Ala), and lactate (Lac) metabolites are shown. 
MIDs were corrected for natural abundances. C) Carbon atom transition for glycolytic 
metabolites from [U-13C] lactate. Red circles represent 13C and white 12C. Red lines 
indicate lactate consumption and metabolism to intracellular pyruvate and alanine. Black 
lines represent production of alanine and lactate from glucose. 
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Figure 4.11. Carbon atom transitions outlining potential mechanisms for generating 
M+2 labeled pyruvate from [U-13C] lactate. Red circles represent 13C and white 12C. The 
red lines depict reactions involving 13C-labeled metabolites. The black lines indicate 
reactions involving unlabeled metabolites. The blue lines represent the two reactions 
responsible for entry of M+3 pyruvate into the TCA cycle. A) Pyruvate conversion to 
acetyl-CoA via the pyruvate dehydrogenase (PDH) enzyme. B) Pyruvate carboxylation to 
oxaloacetate via the pyruvate carboxylase (PC) enzyme.   
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For the TCA cycle metabolites, citrate was highly labeled at 24-h for both high 
lactate cultures, whereas AKG, malate, and aspartate were all significantly less labeled, as 
illustrated by the fractional abundance of M+0 in each metabolite (Figure 4.12). Succinate 
and fumarate were also less labeled than citrate. Succinate and fumarate labeling were 
lower due to significant dilution from consumption of unlabeled amino acids. As 
mentioned above, M+2 pyruvate labeling was observed from [U-13C] lactate after 24-h of 
culture; this would result from metabolism of [U-13C] lactate through one round of the TCA 
cycle and converted back to pyruvate through ME activity. 13C-lactate can enter into the 
TCA cycle either through PDH or PC reactions. While metabolism of 13C-lactate through 
each of these reactions would result in M+2 labeling of pyruvate, as illustrated in Figure 
4.11A (PDH) and Figure 4.11B (PC), each pathway would result in differential citrate 
labeling. The higher fractional abundance of M+2 citrate compared to M+3 would suggest 
that the PDH reaction was more active in metabolism of 13C-lactate into the mitochondria.  
Interestingly, fractional intracellular labeling from 13C-lactate remained relatively 
constant between 24-h and 48-h for glycolytic byproducts (Figure 4.10A and B), while in 
contrast, the fractional labeling of the TCA cycle metabolites was significantly higher at 
48-h, as shown in Figure 4.12 and in Appendix O, Figure O3. These results suggest that 
[U-13C] lactate labeling of intracellular alanine, lactate, and pyruvate reached isotopic 
steady-state by 24-h, while the TCA cycle metabolites had not yet approached isotopic 
steady-state. Also, along with the decreased contribution of [1,2-13C] glucose to pyruvate 
and TCA cycle metabolism for the two high lactate cultures, the uptake and metabolism of 
the [U-13C] lactate tracer implies that lactate can partially replace glucose as a carbon 
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source for iPSC metabolism. A similar metabolic response was observed for various types 
of cancer cells cultured in high lactate supplemented media (Fendt et al., 2013). It is widely 
accepted that cancer cells are capable of consuming and metabolizing lactate as a metabolic 
substrate (Kennedy et al., 2013; Martinez-Outschoorn et al., 2011; Pavlides et al., 2009; 
Sonveaux et al., 2008). Similarly, these results indicate that 13C-lactate was continuously 
in exchange across the cell membrane and served as a metabolic substrate to support K3 
iPSC proliferation throughout exponential growth. 
The high fractional abundance of labeled citrate relative to other TCA metabolites 
also suggests that lactate served as a substrate in support of lipid synthesis. Proliferative 
cells perform de novo lipid synthesis rather than scavenging for free fatty acids, which 
results in truncated TCA cycle metabolism, with high ACL activity to support lipid 
synthesis; this results in citrate and acetyl-CoA primarily supporting lipid synthesis 
(DeBerardinis et al., 2008; Zhang et al., 2016). Lactate-derived carbon supported lipid 
synthesis and histone acetylation in cancer cell metabolism (Chen et al., 2016; Martinez-
Outschoorn et al., 2011). Specifically, cells exposed to 10 mM extracellular lactate 
exhibited increased histone acetylation for a breast cancer cell line and increased 
malignancy and stemness gene expression (Martinez-Outschoorn et al., 2011). Further, in 
an in vivo human lung tumor model, lactate preferentially supported mitochondrial 
metabolism over glucose (Faubert et al., 2017). Similarly, acetyl-CoA production has been 
shown to be critical for the maintenance of PSCs, where decreased glycolytic flux and 
decreased acetyl-CoA production can result in the onset of spontaneous differentiation; 
however, acetate media supplementation prevented early spontaneous differentiation 
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(Moussaieff et al., 2015). Moreover, inhibition of pyruvate dehydrogenase kinase, a 
pyruvate dehydrogenase inhibitor, redirected glucose-derived carbon to acetyl-CoA rather 
than lactate and resulted in increased histone acetylation and a higher percentage of Oct4 
positive cells (Moussaieff et al., 2015). In a similar manner, lactate appears to play a 
metabolic role to K3 iPSC metabolism. Therefore, lactate consumption may play an 
important functional role in iPSC metabolism during proliferation.  
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Figure 4.12. Comparison of fractional abundance of MIDs for TCA metabolites from 
[U-13C] lactate labeling for K3 iPSCs at 24-h. A) Fractional abundance of 13C mass 
isotopomer distributions for TCA metabolites from High Lactate and Low Glucose + High 
Lactate cultures. TCA metabolites represented are citrate (Cit), a-ketoglutarate (AKG), 
glutamate (Glu), succinate (Suc), fumarate (Fum), malate (Mal), and aspartate (Asp). The 
mass isotopomer distributions were corrected for natural abundances.  
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4.4.6. Pluripotency and differentiation potential 
In order to determine the effects of the glucose and lactate concentrations on iPSC 
pluripotency, K3 iPSCs were grown for one and five passages under each culture condition. 
Cells from these cultures were analyzed for pluripotency gene expression using qPCR and 
protein expression by western blot analysis. Three genes were used to monitor pluripotency 
– Oct4, Sox2, and Nanog (Boyer et al., 2005). Oct4 expression was selected to assess 
pluripotency by protein expression via western blots. The gene expression levels for Oct4, 
Sox2, and Nanog are shown in Figure 4.13A and 4.13C for K3 iPSCs cultured for one or 
five passages in the four culture media. For the cultures after one passage, none of the genes 
had significantly different expression (p > 0.05). Sox2 and Nanog expression levels were 
significantly higher for the five passage low glucose + high lactate cultures (p £ 0.05); 
however, glucose and lactate media concentrations did not affect Oct4 gene expression 
levels after five passages (p > 0.05) (Figure 4.13C). Also, normalized Oct4 protein 
expression levels were similar for all four cultures after one and five passages in each 
culture condition (p > 0.05) (Figure 4.13B and D). 
Tight regulation of Oct4 expression is required to maintain pluripotency for PSCs 
in vitro. Elevated Oct4 expression has been shown to induce differentiation towards the 
primitive ectoderm and mesoderm, while loss of Oct4 expression caused differentiation 
towards the trophectoderm (Chambers et al., 2003; Niwa et al., 2000). Sox2 expression 
must be also tightly regulated to maintain pluripotency. Loss of Sox2 expression induces 
differentiation towards the trophectoderm (Chew et al., 2005). In addition, a two- to five-
fold increase in Sox2 expression resulted in differentiation towards the trophectoderm and 
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loss of Oct4 and Nanog expression (Adachi et al., 2010). Similarly, Nanog expression 
represses differentiation towards the primitive ectoderm (Wang et al., 2012). However, 
overexpression of Nanog also prevented differentiation in ESCs (Chambers et al., 2003). 
Interestingly, Oct4 serves as a transcriptional regulator for hexokinase (HK) and 
phosphofructokinase (PFK) – two key glycolytic enzymes – and maintenance of Oct4 
expression and elevated glycolytic fluxes are critical factors for maintaining iPSC 
pluripotency (Kim et al., 2015). In this study, the observed decreased glucose consumption 
due to high lactate did not affect Oct4 expression. Thus, the reduced glucose catabolism 
appears to have resulted from high lactate exposure alone, rather than loss of Oct4 
expression. In previous work, high lactate concentrations have been shown to have variable 
effects on PSC pluripotency; murine ESCs and iPSCs proliferated and maintained 
pluripotency in lactate concentrations up to 40 mM, while hESCs exhibited decreased 
pluripotency through Tra-1-60 expression after continuous passaging in 22 mM lactate 
containing media (Chaudhry et al., 2009; Chen et al., 2010; Gupta et al., 2017; Martinez-
Outschoorn et al., 2011). The results of this study suggest that glucose and lactate 
concentrations within ranges that support exponential growth equal to the control media do 
not negatively affect human K3 iPSC pluripotency. 
Passage five K3 iPSCs were spontaneously differentiated through embryoid body 
(EB) formation to assess the differentiation capacity of iPSCs after prolonged culture in 
low glucose and high lactate culture conditions. Oct4, Sox2, and Nanog gene expression 
levels were measured to assess pluripotency. Additionally, expression levels for three germ 
layer-specific genes were measured in the EBs to assess the germ layer differentiation 
 133 
potential – Pax6 (ectoderm), Gata2 (mesoderm), and Sox17 (endoderm) (Aasen et al., 
2008). After seven days of spontaneous differentiation, EBs from each culture condition 
had lower Nanog expression; however only cells from the low glucose + high lactate 
culture exhibited significant loss of Oct4 and Nanog expression (p £ 0.05) (Figure 4.14A). 
On the other hand, Sox2 expression was higher for the EBs from all four culture conditions. 
In addition to promoting differentiation towards the trophectoderm, elevated Sox2 
expression has previously been shown to play an important role in self-renewal during 
hESC differentiation towards the endoderm (Kallas et al., 2014). The EBs also showed 
slightly elevated expression levels of Pax6 and Gata2, which indicates expression towards 
the ectoderm and mesoderm (Figure 4.14B); however, no change in Sox17 expression was 
observed. Interestingly, EBs from both low glucose cultures exhibited higher Gata2 
expression, suggesting that culturing iPSCs in low glucose concentrations could promote 
spontaneous differentiation towards the mesoderm. Nonetheless, EBs generated from cells 
cultured in each of the four different growth media also contained many cells in a 
pluripotent state after seven days of spontaneous differentiation. Taken together, these 
results illustrate that spontaneous differentiation of EBs from all four culture conditions 
showed initial signs of loss of pluripotency and differentiation towards the mesoderm and 
ectoderm, but longer spontaneous differentiation is required to assess K3 iPSC 
differentiation capacity. 
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Figure 4.13. Comparison of pluripotency gene and protein expression for K3 iPSCs 
after one and five passages due to glucose and lactate concentration. A) Normalized 
gene expression for Oct4, Sox2, and Nanog for undifferentiated iPSCs after one passage in 
Control (¢), Low Glucose (¢), High Lactate (¢), and Low Glucose + High Lactate (¢) 
culture media. B) Normalized protein expression of Oct4 after one passage. C.) Normalized 
gene expression of Oct4, Sox2, and Nanog after five passages in culture test conditions. D) 
Normalized protein expression for Oct4 after five passages in culture test conditions. Error 
bars represent standard error (N = 6). The asterisk (*) indicates that the normalized gene 
or protein expressions were significantly different from the control (p £ 0.05)  
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Figure 4.14. Comparison of gene expression for K3 iPSCs after one passage, five 
passages, and seven days of spontaneous differentiation due to glucose and lactate 
concentration. A) Normalized gene expression for Oct4, Sox2, and Nanog for iPSCs after 
one passage (P1), five passages (P5), and seven days of spontaneous differentiation as 
embryoid bodies (EB 7) in Control (¢), Low Glucose (¢), High Lactate (¢), and Low 
Glucose + High Lactate (¢) culture media. B) Normalized gene expression for Pax6, Gata2, 
and Sox17 for iPSCs after one passage (P1), five passages (P5), and seven days of 
spontaneous differentiation as embryoid bodies (EB 7). Error bars represent standard error 
(N = 3). The asterisk (*) indicates the normalized gene expression was significantly 
different from P1 (p £ 0.05). The pound (#) indicates normalized gene expression was 
significantly different from P5 (p £ 0.05).  
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4.4.7. Metabolic flux analysis 
Detailed intracellular metabolic fluxes were generated for the four culture 
conditions using the parallel 13C-labeling data, the extracellular measured fluxes, and the 
metabolic network. The parallel labeling data used in the MFA model included the [1,2-
13C] glucose and [U-13C] glutamine MIDs for all culture conditions and the [U-13C] lactate 
MIDs for the high lactate culture conditions. The INCA software was used to obtain the 
intracellular metabolic fluxes for K3 iPSCs grown in all four growth media. 
As previously mentioned, the [U-13C] lactate tracer provided evidence that lactate 
was consumed and metabolized by K3 iPSCs in both high lactate cultures (Figures 4.10 
and 4.12); however, net lactate production was observed for K3 iPSCs in all four culture 
conditions (Figure 4.3). Thus, lactate was produced and consumed by iPSCs in the high 
lactate cultures. As no one has previously used 13C-MFA to model the dual consumption 
and production of a metabolic species with an isotopically labeled tracer, a novel approach 
was employed to model the reversible metabolism of the lactate tracer. A diagram of the 
metabolic reactions used to model lactate production and consumption is shown in Figure 
4.15A, where reaction v1 represents the measured net production flux of lactate from the 
cytosol (Lac.c) to the extracellular media (Lac.x), and reaction v2 represents the 
consumption flux of lactate tracer (Lac.t) into the cytosol (Lac.c). The magnitude of the 
lactate tracer flux was not measured; therefore, the lactate tracer flux could not be 
constrained to a known measurement. Instead, the lactate tracer reaction into the cell was 
defined as a reversible reaction and fixed to a net flux of zero. This allowed for the model 
to simulate an infinite exchange of the lactate tracer into and out of the cell without defining 
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a net lactate tracer flux. The model predicted net lactate production fluxes for all four 
culture conditions. Also, lactate tracer exchange fluxes into the cell were also simulated in 
all four conditions, with the model predicting approximately ten times higher lactate 
exchange fluxes for both of the high lactate culture conditions (Figure 4.15B). This 
indicates that the metabolic model was capable of incorporating [U-13C] lactate tracer into 
the cell even though a net lactate production flux was observed. Previously, Brodsky et al. 
(2019) used [U-13C] lactate tracer along with 13C-MFA to determine the contribution of 
lactate to breast cancer metabolism; however, intracellular metabolite labeling from [U-
13C] lactate tracer was not incorporated in the 13C-MFA simulations (Brodsky et al., 2019), 
in part due to much lower intracellular labeling due to lactate. The metabolic network 
reactions used in this work allowed for [U-13C] lactate MIDs to be incorporated into the 
13C-MFA simulations to account for consumption of lactate tracer.  
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Figure 4.15. Lactate tracer uptake and production for the network model reaction. A) 
A diagram of the metabolic reactions used to model lactate production and lactate 
consumption for K3 iPSCs using 13C-MFA. Reaction v1 represents the net lactate 
production flux. Reaction v2 represents the reversible flux of lactate tracer into and out of 
the cell. B) Simulated lactate tracer exchange flux in Control (¢), Low Glucose (¢), High 
Lactate (¢), and Low Glucose + High Lactate (¢) culture media. Error bars represent 
standard error. The asterisk (*) indicates the flux was significantly different from the 
control condition (p £ 0.05). The pound (#) flux was significantly different from the low 
glucose condition (p £ 0.05).  
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The intracellular metabolic flux distributions from 13C-MFA simulations for K3 
iPSCs from all four culture conditions are shown graphically on the metabolic maps shown 
in Figures 4.16 and 4.17. As expected, the glucose consumption and lactate production 
rates had the highest fluxes in each condition. Additionally, the simulations predicted lower 
glucose consumption and lactate production fluxes for the two high lactate culture 
conditions compared to the control and low glucose cultures (Figure 4.18A). In order for 
the model to converge to an acceptable fit for each culture condition, a fatty acid sink 
(FA.snk) reaction was included in the model. Sink reactions have previously been used to 
account for loss of carbon through metabolic reactions not included in the metabolic 
network model (Ahn and Antoniewicz, 2013). Recently, PSCs have been shown to possess 
some metabolic flexibility in response to media formulations, especially with regards to 
acetyl-CoA generation and lipid biosynthesis rates (Moussaieff et al., 2015; Zhang et al., 
2016). Since lipid content was not measured in this study, the fatty acid sink flux allowed 
for flexibility with respect to lipid biosynthesis predictions. Interestingly, the model 
predicted higher fluxes to the fatty acid sink for each of the high lactate cultures (Figures 
4.16 and 4.17). Along with the high fractional labeling of citrate from [U-13C] lactate, these 
metabolic flux simulations indicate that lactate supplementation promoted acetyl-CoA 
production and lipid biosynthesis in each of the high lactate culture conditions. 
Similar to the extracellular concentration measurements, the metabolic flux model 
simulated lower glutamine consumption fluxes, as well as reduced conversion of glutamine 
to AKG. As a result, slightly lower fluxes through the TCA cycle were also predicted, as 
illustrated by consistent citrate synthase (CS), a-ketoglutarate dehydrogenase (AKGD), 
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succinate dehydrogenase (SDH) and fumarase (FUM) fluxes (Figure 4.17B). The 
metabolic flux models also predicted high ME activity for the iPSCs in all four culture 
conditions (Figure 4.18C). However, glutaminolysis was not the major source of pyruvate 
production, with ME fluxes approximately 10% of the glucose consumption fluxes. 
Interestingly, the metabolic model predicted lower ME fluxes for the two high lactate 
conditions (Figure 4.18C); this also corresponded with decreased simulated flux from 
pyruvate to oxaloacetate through PC. This indicates a lower anaplerotic contribution of 
glutamine to mitochondrial pyruvate via ME due to high extracellular lactate. Elevated 
cycling between ME and pyruvate carboxylase (PC) has previously been observed for CHO 
cells and was suggested to be the cause for low oxidative PPP fluxes during early 
exponential growth, since the NADP-dependent isoform of ME can provide NADPH to 
meet cellular demands (Ahn and Antoniewicz, 2011; Templeton et al., 2013). Also, 
oxidative glutaminolysis to pyruvate through ME served as a significant source of NADPH 
for glioma cells (DeBerardinis et al., 2007).  
As mentioned earlier, the increased M+3 AKG and glutamate labeling, and M+2 
succinate, fumarate, malate, and aspartate labeling from [U-13C] glutamine in the high 
lactate cultures represents increased oxidative glutamine metabolism and higher retention 
of 13C-labeled metabolites in the TCA. This was also coupled with increased malate 
dehydrogenase (MDH) activity in the high lactate cultures, as illustrated by increased flux 
of oxaloacetate to malate in the cytosol and increased flux of malate to oxaloacetate in the 
mitochondria (Figure 4.16 and 4.17). Along with this, increased malate transport from the 
cytosol to the mitochondria was predicted. These results suggest increased malate-aspartate 
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shuttle activity in the high lactate culture conditions. The malate-aspartate shuttle is 
responsible for transporting reducing cofactors from the cytosol to the mitochondria 
(Mulukutla et al., 2010). Since lactate was metabolized to pyruvate in the high lactate 
cultures, this would result in elevated cytosolic NADH production. Therefore, increased 
malate shuttle activity would support transport of reducing cofactors generated from lactate 
catabolism into the mitochondria for oxidative phosphorylation. These results illustrate an 
underlying metabolic flexibility of iPSCs in response to low glucose and high lactate 
culture conditions. 
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Figure 4.16. Metabolic flux maps for K3 iPSC predicted from the MFA simulations: 
A) Control and B) High Lactate cultures. The line thicknesses represent the relative 
fluxes, which are also shown numerically (nmol/106 cells·h).  
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Figure 4.17. Metabolic flux maps for K3 iPSC predicted from the MFA simulations: 
A) Low Glucose and B) Low Glucose + High Lactate cultures. The line thicknesses 
represent the relative fluxes, which are also shown numerically (nmol/106 cells·h).  
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Figure 4.18. Comparison of simulated metabolic fluxes from 13C-MFA for K3 iPSCs. 
A) Key extracellular uptake and secretion rates. B) TCA cycle metabolic fluxes. C). 
Anaplerotic fluxes. Control media – ¢; Low Glucose media – £; High Lactate media – 
u; and Low Glucose + High Lactate – ¯. Error bars represent 95% confidence intervals. 
Abbreviations: CS, citrate synthase; ACON/IDH, aconitase/isocitrate dehydrogenase; 
AKGD/SCS, AKG dehydrogenase/succinyl coenzyme A synthetase; SDH succinate 
dehydrogenase; FUM, fumarase; MDH, malate dehydrogenase; GDH/AT, glutamate 
dehydrogenase/aminotransferase; ME, malic enzyme; PC, pyruvate carboxylase.  
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4.5. Conclusions 
In this study, the metabolic responses of K3 iPSCs to different glucose and lactate 
concentrations that range from normal to low for glucose and zero to high (20 mM) for 
lactate were examined using 13C-MFA. Parallel labeling experiments were performed 
using 13C-glucose, 13C-glutamine, and 13C-lactate to determine the contribution of each as 
metabolites to central carbon metabolism. [1,2-13C] glucose and [U-13C] glutamine were 
used to resolve intracellular fluxes through glycolysis and the TCA cycle. For the two high 
lactate culture conditions, the [U-13C] lactate tracer was also used to investigate the 
metabolic contribution of lactate to iPSC metabolism. The metabolic network model 
constructed for iPSCs in this study was adapted from metabolic models constructed for 
Chinese hamster ovary (CHO) cells and for other mammalian cells, including cancer cells. 
The extracellular flux measurements and measured intracellular MIDS were coupled with 
a defined metabolic network to predict intracellular fluxes. Pluripotency of the K3 iPSCs 
were assessed by comparing gene and protein expression levels for cells cultured for one 
and five passages in each of the media.  
While lactate is primarily viewed as a metabolic waste product in in vitro iPSC 
culture, the results from this study suggest that lactate accumulation alone does not 
adversely impact iPSC growth or pluripotency at the concentrations tested. Also, these 
results support the idea that media acidification, which results from lactate production, is 
potentially the root of the problem associated with continuous iPSC culture, rather than 
lactate alone. Therefore, as more iPSC culture processes move towards pH-controlled 
bioreactors, lactate accumulation may not be associated with poor quality iPSCs. In 
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addition, since low glucose and high lactate growth media did not adversely impact iPSC 
proliferation or pluripotency, this indicates that implementation of fed-batch bioprocessing 
conditions for iPSCs is feasible in the future. 
The findings in this study also illustrate that iPSCs possess metabolic flexibility 
with regards to lactate metabolism, which has not been previously reported. This flexibility 
allows for iPSCs to undergo distinct substrate utilization strategies to support self-renewal 
when cultured in a range of glucose and lactate concentrations. In rapidly proliferating 
cells, dual consumption of glucose and lactate could support replication and cell division 
since carbon from glucose and lactate can be compartmentalized to synthesize different 
biomass precursors. Since iPSCs are frequently cultured in 3D aggregates when grown in 
suspension, substrate availability depends on aggregate size and the proximity of cells to 
the aggregate surface. Metabolic flexibility would support proliferation of cells in different 
regions of a cell aggregate without adversely influencing pluripotency. The results from 
this study illustrate that K3 iPSCs possess the ability to metabolize lactate as a metabolic 
substrate to support cell proliferation and pluripotency maintenance, even in the presence 
of sufficient glucose.  
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CHAPTER FIVE 
 
CONCLUSIONS AND FUTURE WORK 
 
5.1. Conclusions 
The work contained in this dissertation utilized 13C-MFA to investigate the Warburg 
phenotype in proliferative mammalian cells and determine the role of lactate as a substrate 
for breast cancer and induced pluripotent stem cell metabolism. In Chapter 3, the 
intracellular metabolic responses of three breast cell lines – MCF 10A, MCF7, and MDA-
MB-231 – to high extracellular lactate were characterized to identify shared and unique 
metabolic traits associated with cancer progression. Interestingly, it was observed that all 
three breast cell lines employed reductive glutamine metabolism in each of the high lactate 
cultures. This suggests a potential response mechanism for breast cancer cells to high 
lactate stress. In Chapter 4, the metabolic responses of human K3 iPSCs to low glucose 
and high lactate media culture concentrations were identified using parallel 13C isotope 
labeling and 13C-MFA. High extracellular lactate resulted in retention of glutamine-derived 
carbon within TCA cycle and lower glutaminolysis to pyruvate and lactate. Surprisingly, 
K3 iPSCs also catabolized extracellular lactate to support mitochondrial oxidative 
metabolism and lipid biosynthesis. Lactate also appears to support lipid synthesis. 
Moreover, iPSCs utilized lactate as a carbon source while maintaining pluripotency. 
Overall, this dissertation work provides intracellular metabolic pathway distributions for 
breast cancer cells and iPSCs in response to high extracellular lactate. This work highlights 
the flexibility of substrate utilization for cancer and pluripotent stem cells and illustrates 
that lactate is more than just an inhibitory byproduct of glycolysis. Indeed, wasteful no 
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more. 
 
5.2. Future Work 
The iPSC work in this dissertation was driven by the clinical need to generate 
sufficient quantities of high quality iPSCs for cell-therapy applications. Therefore, the 
obvious next step in this project is to determine the effects of glucose and lactate 
concentration on iPSCs grown in suspension cultures in controlled bioreactors. Using 
bioreactors will provide a more controlled environment to evaluate the effects of each of 
these culture parameters. Also, the differentiation capacity of iPSC grown in low glucose 
and high lactate culture conditions should be assessed further. This will provide valuable 
information regarding the functional capabilities of iPSCs as a result of culturing in 
different media formulations. Furthermore, since iPSCs are donor-specific, metabolic 
responses to cell culture perturbations should be screened on a wider population of iPSCs 
generated from healthy donors. Ultimately, iPSCs need to be exhaustively characterized to 
develop efficacious cell-therapies. 
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Appendix A 
 
Measured extracellular metabolite concentrations for the three breast cell lines – MCF 
10A, MCF7, and MDA-MB-231 
 
Table A1. Measured extracellular metabolite concentrations for the MCF 10A breast cell 
line at 24-h and 48-h after the media exchange. Averages are biological triplicates for the 
amino acid concentrations and biological 6-replicates for glucose and lactate. Standard 
deviations are provided for these averages. 
 
 
  Average Concentration (mM) 
Cell Lines MCF 10A 
Condition Control High-Lactate 
Metabolite 24-h SD 48-h SD 24-h SD 48-h SD 
Glucose (N=6) 4.3 0.248 3.31 0.345 4.42 0.173 3.63 0.332 
Lactate (N=6) 1.12 0.116 2.81 0.139 10.8 0.217 11.9 0.271 
Glutamine (N=3) 2.72 0.026 2.39 0.07 2.73 0.034 2.37 0.06 
Amino Acids                 
(N=3) 
Alanine 0.03 0.001 0.08 0.002 0.03 0.001 0.08 0.003 
Aspartate 0.01 0.001 0.04 0.003 0.01 0.001 0.03 0.002 
Glutamate 0.03 0.003 0.09 0.005 0.03 0.003 0.07 0.003 
Glycine 0.38 0.006 0.41 0.007 0.38 0.02 0.4 0.013 
Isoleucine 0.7 0.012 0.66 0.009 0.69 0.008 0.66 0.006 
Leucine 0.7 0.012 0.67 0.007 0.7 0.009 0.67 0.015 
Methionine 0.18 0.004 0.17 0.006 0.17 0.004 0.17 0.003 
Phenylalanine 0.35 0.009 0.33 0.01 0.35 0.005 0.33 0.008 
Proline 0.01 0.001 0.01 0.001 0 0.001 0.01 0.001 
Serine 0.31 0.006 0.23 0.008 0.3 0.013 0.21 0.006 
Threonine 0.71 0.004 0.71 0.006 0.71 0.004 0.71 0.005 
Tyrosine 0.35 0.009 0.33 0.006 0.35 0.006 0.33 0.012 
Valine 0.71 0.007 0.68 0.009 0.7 0.005 0.68 0.007 
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Table A2. Measured extracellular metabolite concentrations for the MCF7 breast cell line 
at 24-h and 48-h after the media exchange. Averages are biological triplicates for the amino 
acid concentrations and biological 6-replicates for glucose and lactate. Standard deviations 
are provided for these averages. 
 
  Average Concentration (mM) 
Cell Lines MCF7 
Condition Control High-Lactate 
Metabolite 24-h SD 48-h SD 24-h SD 48-h SD 
Glucose (N=6) 4.32 0.206 3.32 0.231 4.5 0.195 3.78 0.250 
Lactate (N=6) 1.03 0.100 2.55 0.131 20.5 0.108 21.1 0.193 
Glutamine (N=3) 2.72 0.046 2.35 0.060 2.71 0.034 2.31 0.051 
Amino Acids                 
(N=3) 
Alanine 0.04 0.002 0.1 0.004 0.03 0.004 0.09 0.004 
Aspartate 0.02 0.002 0.05 0.005 0.01 0.002 0.04 0.003 
Glutamate 0.04 0.003 0.09 0.005 0.04 0.003 0.09 0.003 
Glycine 0.39 0.016 0.44 0.013 0.39 0.009 0.43 0.017 
Isoleucine 0.69 0.010 0.65 0.003 0.69 0.008 0.65 0.008 
Leucine 0.7 0.005 0.66 0.018 0.7 0.009 0.66 0.009 
Methionine 0.17 0.004 0.16 0.007 0.17 0.003 0.16 0.005 
Phenylalanine 0.35 0.006 0.33 0.007 0.35 0.004 0.33 0.009 
Proline 0.01 0.001 0.02 0.002 0.01 0.001 0.02 0.001 
Serine 0.3 0.015 0.2 0.012 0.29 0.018 0.19 0.013 
Threonine 0.72 0.001 0.71 0.004 0.72 0.002 0.71 0.004 
Tyrosine 0.35 0.005 0.33 0.007 0.35 0.005 0.33 0.009 
Valine 0.69 0.006 0.65 0.009 0.69 0.008 0.64 0.018 
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Table A3. Measured extracellular metabolite concentrations for the MDA-MB-231 breast 
cell line at 24-h and 48-h after the media exchange. Averages are biological triplicates for 
the amino acid concentrations and biological 6-replicates for glucose and lactate. Standard 
deviations are provided for these averages. 
 
  Average Concentration (mM) 
Cell Lines MDA-MB-231 
Condition Control High-Lactate 
Metabolite 24-h SD 48-h SD 24-h SD 48-h SD 
Glucose (N=6) 4.05 0.233 2.38 0.238 4.2 0.124 2.9 0.247 
Lactate (N=6) 1.8 0.206 4.8 0.242 21 0.202 22.7 0.323 
Glutamine (N=3) 2.75 0.047 2.42 0.079 2.73 0.045 2.34 0.061 
Amino Acids                 
(N=3) 
Alanine 0.03 0.002 0.08 0.004 0.03 0.002 0.07 0.003 
Aspartate 0.01 0.001 0.03 0.003 0.01 0.001 0.03 0.003 
Glutamate 0.03 0.004 0.07 0.003 0.03 0.002 0.08 0.003 
Glycine 0.38 0.008 0.42 0.011 0.38 0.010 0.42 0.013 
Isoleucine 0.71 0.009 0.68 0.007 0.7 0.007 0.65 0.009 
Leucine 0.71 0.009 0.68 0.013 0.69 0.007 0.65 0.007 
Methionine 0.18 0.001 0.17 0.003 0.17 0.004 0.16 0.006 
Phenylalanine 0.35 0.002 0.34 0.006 0.35 0.002 0.33 0.014 
Proline 0 0.000 0.01 0.001 0 0.000 0.01 0.001 
Serine 0.32 0.012 0.24 0.011 0.3 0.013 0.2 0.005 
Threonine 0.72 0.001 0.71 0.005 0.71 0.002 0.71 0.006 
Tyrosine 0.35 0.010 0.33 0.007 0.35 0.004 0.33 0.011 
Valine 0.70 0.009 0.67 0.006 0.69 0.002 0.65 0.007 
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Appendix B 
 
Metabolic reactions used in the 13C-MFA simulations for the three breast cell lines 
 
Table B1. The metabolic reactions used in the 13C-MFA simulations for the three breast 
cell lines. Suffixes indicate compartmental location of the metabolite: .ext, extracellular; 
.c, cytosolic; .m, mitochondrial; .tr, tracer; .snk, dilution sink. 
 
v1 Gluc.ext (abcdef) -> G6P.c (abcdef) 
v2 G6P.c (abcdef) <=> F6P.c (net) (abcdef) v3 F6P.c (abcdef) -> FBP.c (abcdef) 
v4 FBP.c (abcdef) <=>DHAP.c (cba) + GAP.c (def)  
v5 DHAP.c (abc) <=> GAP.c (abc) 
v6 GAP.c (abc) <=> 3PG.c (abc)  
v7 3PG.c (abc)<=> Pyr.c (abc) 
v8 G6P.c (abcdef) -> CO2 (a) + Ru5P.c (bcdef)  
v9 Ru5P.c (abcde) <=> R5P.c (abcde) 
v10 Ru5P.c (abcde) <=> X5P.c (net) (abcde) 
v11 X5P.c (abcde) + R5P.c (fghij) <=> GAP.c (cde) + S7P.c (abfghij)  
v12 S7P.c (abcdefg) + GAP.c (hij) <=> E4P.c (defg) + F6P.c (abchij)  
v13 X5P.c (abcde) + E4P.c (fghi) <=> GAP.c (cde) + F6P.c (abfghi)  
v14 Pyr.c (abc) <=> Lact.c (abc) 
v15 Pyr.c (abc)-> CO2 (a) + AcCoA.m (bc) 
v16 AcCoA.m (ab) + OAA.m (cdef) -> Cit.m (fedbac)  
v17 Cit.m (abcdef) <=> AKG.m (abcde) + CO2 (f)  
v18 AKG.m (abcde) -> CO2 (a) + Suc.m (bcde) 
v19 Suc.m (abcd) <=> Fum.m (abcd)  
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v20 Fum.m (abcd) <=> Mal.m (abcd)  
v21 Mal.m (abcd) <=> OAA.m (abcd)  
v22 Gln.c (abcde) -> Glu.c (abcde)  
v23 Ser.c (abc) <=> Pyr.c (abc) 
v24 Gln.ext (abcde) -> Gln.c (abcde)  
v25 Asp.c (abcd) -> Asp.ext (abcd)  
v26 Ser.ext (abc) -> Ser.c (abc) 
v27 Ala.c (abc) -> Ala.ext (abc) 
v28 Glu.c (abcde) -> Glu.ext (abcde)  
v29 Lact.c (abc) -> Lact.ext (abc) 
v30 Glu.c (abcde) <=> AKG.m (abcde)   
v31 Mal.m (abcd) -> Pyr.c (abc)+ CO2 (d) 
v32 Cit.m (abcdef) -> OAA.m (cdef)+ AcCoA.c (ab)  
v33 Pyr.c (abc) + CO2 (d) -> OAA.m (abcd) 
v34 0.95 AcCoA.c + 0.05 DHAP.c -> Lipid 
v35 Pyr.c (abc) + Glu.c (defgh) <=> Ala.c (abc) + AKG.m (defgh) 
v36 OAA.m (abcd) + Glu.c (efghi) <=> Asp.c (abcd) + AKG.m (efghi) 
v37 0.23 Ala.c + 0.14 Asp.c + 0.12 Gln.c + 0.15 Glu.c + 0.16 Ser.c + 0.11 G6P.c  
 + 0.09 R5P.c -> Biomass 
v38 Lact.c (abc) + Lact.tr (def) -> Lact.c (def) + Lact.snk (abc) 
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Appendix C 
 
Metabolism of labeled lactate through the TCA cycle 
 
 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Figure C1. Metabolism of labeled lactate through the TCA cycle. A) M2-labeled TCA 
intermediates are generated from [U-13C] lactate (Lac). B) M1-labeled a-oxoglutarate 
(AKG) and oxaloacetate (OAA) are generated from unlabeled pyruvate (Pyr) combining 
with M2- labeled oxaloacetate (OAA). M1 citrate is generated via citrate synthase through 
the combination of M1-labeled oxaloacetate (OAA) and M0 acetyl-CoA (AcCoA). For 
clarity, some reaction pathways were condensed. 
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Appendix D 
 
Measured intracellular MIDs from [1,2-13C] glucose, [U-13C] glutamine, and [U-13C] lactate for the three breast cell lines  
 
Table D1. Measured intracellular MIDs from the [1,2-13C] glucose tracer for the three breast cell lines for the control and high-
lactate conditions with mean and standard errors. MIDs shown below have not been corrected for natural abundance. A standard 
error of 0.006 represents the lower limit error cutoff reported for most instruments (Ahn and Antoniewicz, 2013; Metallo et al., 
2009), which was applied even when the biological replicates had observed lower standard error.   
 
Cell Line MCF 10A MCF7 MDA-MB-231 
Condition Control High-Lactate Control High-Lactate Control High-Lactate 
 MID SE MID SE MID       SE MID SE MID SE MID SE 
PEP 453             
M0 0.3701 0.0129 0.3501 0.0078 0.3606 0.0119 0.3666 0.0111 0.3459 0.0147 0.3906 0.0060 
M1 0.1654 0.0129 0.1515 0.0078 0.1507 0.0119 0.1527 0.0111 0.1527 0.0147 0.1570 0.0060 
M2 0.3159 0.0129 0.3333 0.0078 0.3330 0.0119 0.3248 0.0111 0.3339 0.0147 0.3042 0.0060 
M3 0.0994 0.0129 0.1045 0.0078 0.1064 0.0119 0.1008 0.0111 0.1097 0.0147 0.0962 0.0060 
M4 0.0394 0.0129 0.0502 0.0078 0.0394 0.0119 0.0448 0.0111 0.0477 0.0147 0.0422 0.0060 
M5 0.0098 0.0129 0.0104 0.0078 0.0099 0.0119 0.0101 0.0111 0.0101 0.0147 0.0098 0.0060 
3PG 585             
M0 0.3128 0.0083 0.3014 0.0075 0.3119 0.0143 0.3060 0.0142 0.3060 0.0140 0.3018 0.0064 
M1 0.1675 0.0083 0.1647 0.0075 0.1650 0.0143 0.1643 0.0142 0.1643 0.0140 0.1653 0.0064 
M2 0.3108 0.0083 0.3194 0.0075 0.3119 0.0143 0.3183 0.0142 0.3183 0.0140 0.3202 0.0064 
M3 0.1292 0.0083 0.1327 0.0075 0.1308 0.0143 0.1314 0.0142 0.1314 0.0140 0.1322 0.0064 
M4 0.0605 0.0083 0.0639 0.0075 0.0603 0.0143 0.0606 0.0142 0.0606 0.0140 0.0610 0.0064 
M5 0.0192 0.0083 0.0180 0.0075 0.0201 0.0143 0.0195 0.0142 0.0195 0.0140 0.0196 0.0064 
DHAP 484             
M0 0.2323 0.0112 0.3273 0.0100 0.3421 0.0137 0.2781 0.0097 0.2781 0.0139 0.3391 0.0103 
M1 0.1413 0.0112 0.1514 0.0100 0.1484 0.0137 0.1379 0.0097 0.1379 0.0139 0.1479 0.0103 
M2 0.4147 0.0112 0.3436 0.0100 0.3401 0.0137 0.3893 0.0097 0.3893 0.0139 0.3391 0.0103 
M3 0.1404 0.0112 0.1165 0.0100 0.1134 0.0137 0.1290 0.0097 0.1290 0.0139 0.1139 0.0103 
M4 0.0617 0.0112 0.0497 0.0100 0.0453 0.0137 0.0556 0.0097 0.0556 0.0139 0.0486 0.0103 
M5 0.0096 0.0112 0.0116 0.0100 0.0106 0.0137 0.0101 0.0097 0.0100 0.0139 0.0113 0.0103 
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Cell Line MCF 10A MCF7 MDA-MB-231 
Condition Control High-Lactate Control High-Lactate Control High-Lactate 
 MID SE MID SE MID       SE MID SE MID SE MID SE 
PYR 174             
M0 0.5318 0.0146 0.5581 0.0071 0.5258 0.0188 0.5350 0.0136 0.4816 0.0132 0.5581 0.0114 
M1 0.1062 0.0146 0.0948 0.0071 0.0969 0.0188 0.0975 0.0136 0.0976 0.0132 0.0948 0.0114 
M2 0.3125 0.0146 0.2983 0.0071 0.3196 0.0188 0.3170 0.0136 0.3579 0.0132 0.2983 0.0114 
M3 0.0320 0.0146 0.0335 0.0071 0.0361 0.0188 0.0345 0.0136 0.0412 0.0132 0.0335 0.0114 
M4 0.0134 0.0146 0.0125 0.0071 0.0134 0.0188 0.0129 0.0136 0.0130 0.0132 0.0125 0.0114 
M5 0.0041 0.0146 0.0029 0.0071 0.0082 0.0188 0.0029 0.0136 0.0087 0.0132 0.0029 0.0114 
ALA 260             
M0 0.4656 0.0148 0.4813 0.0111 0.4661 0.0197 0.4654 0.0101 0.4258 0.0131 0.4912 0.0085 
M1 0.1453 0.0148 0.1348 0.0111 0.1322 0.0197 0.1347 0.0101 0.1331 0.0131 0.1339 0.0085 
M2 0.2993 0.0148 0.2936 0.0111 0.3125 0.0197 0.3069 0.0101 0.3393 0.0131 0.2854 0.0085 
M3 0.0616 0.0148 0.0616 0.0111 0.0637 0.0197 0.0634 0.0101 0.0719 0.0131 0.0600 0.0085 
M4 0.0234 0.0148 0.0231 0.0111 0.0196 0.0197 0.0237 0.0101 0.0240 0.0131 0.0236 0.0085 
M5 0.0048 0.0148 0.0058 0.0111 0.0059 0.0197 0.0059 0.0101 0.0060 0.0131 0.0059 0.0085 
LAC 261             
M0 0.4668 0.0124 0.4862 0.0102 0.4611 0.0197 0.4926 0.0112 0.4233 0.0148 0.4971 0.0152 
M1 0.1451 0.0124 0.1335 0.0102 0.1332 0.0197 0.1360 0.0112 0.1325 0.0148 0.1345 0.0152 
M2 0.2987 0.0124 0.2908 0.0102 0.3176 0.0197 0.2838 0.0112 0.3426 0.0148 0.2807 0.0152 
M3 0.0612 0.0124 0.0610 0.0102 0.0615 0.0197 0.0581 0.0112 0.0717 0.0148 0.0585 0.0152 
M4 0.0234 0.0124 0.0228 0.0102 0.0205 0.0197 0.0236 0.0112 0.0239 0.0148 0.0233 0.0152 
M5 0.0048 0.0124 0.0057 0.0102 0.0061 0.0197 0.0059 0.0112 0.0060 0.0148 0.0058 0.0152 
GLP 571             
M0 0.2072 0.0067 0.2895 0.0086 0.2973 0.0166 0.2415 0.0100 0.2394 0.0145 0.2976 0.0121 
M1 0.1437 0.0067 0.1619 0.0086 0.1589 0.0166 0.1449 0.0100 0.1455 0.0145 0.1601 0.0121 
M2 0.3812 0.0067 0.3278 0.0086 0.3226 0.0166 0.3622 0.0100 0.3606 0.0145 0.3229 0.0121 
M3 0.1642 0.0067 0.1369 0.0086 0.1365 0.0166 0.1531 0.0100 0.1559 0.0145 0.1361 0.0121 
M4 0.0811 0.0067 0.0648 0.0086 0.0682 0.0166 0.0768 0.0100 0.0770 0.0145 0.0644 0.0121 
M5 0.0225 0.0067 0.0191 0.0086 0.0166 0.0166 0.0214 0.0100 0.0216 0.0145 0.0189 0.0121 
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Table D2. Measured intracellular MIDs from [U-13C] glutamine tracer for the three breast cancer cell lines for the control and 
high- lactate conditions with mean and standard errors. MIDs shown below have not been corrected for natural abundance. A 
standard error of 0.006 represents the lower limit error cutoff reported for most instruments (Ahn and Antoniewicz, 2013; Metallo 
et al., 2009), which was applied even when the biological replicates had observed lower standard error. 
 
 
Cell Line MCF 10A MCF7 MDA-MB-231 
Condition Control High-Lactate Control High-Lactate Control High-Lactate 
 MID SE MID SE MID SE MID SE MID SE MID SE 
PYR 174             
M0 0.824 0.0088 0.8022 0.006 0.8068 0.0158 0.8301 0.009 0.837 0.0081 0.808 0.0103 
M1 0.1061 0.0088 0.1124 0.006 0.1187 0.0158 0.107 0.009 0.105 0.0081 0.111 0.0103 
M2 0.0424 0.0088 0.0462 0.006 0.0451 0.0158 0.04 0.009 0.042 0.0081 0.046 0.0103 
M3 0.0242 0.0088 0.0358 0.006 0.0261 0.0158 0.0195 0.009 0.013 0.0081 0.033 0.0103 
M4 0.0024 0.0088 0.0026 0.006 0.0024 0.0158 0.0025 0.009 0.002 0.0081 0.003 0.0103 
M5 0.0009 0.0088 0.0009 0.006 0.0009 0.0158 0.0009 0.009 0.001 0.0081 0.001 0.0103 
ALA 260             
M0 0.7278 0.0094 0.7047 0.0097 0.7235 0.018 0.732 0.006 0.737 0.0083 0.713 0.007 
M1 0.1654 0.0094 0.1693 0.0097 0.1608 0.018 0.1637 0.006 0.165 0.0083 0.167 0.007 
M2 0.0717 0.0094 0.0757 0.0097 0.0769 0.018 0.0713 0.006 0.071 0.0083 0.075 0.007 
M3 0.0276 0.0094 0.0415 0.0097 0.031 0.018 0.025 0.006 0.02 0.0083 0.037 0.007 
M4 0.0066 0.0094 0.0073 0.0097 0.0069 0.018 0.0066 0.006 0.006 0.0083 0.007 0.007 
M5 0.0009 0.0094 0.0014 0.0097 0.0009 0.018 0.0013 0.006 0.001 0.0083 0.001 0.007 
LAC 261             
M0 0.7185 0.0072 0.6983 0.006 0.7079 0.0165 0.7275 0.0066 0.731 0.0081 0.708 0.0118 
M1 0.1684 0.0072 0.173 0.006 0.1741 0.0165 0.1679 0.0066 0.169 0.0081 0.17 0.0118 
M2 0.0752 0.0072 0.0774 0.006 0.0812 0.0165 0.0727 0.0066 0.072 0.0081 0.076 0.0118 
M3 0.0303 0.0072 0.0424 0.006 0.029 0.0165 0.0242 0.0066 0.021 0.0081 0.037 0.0118 
M4 0.0067 0.0072 0.0075 0.006 0.007 0.0165 0.0064 0.0066 0.006 0.0081 0.007 0.0118 
M5 0.0009 0.0072 0.0014 0.006 0.0008 0.0165 0.0012 0.0066 0.001 0.0081 0.001 0.0118 
CIT 459             
M0 0.3039 0.0092 0.2524 0.0074 0.3221 0.0126 0.2455 0.0064 0.308 0.0102 0.251 0.0074 
M1 0.1583 0.0092 0.1359 0.0074 0.1491 0.0126 0.1417 0.0064 0.154 0.0102 0.153 0.0074 
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Cell Line MCF 10A MCF7 MDA-MB-231 
Condition Control High-Lactate Control High-Lactate Control High-Lactate 
 MID SE MID SE MID SE MID SE MID SE MID SE 
M2 0.1427 0.0092 0.1306 0.0074 0.1292 0.0126 0.1322 0.0064 0.133 0.0102 0.135 0.0074 
M3 0.0874 0.0092 0.09 0.0074 0.0895 0.0126 0.0872 0.0064 0.092 0.0102 0.093 0.0074 
M4 0.199 0.0092 0.1845 0.0074 0.1889 0.0126 0.1649 0.0064 0.185 0.0102 0.165 0.0074 
M5 0.068 0.0092 0.1359 0.0074 0.0795 0.0126 0.1417 0.0064 0.082 0.0102 0.131 0.0074 
M6 0.0291 0.0092 0.0487 0.0074 0.0298 0.0126 0.0614 0.0064 0.034 0.0102 0.05 0.0074 
M7 0.0087 0.0092 0.0156 0.0074 0.0089 0.0126 0.0189 0.0064 0.009 0.0102 0.016 0.0074 
M8 0.0029 0.0092 0.0066 0.0074 0.003 0.0126 0.0066 0.0064 0.003 0.0102 0.007 0.0074 
AKG 346             
M0 0.2076 0.006 0.1916 0.006 0.2326 0.0128 0.2037 0.007 0.207 0.0102 0.221 0.006 
M1 0.1023 0.006 0.0993 0.006 0.091 0.0128 0.1034 0.007 0.094 0.0102 0.106 0.006 
M2 0.0789 0.006 0.0725 0.006 0.0808 0.0128 0.0755 0.007 0.08 0.0102 0.074 0.006 
M3 0.1189 0.006 0.139 0.006 0.1163 0.0128 0.1354 0.007 0.113 0.0102 0.129 0.006 
M4 0.0448 0.006 0.0477 0.006 0.0404 0.0128 0.0507 0.007 0.043 0.0102 0.046 0.006 
M5 0.3402 0.006 0.3455 0.006 0.3276 0.0128 0.3256 0.007 0.358 0.0102 0.318 0.006 
M6 0.078 0.006 0.0745 0.006 0.0811 0.0128 0.0744 0.007 0.075 0.0102 0.076 0.006 
M7 0.0292 0.006 0.0301 0.006 0.0303 0.0128 0.0313 0.007 0.028 0.0102 0.031 0.006 
GLU 432             
M0 0.1701 0.0082 0.17 0.006 0.1878 0.009 0.1425 0.0074 0.175 0.0097 0.184 0.0065 
M1 0.0977 0.0082 0.098 0.006 0.0995 0.009 0.0855 0.0074 0.098 0.0097 0.108 0.0065 
M2 0.0791 0.0082 0.076 0.006 0.0832 0.009 0.0617 0.0074 0.082 0.0097 0.076 0.0065 
M3 0.1109 0.0082 0.123 0.006 0.1117 0.009 0.1007 0.0074 0.109 0.0097 0.121 0.0065 
M4 0.0521 0.0082 0.057 0.006 0.0508 0.009 0.0541 0.0074 0.055 0.0097 0.056 0.0065 
M5 0.3353 0.0082 0.3251 0.006 0.3147 0.009 0.3751 0.0074 0.328 0.0097 0.308 0.0065 
M6 0.1049 0.0082 0.101 0.006 0.1015 0.009 0.1235 0.0074 0.104 0.0097 0.099 0.0065 
M7 0.0501 0.0082 0.05 0.006 0.0508 0.009 0.057 0.0074 0.049 0.0097 0.049 0.0065 
GLN 431             
M0 0.027 0.0121 0.0289 0.006 0.0209 0.0184 0.0317 0.006 0.024 0.0086 0.033 0.0073 
M1 0.0108 0.0121 0.0108 0.006 0.0105 0.0184 0.0123 0.006 0.012 0.0086 0.012 0.0073 
M2 0.0049 0.0121 0.0049 0.006 0.0063 0.0184 0.0058 0.006 0.006 0.0086 0.006 0.0073 
M3 0.0023 0.0121 0.0023 0.006 0.0032 0.0184 0.002 0.006 0.003 0.0086 0.002 0.0073 
M4 0.028 0.0121 0.0299 0.006 0.0214 0.0184 0.0324 0.006 0.02 0.0086 0.031 0.0073 
M5 0.6252 0.0121 0.6232 0.006 0.6216 0.0184 0.6239 0.006 0.638 0.0086 0.622 0.0073 
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Cell Line MCF 10A MCF7 MDA-MB-231 
Condition Control High-Lactate Control High-Lactate Control High-Lactate 
 MID SE MID SE MID SE MID SE MID SE MID SE 
M6 0.2048 0.0121 0.2033 0.006 0.2107 0.0184 0.2013 0.006 0.198 0.0086 0.203 0.0073 
M7 0.097 0.0121 0.0969 0.006 0.1054 0.0184 0.0906 0.006 0.099 0.0086 0.091 0.0073 
PRO 258             
M0 0.2022 0.0075 0.2024 0.006 0.2245 0.0126 0.1684 0.0061 0.212 0.0123 0.22 0.0062 
M1 0.1085 0.0075 0.1136 0.006 0.102 0.0126 0.0982 0.0061 0.106 0.0123 0.118 0.0062 
M2 0.1497 0.0075 0.161 0.006 0.1531 0.0126 0.131 0.0061 0.155 0.0123 0.155 0.0062 
M3 0.0493 0.0075 0.0494 0.006 0.051 0.0126 0.0505 0.0061 0.053 0.0123 0.05 0.0062 
M4 0.3818 0.0075 0.3703 0.006 0.3571 0.0126 0.4303 0.0061 0.372 0.0123 0.353 0.0062 
M5 0.0784 0.0075 0.0731 0.006 0.0816 0.0126 0.0842 0.0061 0.071 0.0123 0.073 0.0062 
M6 0.0301 0.0075 0.0302 0.006 0.0306 0.0126 0.0374 0.0061 0.031 0.0123 0.03 0.0061 
SUCC 289             
M0 0.3317 0.006 0.3135 0.0074 0.3542 0.015 0.3304 0.0126 0.33 0.0136 0.358 0.0176 
M1 0.1275 0.006 0.1302 0.0074 0.1302 0.015 0.1369 0.0126 0.125 0.0136 0.136 0.0176 
M2 0.1444 0.006 0.1511 0.0074 0.1354 0.015 0.1479 0.0126 0.131 0.0136 0.143 0.0176 
M3 0.0428 0.006 0.0504 0.0074 0.0417 0.015 0.0484 0.0126 0.04 0.0136 0.048 0.0176 
M4 0.2739 0.006 0.2803 0.0074 0.2604 0.015 0.2647 0.0126 0.294 0.0136 0.245 0.0176 
M5 0.0598 0.006 0.0544 0.0074 0.0573 0.015 0.0523 0.0126 0.057 0.0136 0.051 0.0176 
M6 0.0199 0.006 0.0201 0.0074 0.0208 0.015 0.0194 0.0126 0.023 0.0136 0.019 0.0176 
FUM 287             
M0 0.3642 0.0093 0.3432 0.0083 0.3769 0.0145 0.3564 0.0082 0.378 0.0124 0.37 0.0122 
M1 0.1332 0.0093 0.132 0.0083 0.1296 0.0145 0.1391 0.0082 0.131 0.0124 0.141 0.0122 
M2 0.1414 0.0093 0.1452 0.0083 0.1396 0.0145 0.1434 0.0082 0.138 0.0124 0.141 0.0122 
M3 0.0407 0.0093 0.0528 0.0083 0.0389 0.0145 0.0489 0.0082 0.039 0.0124 0.053 0.0122 
M4 0.2543 0.0093 0.2578 0.0083 0.2443 0.0145 0.2447 0.0082 0.25 0.0124 0.229 0.0122 
M5 0.0458 0.0093 0.0504 0.0083 0.0469 0.0145 0.0492 0.0082 0.045 0.0124 0.049 0.0122 
M6 0.0203 0.0093 0.0187 0.0083 0.0239 0.0145 0.0182 0.0082 0.02 0.0124 0.018 0.0122 
MAL 419             
M0 0.3155 0.0099 0.2949 0.005 0.3287 0.0166 0.31 0.009 0.319 0.0101 0.323 0.0092 
M1 0.1555 0.0099 0.1523 0.005 0.1524 0.0166 0.157 0.009 0.147 0.0101 0.16 0.0092 
M2 0.143 0.0099 0.1499 0.005 0.1394 0.0166 0.1525 0.009 0.142 0.0101 0.15 0.0092 
M3 0.0715 0.0099 0.0688 0.005 0.0797 0.0166 0.062 0.009 0.076 0.0101 0.069 0.0092 
M4 0.2145 0.0099 0.2359 0.005 0.2052 0.0166 0.224 0.009 0.218 0.0101 0.205 0.0092 
M5 0.0724 0.0099 0.0688 0.005 0.0647 0.0166 0.0647 0.009 0.065 0.0101 0.064 0.0092 
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Cell Line MCF 10A MCF7 MDA-MB-231 
Condition Control High-Lactate Control High-Lactate Control High-Lactate 
 MID SE MID SE MID SE MID SE MID SE MID SE 
M6 0.0277 0.0099 0.0294 0.005 0.0299 0.0166 0.0299 0.009 0.033 0.0101 0.029 0.0092 
ASP 418             
M0 0.4362 0.006 0.4966 0.0111 0.4602 0.011 0.3267 0.009 0.46 0.0142 0.498 0.0121 
M1 0.1819 0.006 0.1978 0.0111 0.1902 0.011 0.1584 0.009 0.19 0.0142 0.198 0.0121 
M2 0.1309 0.006 0.1233 0.0111 0.1231 0.011 0.1484 0.009 0.123 0.0142 0.124 0.0121 
M3 0.0553 0.006 0.0393 0.0111 0.0501 0.011 0.0587 0.009 0.056 0.0142 0.044 0.0121 
M4 0.1362 0.006 0.0988 0.0111 0.1202 0.011 0.2082 0.009 0.119 0.0142 0.093 0.0121 
M5 0.0426 0.006 0.0302 0.0111 0.0401 0.011 0.0664 0.009 0.037 0.0142 0.03 0.0121 
M6 0.017 0.006 0.014 0.0111 0.016 0.011 0.0332 0.009 0.016 0.0142 0.014 0.0121 
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Table D3. Measured intracellular MIDs from [U-13C] lactate tracer for the three breast cell lines for the control and high-lactate 
conditions with mean and standard errors. MIDs shown below have not been corrected for natural abundance. A standard error 
of 0.006 represents the lower limit error cutoff reported for most instruments (Ahn and Antoniewicz, 2013; Metallo et al., 2009), 
which was applied even when the biological replicates had observed lower standard error. 
 
 
Cell Line MCF 10A MCF7 MDA-MB-231 
Condition Control High-Lactate Control High-Lactate Control High-Lactate 
 MID SE MID SE MID SE MID SE MID SE MID SE 
PYR 174             
M0 n/a n/a 0.8219 0.0065 n/a n/a 0.8166 0.0066 n/a n/a 0.8172 0.006 
M1 n/a n/a 0.1004 0.0065 n/a n/a 0.1069 0.0066 n/a n/a 0.1034 0.006 
M2 n/a n/a 0.0404 0.0065 n/a n/a 0.0389 0.0066 n/a n/a 0.0384 0.006 
M3 n/a n/a 0.0331 0.0065 n/a n/a 0.0339 0.0066 n/a n/a 0.0374 0.006 
M4 n/a n/a 0.0031 0.0065 n/a n/a 0.002 0.0066 n/a n/a 0.0026 0.006 
M5 n/a n/a 0.0008 0.0065 n/a n/a 0.0014 0.0066 n/a n/a 0.001 0.006 
ALA 260             
M0 n/a n/a 0.7268 0.0088 n/a n/a 0.7236 0.006 n/a n/a 0.7232 0.0072 
M1 n/a n/a 0.1622 0.0088 n/a n/a 0.1616 0.006 n/a n/a 0.1599 0.0072 
M2 n/a n/a 0.0706 0.0088 n/a n/a 0.0663 0.006 n/a n/a 0.0679 0.0072 
M3 n/a n/a 0.0313 0.0088 n/a n/a 0.0391 0.006 n/a n/a 0.0398 0.0072 
M4 n/a n/a 0.0071 0.0088 n/a n/a 0.0069 0.006 n/a n/a 0.0068 0.0072 
M5 n/a n/a 0.0019 0.0088 n/a n/a 0.0024 0.006 n/a n/a 0.0022 0.0072 
LAC 261             
M0 n/a n/a 0.7201 0.006 n/a n/a 0.6884 0.0088 n/a n/a 0.7146 0.0078 
M1 n/a n/a 0.1623 0.006 n/a n/a 0.158 0.0088 n/a n/a 0.1623 0.0078 
M2 n/a n/a 0.071 0.006 n/a n/a 0.0699 0.0088 n/a n/a 0.0689 0.0078 
M3 n/a n/a 0.0364 0.006 n/a n/a 0.0703 0.0088 n/a n/a 0.0435 0.0078 
M4 n/a n/a 0.008 0.006 n/a n/a 0.0098 0.0088 n/a n/a 0.008 0.0078 
M5 n/a n/a 0.0021 0.006 n/a n/a 0.0033 0.0088 n/a n/a 0.0022 0.0078 
CIT 459             
M0 n/a n/a 0.6202 0.0086 n/a n/a 0.6157 0.0114 n/a n/a 0.6182 0.006 
M1 n/a n/a 0.2303 0.0086 n/a n/a 0.2354 0.0114 n/a n/a 0.2331 0.006 
M2 n/a n/a 0.1101 0.0086 n/a n/a 0.1106 0.0114 n/a n/a 0.1107 0.006 
M3 n/a n/a 0.028 0.0086 n/a n/a 0.0272 0.0114 n/a n/a 0.027 0.006 
M4 n/a n/a 0.0073 0.0086 n/a n/a 0.007 0.0114 n/a n/a 0.0066 0.006 
M5 n/a n/a 0.0013 0.0086 n/a n/a 0.0013 0.0114 n/a n/a 0.0014 0.006 
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Cell Line MCF 10A MCF7 MDA-MB-231 
Condition Control High-Lactate Control High-Lactate Control High-Lactate 
 MID SE MID SE MID SE MID SE MID SE MID SE 
M6 n/a n/a 0.0011 0.0086 n/a n/a 0.0011 0.0114 n/a n/a 0.0011 0.006 
M7 n/a n/a 0.0008 0.0086 n/a n/a 0.0009 0.0114 n/a n/a 0.0009 0.006 
M8 n/a n/a 0.0008 0.0086 n/a n/a 0.0008 0.0114 n/a n/a 0.0008 0.006 
AKG 346             
M0 n/a n/a 0.7131 0.009 n/a n/a 0.7145 0.006 n/a n/a 0.7147 0.006 
M1 n/a n/a 0.1882 0.009 n/a n/a 0.1898 0.006 n/a n/a 0.1884 0.006 
M2 n/a n/a 0.0791 0.009 n/a n/a 0.0767 0.006 n/a n/a 0.0774 0.006 
M3 n/a n/a 0.0139 0.009 n/a n/a 0.0127 0.006 n/a n/a 0.0138 0.006 
M4 n/a n/a 0.0029 0.009 n/a n/a 0.0032 0.006 n/a n/a 0.0029 0.006 
M5 n/a n/a 0.0011 0.009 n/a n/a 0.0011 0.006 n/a n/a 0.0011 0.006 
M6 n/a n/a 0.0009 0.009 n/a n/a 0.001 0.006 n/a n/a 0.0007 0.006 
M7 n/a n/a 0.0006 0.009 n/a n/a 0.0008 0.006 n/a n/a 0.0007 0.006 
GLU 432             
M0 n/a n/a 0.6183 0.0125 n/a n/a 0.6257 0.006 n/a n/a 0.6248 0.006 
M1 n/a n/a 0.2354 0.0125 n/a n/a 0.2304 0.006 n/a n/a 0.2325 0.006 
M2 n/a n/a 0.1078 0.0125 n/a n/a 0.108 0.006 n/a n/a 0.108 0.006 
M3 n/a n/a 0.0293 0.0125 n/a n/a 0.0269 0.006 n/a n/a 0.0263 0.006 
M4 n/a n/a 0.0058 0.0125 n/a n/a 0.0061 0.006 n/a n/a 0.0056 0.006 
M5 n/a n/a 0.0019 0.0125 n/a n/a 0.0016 0.006 n/a n/a 0.0014 0.006 
M6 n/a n/a 0.0009 0.0125 n/a n/a 0.0009 0.006 n/a n/a 0.0009 0.006 
M7 n/a n/a 0.0001 0.0125 n/a n/a 0.0003 0.006 n/a n/a 0.0001 0.006 
GLN 431             
M0 n/a n/a 0.6261 0.006 n/a n/a 0.6253 0.0088 n/a n/a 0.624 0.006 
M1 n/a n/a 0.2323 0.006 n/a n/a 0.2344 0.0088 n/a n/a 0.2342 0.006 
M2 n/a n/a 0.108 0.006 n/a n/a 0.1065 0.0088 n/a n/a 0.1073 0.006 
M3 n/a n/a 0.0251 0.006 n/a n/a 0.0259 0.0088 n/a n/a 0.0262 0.006 
M4 n/a n/a 0.006 0.006 n/a n/a 0.0057 0.0088 n/a n/a 0.0059 0.006 
M5 n/a n/a 0.0012 0.006 n/a n/a 0.0012 0.0088 n/a n/a 0.0013 0.006 
M6 n/a n/a 0.0008 0.006 n/a n/a 0.0008 0.0088 n/a n/a 0.0008 0.006 
M7 n/a n/a 0.0001 0.006 n/a n/a 0.0001 0.0088 n/a n/a 0.0001 0.006 
PRO 258             
M0 n/a n/a 0.7343 0.0091 n/a n/a 0.7378 0.0048 n/a n/a 0.7373 0.006 
M1 n/a n/a 0.1811 0.0091 n/a n/a 0.1802 0.0048 n/a n/a 0.1778 0.006 
M2 n/a n/a 0.0704 0.0091 n/a n/a 0.0704 0.0048 n/a n/a 0.0698 0.006 
M3 n/a n/a 0.0101 0.0091 n/a n/a 0.0082 0.0048 n/a n/a 0.0113 0.006 
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Cell Line MCF 10A MCF7 MDA-MB-231 
Condition Control High-Lactate Control High-Lactate Control High-Lactate 
 MID SE MID SE MID SE MID SE MID SE MID SE 
M4 n/a n/a 0.003 0.0091 n/a n/a 0.0023 0.0048 n/a n/a 0.0025 0.006 
M5 n/a n/a 0.0007 0.0091 n/a n/a 0.0008 0.0048 n/a n/a 0.0007 0.006 
M6 n/a n/a 0.0003 0.0091 n/a n/a 0.0003 0.0048 n/a n/a 0.0004 0.006 
SUCC 289             
M0 n/a n/a 0.7346 0.0097 n/a n/a 0.7368 0.006 n/a n/a 0.735 0.006 
M1 n/a n/a 0.1736 0.0097 n/a n/a 0.1743 0.006 n/a n/a 0.1754 0.006 
M2 n/a n/a 0.0763 0.0097 n/a n/a 0.0746 0.006 n/a n/a 0.0738 0.006 
M3 n/a n/a 0.0108 0.0097 n/a n/a 0.0109 0.006 n/a n/a 0.0114 0.006 
M4 n/a n/a 0.0029 0.0097 n/a n/a 0.0026 0.006 n/a n/a 0.0029 0.006 
M5 n/a n/a 0.0009 0.0097 n/a n/a 0.0006 0.006 n/a n/a 0.0009 0.006 
M6 n/a n/a 0.0005 0.0097 n/a n/a 0.0002 0.006 n/a n/a 0.0005 0.006 
FUM 287             
M0 n/a n/a 0.7349 0.006 n/a n/a 0.7345 0.0061 n/a n/a 0.7357 0.0101 
M1 n/a n/a 0.1739 0.006 n/a n/a 0.1756 0.0061 n/a n/a 0.1751 0.0101 
M2 n/a n/a 0.075 0.006 n/a n/a 0.0735 0.0061 n/a n/a 0.0737 0.0101 
M3 n/a n/a 0.012 0.006 n/a n/a 0.0126 0.0061 n/a n/a 0.0119 0.0101 
M4 n/a n/a 0.0027 0.006 n/a n/a 0.0027 0.0061 n/a n/a 0.0026 0.0101 
M5 n/a n/a 0.0009 0.006 n/a n/a 0.0005 0.0061 n/a n/a 0.0006 0.0101 
M6 n/a n/a 0.0005 0.006 n/a n/a 0.0004 0.0061 n/a n/a 0.0003 0.0101 
MAL 419             
M0 n/a n/a 0.6328 0.0123 n/a n/a 0.6325 0.0084 n/a n/a 0.6338 0.006 
M1 n/a n/a 0.227 0.0123 n/a n/a 0.2278 0.0084 n/a n/a 0.2262 0.006 
M2 n/a n/a 0.1075 0.0123 n/a n/a 0.1074 0.0084 n/a n/a 0.1075 0.006 
M3 n/a n/a 0.0251 0.0123 n/a n/a 0.0258 0.0084 n/a n/a 0.0251 0.006 
M4 n/a n/a 0.0055 0.0123 n/a n/a 0.0043 0.0084 n/a n/a 0.005 0.006 
M5 n/a n/a 0.0009 0.0123 n/a n/a 0.001 0.0084 n/a n/a 0.0014 0.006 
M6 n/a n/a 0.0008 0.0123 n/a n/a 0.0009 0.0084 n/a n/a 0.0009 0.006 
ASP 418             
M0 n/a n/a 0.6289 0.0149 n/a n/a 0.6312 0.0135 n/a n/a 0.6319 0.0138 
M1 n/a n/a 0.2295 0.0149 n/a n/a 0.2295 0.0135 n/a n/a 0.2286 0.0138 
M2 n/a n/a 0.1096 0.0149 n/a n/a 0.1067 0.0135 n/a n/a 0.107 0.0138 
M3 n/a n/a 0.0249 0.0149 n/a n/a 0.0251 0.0135 n/a n/a 0.0253 0.0138 
M4 n/a n/a 0.0052 0.0149 n/a n/a 0.005 0.0135 n/a n/a 0.005 0.0138 
M5 n/a n/a 0.0011 0.0149 n/a n/a 0.0016 0.0135 n/a n/a 0.0013 0.0138 
M6 n/a n/a 0.0007 0.0149 n/a n/a 0.0008 0.0135 n/a n/a 0.0007 0.0138 
 165 
Appendix E 
 
Metabolite isotope labeling distributions from [1,2-13C] glucose and [U-13C] glutamine 
for three breast cell lines 
 
 
 
Figure E1. Metabolite isotope labeling distribution from [1,2-13C] glucose for the MCF 
10A, MCF7, and MDA-MB-231 cultures for both control and high-lactate conditions. 
MIDs shown below have been corrected for natural abundance. 
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Figure E2. Metabolite isotope labeling distribution from [U-13C] glutamine for the 
MCF 10A, MCF7, and MDA-MB-231 cultures for both control and high-lactate 
conditions. MIDs shown below have been corrected for natural abundance. 
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Appendix F 
 
Metabolic flux maps for three breast cell lines grown in control and high-lactate cultures 
 
 
 
Figure F1. Metabolic flux maps for MCF 10A predicted from the MFA simulations: A) control and B) high-lactate cultures. 
The line thicknesses represent the relative fluxes, which are also shown numerically (nmol/106 cells·h) with standard deviation.   
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Figure F2. Metabolic flux maps for MCF7 predicted from the MFA simulations: A) control and B) high-lactate cultures. The 
line thicknesses represent the relative fluxes, which are also shown numerically (nmol/106 cells·h) with standard deviations. 
  
 169 
 
 
 
Figure F3. Metabolic flux maps for MDA-MB-231 predicted from the MFA simulations: A) control and B) high-lactate 
cultures. The line thicknesses represent the relative fluxes, which are also shown numerically (nmol/106 cells·h) with standard 
deviations. 
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Appendix G 
 
Metabolic flux analysis results for three breast cell lines grown in control and high-lactate 
cultures 
 
Table G1. Metabolic flux analysis results for MCF 10A control cultures using [1,2-13C] 
glucose and [U-13C] glutamine. The fluxes are shown with 95% confidence intervals. The 
sum of squared residuals (SSR) was 60.0 with an expected range of 34.0 to 73.8. 
 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Gluc.ext -> G6P.c 226.264 179.76 276.13 
G6P.c <=> F6P.c (net) 150.514 118.53 188.56 
G6P.c <=> F6P.c (exch) (>1e4, >1e4) >10000  >10000 
F6P.c -> FBP.c 198.197 156.94 242.61 
FBP.c <=> DHAP.c + GAP.c (net) 198.197 156.94 242.61 
FBP.c <=> DHAP.c + GAP.c (exch) (0.0, >1e4) 0  >10000 
DHAP.c <=> GAP.c (net) 197.247 155.99 241.66 
DHAP.c <=> GAP.c (exch) 333.237 249.63 436.75 
GAP.c <=> 3PG.c (net) 419.285 331.51 513.41 
GAP.c <=> 3PG.c (exch) (0.0, >1e4) 0  >10000 
3PG.c -> Pyr.c 419.285 331.51 513.41 
G6P.c -> CO2 + Ru5P.c 73.426 49.97 95.25 
Ru5P.c <=> R5P.c (net) 25.743 17.93 33.02 
Ru5P.c <=> R5P.c (exch) (>1e4, >1e4) 0  >10000 
Ru5P.c <=> X5P.c (net) 47.683 32.12 62.23 
Ru5P.c <=> X5P.c (exch) (0.0, >1e4) 0  >10000 
X5P.c + R5P.c <=> GAP.c + S7P.c (net) 23.841 16.06 31.11 
X5P.c + R5P.c <=> GAP.c + S7P.c (exch) 1.685 0 18.81 
S7P.c + GAP.c <=> E4P.c + F6P.c (net) 23.841 16.06 31.11 
S7P.c + GAP.c <=> E4P.c + F6P.c (exch) (>1e4, >1e4) 0  >10000 
X5P.c + E4P.c <=> GAP.c + F6P (net) 23.841 16.06 31.11 
X5P.c + E4P.c <=> GAP.c + F6P (exch) 0 0 19.75 
Pyr.c <=> Lact.c (net) 373.984 288.09 467.14 
Pyr.c <=> Lact.c (exch) (>1000, >1e4) 351.11  >10000 
Pyr.c -> CO2 + AcCoA.m 64.337 54.81 76.6 
AcCoA.m + OAC.m -> Cit.m 64.337 54.81 76.6 
Cit.m <=> AKG.m + CO2 (net) 46.289 37.58 58.03 
Cit.m <=> AKG.m + CO2 (exch) 1.786 0 3.9 
AKG.m -> CO2 + Suc.m 73.402 59.19 94.47 
Suc.m <=> Fum.m (net) 73.402 59.19 94.47 
Suc.m <=> Fum.m (exch) 268.25 160.72 538.33 
Fum.m <=> Mal.m (net) 73.402 59.19 94.47 
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  nmol/106 cells/h Lower Bound Upper Bound 
Fum.m <=> Mal.m (exch) (609.3, 928.4) 297.52  >10000 
Mal.m <=> OAA.m (net) 18.644 14.73 22.67 
Mal.m <=> OAA.m (exch) (642.6, 909.8) 333.54  >10000 
Gln.c -> Glu.c 42.29 34.77 52.21 
Ser.c <=> Pyr.c (net) 15.633 9.94 21.33 
Ser.c <=> Pyr.c (exch) (>1000, >1e4) 0  >10000 
Gln.ext -> Gln.c 44.825 37.15 54.8 
Asp.c -> Asp.ext 4.897 3.34 6.46 
Ser.ext -> Ser.c 19.013 13.36 24.68 
Ala.c -> Ala.ext 10.996 8.07 13.92 
Glu.c -> Glu.ext 12.007 8.32 15.7 
Lact.c -> Lact.ext 373.984 288.09 467.14 
Glu.c <=> AKG.m (net) 3.403 0 13.46 
Glu.c <=> AKG.m (exch) (0.0, 424.8) 0 660.43 
Mal.m -> Pyr.c + CO2 54.759 41.87 75.66 
Cit.m -> OAA.m + AcCoA.c 18.048 14.53 21.56 
Pyr.c + CO2 -> OAA.m 35.5 27.82 47.12 
0.95 AcCoA.c + 0.05 DHAP.c -> Lipid 18.998 15.29 22.69 
Pyr.c + Glu.c <=> Ala.c + AKG.m (net) 15.856 12.77 18.93 
Pyr.c + Glu.c <=> Ala.c + AKG.m (exch) 375.738 0 660.43 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(net) 7.855 6.19 9.51 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(exch) (0.0, 424.8) 0 660.43 
0.23 Ala.c + 0.14 Asp.c + 0.12 Gln.c + 
0.15 Glu.c + 0.16 Ser.c + 0.11 G6P.c + 
0.09 R5P.c -> Biomass 21.129 17.04 25.21 
Lact.c + Lact.tr -> Lact.c + Lact.snk 43.123 20.25 74.95 
Glu.c <=> AKG.m (total) 27.114   
Net CO2 production 276.713 226.45 342.45 
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Table G2. Metabolic flux analysis results for MCF 10A high-lactate cultures using [1,2-
13C] glucose and [U-13C] glutamine. The fluxes are shown with 95% confidence intervals. 
The sum of squared residuals (SSR) was 45.0 with an expected range of 34.8 to 75.0. 
 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Gluc.ext -> G6P.c 201.406 162.31 243.22 
G6P.c <=> F6P.c (net) 156.651 123.84 196.17 
G6P.c <=> F6P.c (exch) (>1e4, >1e4) 0 >10000 
F6P.c -> FBP.c 183.631 146 221.22 
FBP.c <=> DHAP.c + GAP.c (net) 183.631 146 221.22 
FBP.c <=> DHAP.c + GAP.c (exch) (0.0, >1e4) 0 >10000 
DHAP.c <=> GAP.c (net) 182.861 145.3 220.68 
DHAP.c <=> GAP.c (exch) (>1000, >1000) >1000  >10000 
GAP.c <=> 3PG.c (net) 379.981 302.12 459.52 
GAP.c <=> 3PG.c (exch) (0.0, >1e4) 0  >10000 
3PG.c -> Pyr.c 379.981 302.12 459.52 
G6P.c -> CO2 + Ru5P.c 42.398 22.42 56.24 
Ru5P.c <=> R5P.c (net) 15.418 8.76 20.05 
Ru5P.c <=> R5P.c (exch) (>1e4, >1e4) 0  >10000 
Ru5P.c <=> X5P.c (net) 26.98 13.65 36.2 
Ru5P.c <=> X5P.c (exch) (0.0, >1e4) 0  >10000 
X5P.c + R5P.c <=> GAP.c + S7P.c (net) 13.49 6.83 18.1 
X5P.c + R5P.c <=> GAP.c + S7P.c (exch) (>1e4, >1e4) 0  >10000 
S7P.c + GAP.c <=> E4P.c + F6P.c (net) 13.49 6.83 18.1 
S7P.c + GAP.c <=> E4P.c + F6P.c (exch) 3.214 0 16.9 
X5P.c + E4P.c <=> GAP.c + F6P (net) 13.49 6.83 18.1 
X5P.c + E4P.c <=> GAP.c + F6P (exch) 0 0 22.54 
Pyr.c <=> Lact.c (net) 343.45 266.56 421.74 
Pyr.c <=> Lact.c (exch) (>1e4, >1e4) >10000  >10000 
Pyr.c -> CO2 + AcCoA.m 61.356 51.64 72.08 
AcCoA.m + OAC.m -> Cit.m 61.356 51.64 72.08 
Cit.m <=> AKG.m + CO2 (net) 46.729 38.24 56.5 
Cit.m <=> AKG.m + CO2 (exch) 17.296 13.73 21.52 
AKG.m -> CO2 + Suc.m 78.318 62.97 96.02 
Suc.m <=> Fum.m (net) 78.318 62.97 96.02 
Suc.m <=> Fum.m (exch) 277.593 177.68 476.69 
Fum.m <=> Mal.m (net) 78.318 62.97 96.02 
Fum.m <=> Mal.m (exch) (>1e4, >1e4) >10000  >10000 
Mal.m <=> OAA.m (net) 21.112 17.56 25 
Mal.m <=> OAA.m (exch) 632.85 362.99  >1000 
Gln.c -> Glu.c 45.321 37.65 53.99 
Ser.c <=> Pyr.c (net) 16.099 8.29 23.91 
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  nmol/106 cells/h Lower Bound Upper Bound 
Ser.c <=> Pyr.c (exch) (>1e4, >1e4) 0  >10000 
Gln.ext -> Gln.c 47.892 40.16 56.58 
Asp.c -> Asp.ext 3.83 2.47 5.19 
Ser.ext -> Ser.c 19.527 11.74 27.31 
Ala.c -> Ala.ext 11.107 7.4 14.81 
Glu.c -> Glu.ext 10.518 7.03 14.01 
Lact.c -> Lact.ext 343.45 266.56 421.74 
Glu.c <=> AKG.m (net) 8.725 0.35 17.97 
Glu.c <=> AKG.m (exch) (0.0, >1000) 0  >1000 
Mal.m -> Pyr.c + CO2 57.207 43.44 73.15 
Cit.m -> OAA.m + AcCoA.c 14.627 11.33 18 
Pyr.c + CO2 -> OAA.m 32.447 25.88 40.24 
0.95 AcCoA.c + 0.05 DHAP.c -> Lipid 15.397 11.92 18.95 
Pyr.c + Glu.c <=> Ala.c + AKG.m (net) 16.034 12.22 19.85 
Pyr.c + Glu.c <=> Ala.c + AKG.m (exch) (0.0, >1000) 0  >1000 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(net) 6.83 5.35 8.31 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(exch) (0.0, >1000) 0  >1000 
0.23 Ala.c + 0.14 Asp.c + 0.12 Gln.c + 
0.15 Glu.c + 0.16 Ser.c + 0.11 G6P.c + 
0.09 R5P.c -> Biomass 21.425 17.34 25.51 
Lact.c + Lact.tr -> Lact.c + Lact.snk 82.742 56.54 112.82 
Glu.c <=> AKG.m (total) 31.589   
Net CO2 production 253.56 202.62 306.3 
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Table G3. Metabolic flux analysis results for MCF7 control cultures using [1,2-13C] 
glucose and [U-13C] glutamine using the biological replicate MIDs for intracellular 
glutamine, which had a very high standard error. The fluxes are shown with 95% 
confidence intervals. The sum of squared residuals (SSR) was 30.8 with an expected range 
of 31.6 to 70.2. Table G7 has the metabolic flux results for this same culture where the 
standard error was replaced with 0.6 mol% for one biological replicate. The fluxes are not 
significantly different between the two simulations.  
 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Gluc.ext -> G6P.c 197.813 150.91 244.41 
G6P.c <=> F6P.c (net) 149.733 112.58 190.06 
G6P.c <=> F6P.c (exch) (>1000, >1e4) 0  >10000 
F6P.c -> FBP.c 178.799 135.8 221.9 
FBP.c <=> DHAP.c + GAP.c (net) 178.799 135.8 221.9 
FBP.c <=> DHAP.c + GAP.c (exch) (0.0, >1e4) 0  >10000 
DHAP.c <=> GAP.c (net) 177.784 134.79 220.88 
DHAP.c <=> GAP.c (exch) (>1000, >1e4) >1000  >10000 
GAP.c <=> 3PG.c (net) 371.116 281.09 460.47 
GAP.c <=> 3PG.c (exch) (0.0, >1e4) 0  >10000 
3PG.c -> Pyr.c 371.116 281.09 460.47 
G6P.c -> CO2 + Ru5P.c 45.615 24.29 67.51 
Ru5P.c <=> R5P.c (net) 16.55 9.4 23.86 
Ru5P.c <=> R5P.c (exch) (>1e4, >1e4) 0  >10000 
Ru5P.c <=> X5P.c (net) 29.066 14.82 43.66 
Ru5P.c <=> X5P.c (exch) (>1e4, >1e4) 0  >10000 
X5P.c + R5P.c <=> GAP.c + S7P.c (net) 14.533 7.41 21.83 
X5P.c + R5P.c <=> GAP.c + S7P.c (exch) (>1e4, >1e4) 0  >10000 
S7P.c + GAP.c <=> E4P.c + F6P.c (net) 14.533 7.41 21.83 
S7P.c + GAP.c <=> E4P.c + F6P.c (exch) 5.97 0 24.83 
X5P.c + E4P.c <=> GAP.c + F6P (net) 14.533 7.41 21.83 
X5P.c + E4P.c <=> GAP.c + F6P (exch) 0 0 23.39 
Pyr.c <=> Lact.c (net) 319.933 231.31 407.98 
Pyr.c <=> Lact.c (exch) (>1000, >1e4) 233.28  >10000 
Pyr.c -> CO2 + AcCoA.m 65.162 51.32 81.11 
AcCoA.m + OAC.m -> Cit.m 65.162 51.32 81.11 
Cit.m <=> AKG.m + CO2 (net) 45.885 32.23 61.56 
Cit.m <=> AKG.m + CO2 (exch) 4.757 1.55 8.22 
AKG.m -> CO2 + Suc.m 72.238 48.32 99.57 
Suc.m <=> Fum.m (net) 72.238 48.32 99.57 
Suc.m <=> Fum.m (exch) (>1e4, >1e4) >10000  >10000 
Fum.m <=> Mal.m (net) 72.238 48.32 99.57 
Fum.m <=> Mal.m (exch) (198.0, 257.8) 101.87  >10000 
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  nmol/106 cells/h Lower Bound Upper Bound 
Mal.m <=> OAA.m (net) 14.824 7.06 21.41 
Mal.m <=> OAA.m (exch) 386.058 171.19  >1000 
Gln.c -> Glu.c 40.749 29.66 53.29 
Ser.c <=> Pyr.c (net) 16.406 8.58 24.27 
Ser.c <=> Pyr.c (exch) (>1000, >1e4) 0  >10000 
Gln.ext -> Gln.c 43.438 32.29 55.94 
Asp.c -> Asp.ext 6.485 3.95 9.02 
Ser.ext -> Ser.c 19.991 12.2 27.8 
Ala.c -> Ala.ext 14.004 9.52 18.49 
Glu.c -> Glu.ext 11.035 7.15 14.92 
Lact.c -> Lact.ext 319.933 231.31 407.98 
Glu.c <=> AKG.m (net) -2.426 -14.09 10.59 
Glu.c <=> AKG.m (exch) (0.0, 865.7) 0  >1000 
Mal.m -> Pyr.c + CO2 57.414 32.1 87.68 
Cit.m -> OAA.m + AcCoA.c 19.277 15.59 22.97 
Pyr.c + CO2 -> OAA.m 40.683 25.73 59.39 
0.95 AcCoA.c + 0.05 DHAP.c -> Lipid 20.291 16.41 24.18 
Pyr.c + Glu.c <=> Ala.c + AKG.m (net) 19.157 14.56 23.76 
Pyr.c + Glu.c <=> Ala.c + AKG.m (exch) (0.0, 865.7) 0  >10000 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(net) 9.622 7.01 12.23 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(exch) (0.0, 865.7) 0  >10000 
0.23 Ala.c + 0.14 Asp.c + 0.12 Gln.c + 
0.15 Glu.c + 0.16 Ser.c + 0.11 G6P.c + 
0.09 R5P.c -> Biomass 22.408 17.93 26.89 
Lact.c + Lact.tr -> Lact.c + Lact.snk 32.816 7.77 63.01 
Glu.c <=> AKG.m (total) 26.353   
Net CO2 production 245.632 179.25 321.85 
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Table G4. Metabolic flux analysis results for MCF7 high-lactate cultures using [1,2-13C] 
glucose and [U-13C] glutamine. The fluxes are shown with 95% confidence intervals. The 
sum of squared residuals (SSR) was 67.7 with an expected range of 30.8 to 69.0.  
 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Gluc.ext -> G6P.c 157.959 96.22 170.61 
G6P.c <=> F6P.c (net) 118.7 70.41 132.1 
G6P.c <=> F6P.c (exch) (>1e4, >1e4) 0  >10000 
F6P.c -> FBP.c 141.752 84.68 153.61 
FBP.c <=> DHAP.c + GAP.c (net) 141.752 84.68 153.61 
FBP.c <=> DHAP.c + GAP.c (exch) (0.0, >1e4) 0  >10000 
DHAP.c <=> GAP.c (net) 141.081 84.19 152.92 
DHAP.c <=> GAP.c (exch) 517.276 291.86 613.93 
GAP.c <=> 3PG.c (net) 294.359 175.81 318.7 
GAP.c <=> 3PG.c (exch) (0.0, >1e4) 0  >10000 
3PG.c -> Pyr.c 294.359 175.81 318.7 
G6P.c -> CO2 + Ru5P.c 36.684 13.11 43.82 
Ru5P.c <=> R5P.c (net) 13.632 5.75 16.03 
Ru5P.c <=> R5P.c (exch) (0.0, >1e4) 0  >10000 
Ru5P.c <=> X5P.c (net) 23.052 7.34 27.81 
Ru5P.c <=> X5P.c (exch) (0.0,  45.4) 0  >10000 
X5P.c + R5P.c <=> GAP.c + S7P.c (net) 11.526 3.67 13.9 
X5P.c + R5P.c <=> GAP.c + S7P.c (exch) (415.8, 415.8) 0  >10000 
S7P.c + GAP.c <=> E4P.c + F6P.c (net) 11.526 3.67 13.9 
S7P.c + GAP.c <=> E4P.c + F6P.c (exch) (0.0, 0.4) 0  >10000 
X5P.c + E4P.c <=> GAP.c + F6P (net) 11.526 3.67 13.9 
X5P.c + E4P.c <=> GAP.c + F6P (exch) 0 0 13.76 
Pyr.c <=> Lact.c (net) 253.443 139.96 277.5 
Pyr.c <=> Lact.c (exch) 405.053 61.34 907.77 
Pyr.c -> CO2 + AcCoA.m 48.238 36.79 53.83 
AcCoA.m + OAC.m -> Cit.m 48.238 36.79 53.83 
Cit.m <=> AKG.m + CO2 (net) 35.486 26.93 40.46 
Cit.m <=> AKG.m + CO2 (exch) 19.249 14.16 21.84 
AKG.m -> CO2 + Suc.m 54.276 39.6 62.37 
Suc.m <=> Fum.m (net) 54.276 39.6 62.37 
Suc.m <=> Fum.m (exch) (155.9, 221.5) 97.48  >10000 
Fum.m <=> Mal.m (net) 54.276 39.6 62.37 
Fum.m <=> Mal.m (exch) (>1e4, >1e4) >10000  >10000 
Mal.m <=> OAA.m (net) 23.197 18.3 26.37 
Mal.m <=> OAA.m (exch) (>1e4, >1e4) 438.92  >10000 
Gln.c -> Glu.c 36.246 28.23 40.55 
Ser.c <=> Pyr.c (net) 16.022 7.21 27.67 
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  nmol/106 cells/h Lower Bound Upper Bound 
Ser.c <=> Pyr.c (exch) (197.4, >1e4) 0  >10000 
Gln.ext -> Gln.c 39.055 30.93 43.37 
Asp.c -> Asp.ext 6.199 4.06 8.3 
Ser.ext -> Ser.c 19.766 10.95 31.38 
Ala.c -> Ala.ext 12.632 7.88 16.85 
Glu.c -> Glu.ext 13.946 9.41 18.26 
Lact.c -> Lact.ext 253.443 139.96 277.5 
Glu.c <=> AKG.m (net) -8.701 -17.65 -3.55 
Glu.c <=> AKG.m (exch) (0.0, 105.3) 0 126.99 
Mal.m -> Pyr.c + CO2 31.078 18.26 38.47 
Cit.m -> OAA.m + AcCoA.c 12.751 8.67 15.64 
Pyr.c + CO2 -> OAA.m 21.764 15.58 25.74 
0.95 AcCoA.c + 0.05 DHAP.c -> Lipid 13.423 9.13 16.46 
Pyr.c + Glu.c <=> Ala.c + AKG.m (net) 18.015 13.1 22.29 
Pyr.c + Glu.c <=> Ala.c + AKG.m (exch) 92.939 0 126.99 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(net) 9.475 7.22 11.62 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(exch) (0.0, 105.3) 0 126.99 
0.23 Ala.c + 0.14 Asp.c + 0.12 Gln.c + 
0.15 Glu.c + 0.16 Ser.c + 0.11 G6P.c + 
0.09 R5P.c -> Biomass 23.404 18.9 27.46 
Lact.c + Lact.tr -> Lact.c + Lact.snk 65.652 20.76 83.1 
Glu.c <=> AKG.m (total) 18.789   
Net CO2 production 183.998 130.52 205.72 
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Table G5. Metabolic flux analysis results for MDA-MB-231 control cultures using [1,2-
13C] glucose and [U-13C] glutamine. The fluxes are shown with 95% confidence intervals. 
The sum of squared residuals (SSR) was 62.1 with an expected range of 34.8 to 75.0. 
 
 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Gluc.ext -> G6P.c 323.662 241.31 407.08 
G6P.c <=> F6P.c (net) 238.695 177.95 313.69 
G6P.c <=> F6P.c (exch) (>1e4, >1e4) 0  >10000 
F6P.c -> FBP.c 291.889 217.43 368.7 
FBP.c <=> DHAP.c + GAP.c (net) 291.889 217.43 368.7 
FBP.c <=> DHAP.c + GAP.c (exch) (0.0, >1e4) 0  >10000 
DHAP.c <=> GAP.c (net) 290.671 216.23 367.46 
DHAP.c <=> GAP.c (exch) 1005.797 691.44  >1000 
GAP.c <=> 3PG.c (net) 609.157 452.44 768.83 
GAP.c <=> 3PG.c (exch) (0.0, >1e4) 0  >10000 
3PG.c -> Pyr.c 609.157 452.44 768.83 
G6P.c -> CO2 + Ru5P.c 82.12 42.77 114.93 
Ru5P.c <=> R5P.c (net) 28.926 15.8 39.87 
Ru5P.c <=> R5P.c (exch) (0.0, >1e4) 0  >10000 
Ru5P.c <=> X5P.c (net) 53.193 26.96 75.06 
Ru5P.c <=> X5P.c (exch) (0.0, >1e4) 0  >10000 
X5P.c + R5P.c <=> GAP.c + S7P.c (net) 26.597 13.48 37.53 
X5P.c + R5P.c <=> GAP.c + S7P.c (exch) (>1e4, >1e4) 0  >10000 
S7P.c + GAP.c <=> E4P.c + F6P.c (net) 26.597 13.48 37.53 
S7P.c + GAP.c <=> E4P.c + F6P.c (exch) 2.36 0 31.22 
X5P.c + E4P.c <=> GAP.c + F6P (net) 26.597 13.48 37.53 
X5P.c + E4P.c <=> GAP.c + F6P (exch) 0 0 39.96 
Pyr.c <=> Lact.c (net) 563.768 407.51 723.24 
Pyr.c <=> Lact.c (exch) (0.0, >1e4) 0  >10000 
Pyr.c -> CO2 + AcCoA.m 51.947 40.32 66.36 
AcCoA.m + OAC.m -> Cit.m 51.947 40.32 66.36 
Cit.m <=> AKG.m + CO2 (net) 28.816 18.37 43.1 
Cit.m <=> AKG.m + CO2 (exch) 6.307 4.27 8.98 
AKG.m -> CO2 + Suc.m 46.494 26.68 73.21 
Suc.m <=> Fum.m (net) 46.494 26.68 73.21 
Suc.m <=> Fum.m (exch) 92.427 43.99 212.9 
Fum.m <=> Mal.m (net) 46.494 26.68 73.21 
Fum.m <=> Mal.m (exch) (>1000, >1e4) 266.76  >10000 
Mal.m <=> OAA.m (net) 12.57 9.22 16 
Mal.m <=> OAA.m (exch) 353.445 161.88  >1000 
Gln.c -> Glu.c 30.163 20.23 43 
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  nmol/106 cells/h Lower Bound Upper Bound 
Ser.c <=> Pyr.c (net) 11.898 5.22 18.51 
Ser.c <=> Pyr.c (exch) (>1e4, >1e4) 0  >10000 
Gln.ext -> Gln.c 33.269 23.28 46.2 
Asp.c -> Asp.ext 3.451 2.09 4.81 
Ser.ext -> Ser.c 16.039 9.41 22.62 
Ala.c -> Ala.ext 9.989 6.48 13.5 
Glu.c -> Glu.ext 8.603 5.49 11.72 
Lact.c -> Lact.ext 563.768 407.51 723.24 
Glu.c <=> AKG.m (net) -5.34 -15.81 7.66 
Glu.c <=> AKG.m (exch) (0.0, 628.4) 0  >1000 
Mal.m -> Pyr.c + CO2 33.924 14.38 60.72 
Cit.m -> OAA.m + AcCoA.c 23.131 19.07 27.23 
Pyr.c + CO2 -> OAA.m 23.321 13.27 37.66 
0.95 AcCoA.c + 0.05 DHAP.c -> Lipid 24.348 20.08 28.67 
Pyr.c + Glu.c <=> Ala.c + AKG.m (net) 15.943 12.25 19.64 
Pyr.c + Glu.c <=> Ala.c + AKG.m (exch) (0.0, 628.4) 0  >1000 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(net) 7.075 5.54 8.61 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(exch) (0.0, 628.4) 0  >1000 
0.23 Ala.c + 0.14 Asp.c + 0.12 Gln.c + 
0.15 Glu.c + 0.16 Ser.c + 0.11 G6P.c + 
0.09 R5P.c -> Biomass 25.884 20.82 30.95 
Lact.c + Lact.tr -> Lact.c + Lact.snk 2.1 0 31.21 
Glu.c <=> AKG.m (total) 17.678   
Net CO2 production 219.979 152.69 294.91 
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Table G6. Metabolic flux analysis results for MDA-MB-231 high-lactate cultures using 
[1,2- 13C] glucose and [U-13C] glutamine. The fluxes are shown with 95% confidence 
intervals. The sum of squared residuals (SSR) was 38.3 with an expected range of 34.8 to 
75.0. 
 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Gluc.ext -> G6P.c 269.671 209.66 333.36 
G6P.c <=> F6P.c (net) 213.317 164.04 266.24 
G6P.c <=> F6P.c (exch) (>1e4, >1e4) 0  >10000 
F6P.c -> FBP.c 247.391 191.86 306.37 
FBP.c <=> DHAP.c + GAP.c (net) 247.391 191.86 306.37 
FBP.c <=> DHAP.c + GAP.c (exch) (0.0, >1e4) 0  >10000 
DHAP.c <=> GAP.c (net) 246.347 190.85 305.29 
DHAP.c <=> GAP.c (exch) (>1e4, >1e4) >1000  >10000 
GAP.c <=> 3PG.c (net) 510.774 395.1 632.72 
GAP.c <=> 3PG.c (exch) (0.0, >1e4) 0  >10000 
3PG.c -> Pyr.c 510.774 395.1 632.72 
G6P.c -> CO2 + Ru5P.c 53.47 31.02 74.99 
Ru5P.c <=> R5P.c (net) 19.397 11.96 26.58 
Ru5P.c <=> R5P.c (exch) (0.0, >1e4) 0  >10000 
Ru5P.c <=> X5P.c (net) 34.074 19.09 48.42 
Ru5P.c <=> X5P.c (exch) (0.0, >1e4) 0  >10000 
X5P.c + R5P.c <=> GAP.c + S7P.c (net) 17.037 9.54 24.21 
X5P.c + R5P.c <=> GAP.c + S7P.c (exch) (0.0,  4.3) 0  >10000 
S7P.c + GAP.c <=> E4P.c + F6P.c (net) 17.037 9.54 24.21 
S7P.c + GAP.c <=> E4P.c + F6P.c (exch) (>1000, >1e4) 0  >10000 
X5P.c + E4P.c <=> GAP.c + F6P (net) 17.037 9.54 24.21 
X5P.c + E4P.c <=> GAP.c + F6P (exch) 0.791 0 24.62 
Pyr.c <=> Lact.c (net) 459.32 346.09 578.84 
Pyr.c <=> Lact.c (exch) (>1000, >1000) >1000  >10000 
Pyr.c -> CO2 + AcCoA.m 84.266 68.37 102.99 
AcCoA.m + OAC.m -> Cit.m 84.266 68.37 102.99 
Cit.m <=> AKG.m + CO2 (net) 64.437 49.71 82.34 
Cit.m <=> AKG.m + CO2 (exch) 31.16 24.15 39.76 
AKG.m -> CO2 + Suc.m 104.519 79.32 135.31 
Suc.m <=> Fum.m (net) 104.519 79.32 135.31 
Suc.m <=> Fum.m (exch) (652.8, >1000) 263.79  >10000 
Fum.m <=> Mal.m (net) 104.519 79.32 135.31 
Fum.m <=> Mal.m (exch) (>1000, >1e4) 668.42  >10000 
Mal.m <=> OAA.m (net) 25.781 19.91 32.28 
Mal.m <=> OAA.m (exch) (>1e4, >1e4)  >1000  >10000 
Gln.c -> Glu.c 54.444 43.11 68.02 
Ser.c <=> Pyr.c (net) 15.336 4.6 26.08 
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Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Ser.c <=> Pyr.c (exch) (169.7, >1e4) 0  >10000 
Gln.ext -> Gln.c 57.59 46.16 71.17 
Asp.c -> Asp.ext 4.643 2.5 6.78 
Ser.ext -> Ser.c 19.531 8.82 30.24 
Ala.c -> Ala.ext 8.262 4.36 12.16 
Glu.c -> Glu.ext 10.428 5.58 15.27 
Lact.c -> Lact.ext 459.32 346.09 578.84 
Glu.c <=> AKG.m (net) 17.476 5.55 31.48 
Glu.c <=> AKG.m (exch) 366.926 0  >1000 
Mal.m -> Pyr.c + CO2 78.738 55.59 107.5 
Cit.m -> OAA.m + AcCoA.c 19.83 15.75 23.95 
Pyr.c + CO2 -> OAA.m 46.969 34.67 62.74 
0.95 AcCoA.c + 0.05 DHAP.c -> Lipid 20.873 16.58 25.21 
Pyr.c + Glu.c <=> Ala.c + AKG.m (net) 14.293 10.22 18.36 
Pyr.c + Glu.c <=> Ala.c + AKG.m (exch) 357.26 0  >1000 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(net) 8.314 6.06 10.57 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(exch) (0.0, 964.0) 0  >1000 
0.23 Ala.c + 0.14 Asp.c + 0.12 Gln.c + 
0.15 Glu.c + 0.16 Ser.c + 0.11 G6P.c + 
0.09 R5P.c -> Biomass 26.22 21.15 31.31 
Lact.c + Lact.tr -> Lact.c + Lact.snk 147.176 96.59 216.76 
Glu.c <=> AKG.m (total) 40.083   
Net CO2 production 338.461 261.22 428.14 
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Table G7. Metabolic flux analysis results for MCF7 control cultures using [1,2-13C] 
glucose and [U-13C] glutamine using the 0.6 mol% standard error for the MIDs for 
intracellular glutamine, where the biological replicates had high standard error. The fluxes 
are shown with 95% confidence intervals. The sum of squared residuals (SSR) was 56.4 
with an expected range of 30.8 to 69.0. Table G3 has the metabolic flux results for this 
culture when the standard error for the biological replicates was used.  The fluxes are not 
significantly different between the two simulations. 
 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Gluc.ext -> G6P.c 197.061 149.98 243.88 
G6P.c <=> F6P.c (net) 150.994 138.25 191.77 
G6P.c <=> F6P.c (exch) (>1000, >1e4) 0  >10000 
F6P.c -> FBP.c 178.712 135.05 222.12 
FBP.c <=> DHAP.c + GAP.c (net) 178.712 135.05 222.12 
FBP.c <=> DHAP.c + GAP.c (exch) (0.0, >1e4) 0  >10000 
DHAP.c <=> GAP.c (net) 177.697 134.04 221.1 
DHAP.c <=> GAP.c (exch) (>1000, >1000) >1000  >10000 
GAP.c <=> 3PG.c (net) 370.268 279.69 460.17 
GAP.c <=> 3PG.c (exch) (0.0, >1e4) 0  >10000 
3PG.c -> Pyr.c 370.268 279.69 460.17 
G6P.c -> CO2 + Ru5P.c 43.598 22.77 46.94 
Ru5P.c <=> R5P.c (net) 15.88 8.94 17 
Ru5P.c <=> R5P.c (exch) (>1e4, >1e4) 0  >10000 
Ru5P.c <=> X5P.c (net) 27.718 13.83 29.95 
Ru5P.c <=> X5P.c (exch) (0.0, 624.4) 0  >10000 
X5P.c + R5P.c <=> GAP.c + S7P.c (net) 13.859 6.91 14.97 
X5P.c + R5P.c <=> GAP.c + S7P.c (exch) 5.122 0 24.56 
S7P.c + GAP.c <=> E4P.c + F6P.c (net) 13.859 6.91 14.97 
S7P.c + GAP.c <=> E4P.c + F6P.c (exch) (>1000, >1e4) 0  >10000 
X5P.c + E4P.c <=> GAP.c + F6P (net) 13.859 6.91 14.97 
X5P.c + E4P.c <=> GAP.c + F6P (exch) 0 0 61.78 
Pyr.c <=> Lact.c (net) 319.073 229.84 407.69 
Pyr.c <=> Lact.c (exch) (>1000, >1e4) 200.13  >10000 
Pyr.c -> CO2 + AcCoA.m 65.08 51.25 81 
AcCoA.m + OAC.m -> Cit.m 65.08 51.25 81 
Cit.m <=> AKG.m + CO2 (net) 45.806 32.18 61.45 
Cit.m <=> AKG.m + CO2 (exch) 4.737 1.54 8.2 
AKG.m -> CO2 + Suc.m 72.082 48.15 99.54 
Suc.m <=> Fum.m (net) 72.082 48.15 99.54 
Suc.m <=> Fum.m (exch) (>1e4, >1e4) >10000  >10000 
Fum.m <=> Mal.m (net) 72.082 48.15 99.54 
Fum.m <=> Mal.m (exch) 223.139 101.45 923.97 
 183 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Mal.m <=> OAA.m (net) 14.806 7.05 21.37 
Mal.m <=> OAA.m (exch) 384.54 170.71  >1000 
Gln.c -> Glu.c 40.677 29.56 53.19 
Ser.c <=> Pyr.c (net) 16.404 8.58 24.22 
Ser.c <=> Pyr.c (exch) (>1000, >1e4) 0  >10000 
Gln.ext -> Gln.c 43.371 32.19 55.94 
Asp.c -> Asp.ext 6.485 3.95 9.02 
Ser.ext -> Ser.c 19.996 12.21 27.79 
Ala.c -> Ala.ext 14.002 9.52 18.48 
Glu.c -> Glu.ext 11.034 7.14 14.92 
Lact.c -> Lact.ext 319.073 229.84 407.69 
Glu.c <=> AKG.m (net) -2.518 -14.21 10.47 
Glu.c <=> AKG.m (exch) (0.0, 865.2) 0  >1000 
Mal.m -> Pyr.c + CO2 57.276 32.04 87.48 
Cit.m -> OAA.m + AcCoA.c 19.274 15.57 22.97 
Pyr.c + CO2 -> OAA.m 40.628 25.72 59.31 
0.95 AcCoA.c + 0.05 DHAP.c -> Lipid 20.289 16.39 24.17 
Pyr.c + Glu.c <=> Ala.c + AKG.m (net) 19.166 14.55 23.76 
Pyr.c + Glu.c <=> Ala.c + AKG.m (exch) (0.0, 865.2) 0  >10000 
OAA.m + Glu.c <=> Asp.c + AKG.m (net) 9.628 7.01 12.24 
OAA.m + Glu.c <=> Asp.c + AKG.m 
(exch) (0.0, 865.2) 0  >10000 
0.23 Ala.c + 0.14 Asp.c + 0.12 Gln.c + 
0.15 Glu.c + 0.16 Ser.c + 0.11 G6P.c + 
0.09 R5P.c -> Biomass 22.451 17.97 26.93 
Lact.c + Lact.tr -> Lact.c + Lact.snk 31.054 5.9 64.89 
Glu.c <=> AKG.m (total) 26.276   
Net CO2 production 243.213 176.69 319.8 
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Appendix H 
 
Measured and simulated MIDs from 13C-MFA simulations for three breast cell lines 
 
 
 
 
 
Figure H1. Measured and simulated MIDs for intracellular metabolites from [1,2-13C] 
glucose labeling for MCF 10A control cultures. MIDs shown below have been corrected 
for natural abundance. 
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Figure H2. Measured and simulated MIDs for intracellular metabolites from [1,2-13C] 
glucose labeling for MCF 10A high-lactate cultures. MIDs shown below have been 
corrected for natural abundance. 
  
 186 
 
 
 
Figure H3. Measured and simulated MIDs for intracellular metabolites from [1,2-13C] 
glucose labeling for MCF7 control cultures. MIDs shown below have been corrected for 
natural abundance. 
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Figure H4. Measured and simulated MIDs for intracellular metabolites from [1,2-13C] 
glucose labeling for MCF7 high-lactate cultures. MIDs shown below have been corrected 
for natural abundance.   
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Figure H5. Measured and simulated MIDs for intracellular metabolites from [1,2-13C] 
glucose labeling for MDA-MB-231 control cultures. MIDs shown below have been 
corrected for natural abundance. 
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Figure H6. Measured and simulated MIDs for intracellular metabolites from [1,2-13C] 
glucose labeling for MDA-MB-231 high-lactate cultures. MIDs shown below have been 
corrected for natural abundance. 
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Figure H7. Measured and simulated MIDs for intracellular metabolites from [U-13C] 
glutamine labeling for MCF 10A control cultures. MIDs shown below have been 
corrected for natural abundance. 
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Figure H8. Measured and simulated MIDs for intracellular metabolites from [U-13C] 
glutamine labeling for MCF 10A high-lactate cultures. MIDs shown below have been 
corrected for natural abundance. 
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Figure H9. Measured and simulated MIDs for intracellular metabolites from [U-13C] 
glutamine labeling for MCF7 control cultures. MIDs shown below have been corrected 
for natural abundance. 
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Figure H10. Measured and simulated MIDs for intracellular metabolites from [U-13C] 
glutamine labeling for MCF7 high-lactate cultures. MIDs shown below have been 
corrected for natural abundance. 
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Figure H11. Measured and simulated MIDs for intracellular metabolites from [U-13C] 
glutamine labeling for MDA-MB-231 control cultures. MIDs shown below have been 
corrected for natural abundance. 
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Figure H12. Measured and simulated MIDs for intracellular metabolites from [U-13C] 
glutamine labeling for MDA-MB-231 high-lactate cultures. MIDs shown below have 
been corrected for natural abundance. 
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Appendix I 
 
Measured extracellular metabolite concentrations for K3 iPSCs 
 
Table I1. Measured extracellular metabolite concentrations for the K3 iPSCs grown in 
control culture at 0, 12, 24, 36, and 48-h after the media exchange. Averages are from 
biological 6-replicates. Standard errors are provided for these averages. 
 
Control  Average Concentration (mM) 
Metabolite 0-h SE 12-h SE 24-h SE 36-h SE 48-h SE 
Glucose 18.72 0.03 17.40 0.09 15.91 0.17 14.27 0.28 12.62 0.24 
Lactate 0.00 0.00 1.61 0.13 4.07 0.19 7.12 0.29 9.33 0.22 
Pyruvate 0.42 0.01 0.33 0.01 0.22 0.01 0.14 0.01 0.13 0.01 
Glutamine 2.54 0.03 2.32 0.02 2.09 0.04 1.84 0.04 1.54 0.04 
Ammonia 0.03 0.01 0.15 0.01 0.32 0.01 0.52 0.01 0.71 0.02 
Amino Acids                     
Alanine 0.03 0.00 0.06 0.00 0.10 0.00 0.15 0.00 0.18 0.01 
Asparagine 0.08 0.01 0.06 0.01 0.05 0.00 0.07 0.01 0.06 0.00 
Aspartate 0.04 0.00 0.03 0.00 0.03 0.00 0.03 0.00 0.02 0.00 
Glutamate 0.03 0.00 0.07 0.00 0.12 0.00 0.17 0.00 0.21 0.00 
Glycine 0.24 0.01 0.25 0.01 0.25 0.01 0.25 0.01 0.22 0.01 
Histidine 0.11 0.01 0.09 0.01 0.09 0.01 0.09 0.01 0.08 0.01 
Isoleucine 0.71 0.02 0.64 0.02 0.55 0.02 0.48 0.02 0.42 0.01 
Leucine 0.49 0.01 0.44 0.01 0.39 0.01 0.33 0.02 0.27 0.01 
Lysine 0.54 0.05 0.67 0.06 0.66 0.01 0.62 0.03 0.57 0.03 
Methionine 0.09 0.01 0.07 0.00 0.06 0.00 0.05 0.00 0.05 0.00 
Phenylalanine 0.17 0.01 0.21 0.01 0.19 0.01 0.18 0.01 0.16 0.01 
Proline 0.12 0.00 0.12 0.00 0.12 0.00 0.12 0.00 0.11 0.00 
Serine 0.39 0.01 0.37 0.01 0.31 0.01 0.27 0.01 0.20 0.01 
Threonine 0.24 0.02 0.25 0.01 0.23 0.01 0.22 0.01 0.18 0.01 
Tryptophan 0.01 0.00 0.02 0.00 0.01 0.00 0.01 0.00 0.01 0.00 
Tyrosine 0.16 0.02 0.20 0.02 0.19 0.01 0.16 0.01 0.15 0.01 
Valine 0.30 0.01 0.28 0.01 0.25 0.01 0.23 0.01 0.20 0.01 
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Table I2. Measured extracellular metabolite concentrations for the K3 iPSCs grown in low 
glucose culture at 0, 12, 24, 36, and 48-h after the media exchange. Averages are from 
biological 6-replicates. Standard errors are provided for these averages. 
 
Low glucose  Average Concentration (mM) 
Metabolite 0-h SE 12-h SE 24-h SE 36-h SE 48-h SE 
Glucose 5.99 0.02 4.91 0.05 3.47 0.09 1.72 0.14 0.24 0.09 
Lactate 0.00 0.00 1.65 0.09 4.07 0.14 6.74 0.16 8.95 0.12 
Pyruvate 0.43 0.01 0.35 0.00 0.22 0.01 0.14 0.00 0.13 0.01 
Glutamine 2.55 0.02 2.34 0.01 2.11 0.01 1.82 0.02 1.53 0.02 
Ammonia 0.03 0.01 0.16 0.01 0.33 0.01 0.50 0.01 0.72 0.02 
Amino Acids                     
Alanine 0.03 0.00 0.06 0.00 0.10 0.00 0.14 0.00 0.20 0.01 
Asparagine 0.06 0.01 0.05 0.00 0.05 0.00 0.07 0.00 0.07 0.00 
Aspartate 0.03 0.00 0.03 0.00 0.03 0.00 0.02 0.00 0.02 0.00 
Glutamate 0.04 0.01 0.08 0.00 0.13 0.00 0.17 0.00 0.21 0.00 
Glycine 0.24 0.01 0.22 0.00 0.23 0.00 0.24 0.00 0.23 0.01 
Histidine 0.11 0.01 0.10 0.00 0.08 0.00 0.08 0.01 0.08 0.00 
Isoleucine 0.72 0.04 0.62 0.02 0.53 0.01 0.49 0.01 0.45 0.01 
Leucine 0.48 0.01 0.42 0.01 0.35 0.01 0.32 0.00 0.30 0.01 
Lysine 0.67 0.02 0.64 0.01 0.66 0.01 0.61 0.04 0.61 0.03 
Methionine 0.09 0.01 0.07 0.00 0.06 0.00 0.05 0.00 0.05 0.00 
Phenylalanine 0.20 0.01 0.20 0.00 0.19 0.00 0.17 0.01 0.17 0.01 
Proline 0.12 0.00 0.11 0.00 0.11 0.00 0.11 0.00 0.12 0.00 
Serine 0.39 0.03 0.32 0.01 0.28 0.01 0.25 0.01 0.19 0.01 
Threonine 0.23 0.01 0.21 0.01 0.20 0.01 0.21 0.00 0.19 0.00 
Tryptophan 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 
Tyrosine 0.18 0.01 0.18 0.01 0.17 0.00 0.15 0.01 0.14 0.01 
Valine 0.30 0.01 0.27 0.00 0.24 0.01 0.23 0.01 0.21 0.01 
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Table I3. Measured extracellular metabolite concentrations for the K3 iPSCs grown in 
high lactate culture at 0, 12, 24, 36, and 48-h after the media exchange. Averages are from 
biological 6-replicates. Standard errors are provided for these averages. 
 
High lactate Average Concentration (mM) 
Metabolite 0-h SE 12-h SE 24-h SE 36-h SE 48-h SE 
Glucose 18.69 0.01 17.54 0.09 16.31 0.21 15.12 0.25 13.70 0.26 
Lactate 21.35 0.06 22.11 0.06 24.18 0.09 26.46 0.21 27.77 0.21 
Pyruvate 0.42 0.01 0.35 0.00 0.30 0.01 0.24 0.01 0.21 0.01 
Glutamine 2.51 0.03 2.32 0.02 2.12 0.01 1.93 0.02 1.68 0.02 
Ammonia 0.03 0.01 0.15 0.01 0.29 0.01 0.42 0.02 0.59 0.01 
Amino Acids                     
Alanine 0.02 0.00 0.05 0.01 0.08 0.01 0.13 0.01 0.17 0.00 
Asparagine 0.06 0.00 0.06 0.00 0.07 0.00 0.07 0.00 0.07 0.00 
Aspartate 0.03 0.00 0.02 0.00 0.02 0.00 0.02 0.00 0.02 0.00 
Glutamate 0.03 0.00 0.06 0.00 0.10 0.00 0.15 0.00 0.18 0.00 
Glycine 0.20 0.00 0.20 0.00 0.21 0.00 0.21 0.01 0.21 0.01 
Histidine 0.08 0.00 0.08 0.00 0.08 0.00 0.08 0.01 0.07 0.00 
Isoleucine 0.62 0.01 0.54 0.02 0.54 0.02 0.48 0.01 0.41 0.01 
Leucine 0.37 0.01 0.33 0.01 0.34 0.01 0.30 0.01 0.27 0.01 
Lysine 0.51 0.01 0.50 0.01 0.57 0.02 0.53 0.01 0.52 0.02 
Methionine 0.07 0.01 0.05 0.00 0.06 0.00 0.05 0.00 0.05 0.00 
Phenylalanine 0.12 0.00 0.12 0.00 0.14 0.00 0.14 0.00 0.14 0.00 
Proline 0.09 0.00 0.09 0.00 0.10 0.00 0.10 0.00 0.10 0.00 
Serine 0.36 0.00 0.31 0.01 0.32 0.01 0.24 0.01 0.19 0.01 
Threonine 0.18 0.00 0.17 0.00 0.19 0.00 0.18 0.01 0.18 0.00 
Tryptophan 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 
Tyrosine 0.11 0.00 0.11 0.00 0.13 0.00 0.12 0.00 0.12 0.00 
Valine 0.24 0.00 0.22 0.01 0.23 0.01 0.21 0.01 0.19 0.00 
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Table I4. Measured extracellular metabolite concentrations for the K3 iPSCs grown in low 
glucose + high lactate culture at 0, 12, 24, 36, and 48-h after the media exchange. Averages 
are from biological 6-replicates. Standard errors are provided for these averages. 
 
Low glucose + 
high  lactate Average Concentration (mM) 
Metabolite 0-h SE 12-h SE 24-h SE 36-h SE 48-h SE 
Glucose 5.98 0.05 5.08 0.06 3.94 0.10 2.45 0.09 1.21 0.15 
Lactate 21.39 0.15 22.11 0.13 24.31 0.11 26.42 0.15 28.25 0.24 
Pyruvate 0.43 0.01 0.35 0.00 0.30 0.01 0.25 0.01 0.22 0.01 
Glutamine 2.55 0.03 2.35 0.01 2.17 0.01 1.92 0.02 1.70 0.02 
Ammonia 0.04 0.01 0.15 0.01 0.28 0.01 0.45 0.01 0.63 0.01 
Amino Acids                     
Alanine 0.02 0.00 0.05 0.00 0.08 0.01 0.12 0.01 0.18 0.01 
Asparagine 0.07 0.00 0.06 0.00 0.06 0.01 0.06 0.01 0.06 0.01 
Aspartate 0.02 0.00 0.02 0.00 0.02 0.00 0.02 0.00 0.02 0.00 
Glutamate 0.03 0.00 0.07 0.00 0.11 0.00 0.15 0.00 0.18 0.00 
Glycine 0.21 0.00 0.20 0.00 0.21 0.00 0.21 0.01 0.22 0.01 
Histidine 0.10 0.01 0.08 0.00 0.08 0.00 0.08 0.00 0.07 0.00 
Isoleucine 0.60 0.01 0.56 0.02 0.48 0.03 0.43 0.02 0.39 0.01 
Leucine 0.38 0.00 0.35 0.00 0.30 0.02 0.29 0.01 0.26 0.01 
Lysine 0.53 0.01 0.53 0.01 0.49 0.03 0.47 0.05 0.48 0.02 
Methionine 0.06 0.00 0.06 0.00 0.06 0.00 0.06 0.00 0.06 0.00 
Phenylalanine 0.14 0.00 0.12 0.00 0.13 0.01 0.15 0.01 0.15 0.01 
Proline 0.09 0.00 0.09 0.00 0.09 0.00 0.09 0.01 0.11 0.00 
Serine 0.33 0.01 0.29 0.01 0.23 0.02 0.18 0.04 0.18 0.02 
Threonine 0.19 0.00 0.17 0.00 0.17 0.01 0.16 0.02 0.17 0.01 
Tryptophan 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.02 0.01 
Tyrosine 0.12 0.00 0.12 0.00 0.11 0.01 0.12 0.01 0.12 0.00 
Valine 0.24 0.00 0.23 0.00 0.23 0.01 0.21 0.01 0.21 0.01 
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Appendix J 
 
Measured extracellular amino acid concentration profiles for K3 iPSCs  
 
 
 
Figure J1. Measured extracellular amino acid concentration profiles for K3 iPSCs. Control 
media – ¢; Low Glucose media – £; High Lactate media – u; and Low Glucose + High 
Lactate – ¯. Error bars represent standard errors. 
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Figure J1 (continued). Measured extracellular amino acid concentration profiles for K3 
iPSCs. Control media – ¢; Low Glucose media – £; High Lactate media – u; and Low 
Glucose + High Lactate – ¯. Error bars represent standard errors. 
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Appendix K 
 
Metabolic flux analysis model description and assumptions for iPSC study 
 
1. Cellular metabolism and isotopic labeling are at isotopic steady state. K3 iPSCs were 
cultured in the presence of [1,2-13C] glucose, [U-13C] glutamine, and [U-13C] lactate 
in parallel for 48 hours, with intracellular samples taken at 24 and 48 hours.  
2. CO2 is an unbalanced metabolite within the MFA model. 
3. Two compartments (cytosolic and mitochondrial) are assumed to exist for pyruvate, 
citrate, fumarate, malate, and oxaloacetate. The two pyruvate compartments are 
included to account for differential labeling observed for lactate and alanine. This has 
previously reported for 13C-MFA to account for lactate being primarily derived from 
glucose, while alanine contains more labeling from glutamine (Gaglio et al., 2011; 
Metallo et al., 2012). Since cytosolic and mitochondrial pools could not be 
distinguished from one another for intracellular metabolites MIDs, mixing reactions 
are included for citrate, fumarate, and malate to account for a single sampled 
metabolite pool.  
4. Fumarate and succinate are symmetrical metabolites. 
5. Dilution pools of unlabeled succinate and fumarate are assumed to exist. These pools 
do not participate in central carbon metabolism. These dilution fluxes are included to 
account for dilution of labeled intracellular pools and to account for uptake of amino 
acids which are not included in the central carbon metabolic model. 
6. A lactate dilution flux (Lac.c <-> Lac.t + dummyL) is included in the model to allow 
for uptake and intracellular labeling from [U-13C] lactate. The net flux of this reaction 
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is fixed to zero, so it did not participate in carbon balancing. However, this reaction 
allows the model to simulate infinite exchange between lactate tracer (lac.t) and 
cytosolic lactate (lac.c) pools to resolve intracellular isotope labeling from [U-13C] 
lactate tracer. 
7. Previously, PSCs have been shown to accumulate different total amounts of lipids 
depending on the cell culture media used without impacting growth rate (Zhang et al., 
2016). A fatty acid sink reaction was included in the model to account for this. This 
fatty acid sink reaction was also required to reach an acceptable model convergence 
for each culture condition.  
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Appendix L 
 
Metabolic reactions used in the 13C-MFA simulations for K3 iPSCs 
 
Table L1. The metabolic reactions used in the 13C-MFA simulations for the K3 iPSC 
cultures. Suffixes indicate compartmental location of the metabolite: .x, extracellular; .c, 
cytosolic; .m, mitochondrial; .t, tracer; .p, pooled; .d, diluted; .snk, dilution sink. 
 
v1 Glc.x (abcdef) -> Glc (abcdef) 
v2 Glc (abcdef) -> Pyr.c (cba) + Pyr.c (def) 
v3 Pyr.c (abc) <-> Lac.c (abc) 
v4 Pyr.m (abc) -> CO2 (a) + AcCoA.m (bc) 
v5 AcCoA.m (ab) + OAA.m (cdef) -> Cit.m (fedbac) 
v6 Cit.m (abcdef) <-> AKG.m (abcde) + CO2 (f) 
v7 AKG.m (abcde) -> CO2 (a) + Suc.m (bcde) 
v8 Suc.m (abcd) <-> Fum.m (abcd) 
v9 Fum.m (abcd) <-> Mal.m (abcd) 
v10 Mal.m (abcd) <-> OAA.m (abcd) 
v11 Gln (abcde) <-> Glu (abcde) 
v12 Glu (abcde) <-> AKG.m (abcde) 
v13 Ser (abc) -> Pyr.c (abc) 
v14 Ser (abc) -> Gly (ab) + MEETHF (c) 
v15 Gln.x (abcde) -> Gln (abcde) 
v16 Ser.x (abc) -> Ser (abc) 
v17 Ala (abc) -> Ala.x (abc) 
v18 Pyr.x (abc) -> Pyr.c (abc) 
v19 Glu (abcde) -> Glu.x (abcde) 
v20 Lac.c (abc) -> Lac.x (abc) 
v21 Asp.x (abcd) -> Asp (abcd) 
v25 Pyr.c (abc) <-> Pyr.m (abc) 
v22 Pyr.m (abc) + CO2 (d) -> OAA.m (abcd) 
v23 Mal.m (abcd) -> Pyr.m (abc) + CO2 (d) 
v24 Pyr.m (abc) <-> Ala (abc) 
v26 Cit.m (abcdef) -> Cit.c (abcdef) 
v27 Cit.c (abcdef) -> OAA.c (fcba) + AcCoA.c (ed) 
v28 AcCoA.c -> Lipids 
v29 OAA.c (abcd) <-> Asp (abcd) 
v30 OAA.c (abcd) <-> Mal.c (abcd) 
v31 Mal.c (abcd) <-> Mal.m (abcd) 
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v32 Mal.c (abcd) <-> Fum.c (abcd) 
v33 Asp (abcd) <-> Fum.c (abcd) 
v34 
0.19*Ala + 0.11*Asp + 0.1*Gln + 0.12*Glu + 0.17*Gly + 0.14*Ser + 0.16*Glc 
-> Biomass 
v35 Lac.c <-> Lac.t + dummyL 
v36 AcCoA.c -> sink 
v37 0*Cit.c (abcdef) -> Cit.p (abcdef) 
v38 0*Cit.m (abcdef) -> Cit.p (abcdef) 
v39 Cit.p (abcdef) -> sink 
v40 0*Mal.c (abcd) -> Mal.p (abcd) 
v41 0*Mal.m (abcd) -> Mal.p (abcd) 
v42 Mal.p (abcd) -> sink 
v43 0*Fum.c (abcd) -> Fum.p (abcd) 
v44 0*Fum.m (abcd) -> Fum.p (abcd) 
v45 Fum.p (abcd) -> sink 
v46 0*Suc.m (abcd) -> Suc.d (abcd) 
v47 0*Suc.u (abcd) -> Suc.d (abcd) 
v48 Suc.d -> sink 
v49 0*Fum.e (abcd) -> Fum.d (abcd) 
v50 0*Fum.u (abcd) -> Fum.d (abcd) 
v51 Fum.d -> sink 
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Appendix M 
 
GC-MS metabolite mass fragments used for intracellular isotope quantification for K3 
iPSCs 
 
Table M1. GC-MS metabolite mass fragments used for intracellular isotope quantification. 
 
Metabolite Mass Carbon atoms Fragment formula 
Organic acids    
Pyruvate 174 1-2-3 C6H12O3NSi 
Lactate 261 1-2-3 C11H26O2NSi2 
Fumarate 287 1-2-3-4 C12H23O4Si2 
Succinate 289 1-2-3-4 C12H25O4Si2 
AKG 346 1-2-3-4-5 C14H28O5NSi2 
Malate 419 1-2-3-4 C18H39O5Si3 
Citrate 591 1-2-3-4-5-6 C26H55O7Si4 
Amino acids    
Alanine 260 1-2-3 C11H26O2NSi2 
Aspartate 418 1-2-3-4 C18H40O4NSi3 
Glutamine 431 1-2-3-4-5 C19H43N2O3Si3 
Glutamate 432 1-2-3-4-5 C19H42O4NSi3 
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Appendix N 
 
Measured intracellular MIDs from [1,2-13C] glucose, [U-13C] glutamine, and [U-13C] lactate for K3 iPSCs 
 
Table N1. Measured intracellular MIDs from the [1,2-13C] glucose tracer for K3 iPSCs for the Control, Low Glucose, High 
Lactate, and Low Glucose + High Lactate conditions with mean and standard errors. MIDs shown below have been corrected for 
natural abundance.  
 
Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
PYR 174                 
M+0 0.706 0.037 0.641 0.031 0.710 0.038 0.639 0.023 0.903 0.001 0.859 0.002 0.910 0.005 0.856 0.006 
M+1 -0.007 0.006 -0.002 0.005 -0.010 0.035 0.003 0.006 -0.042 0.004 -0.025 0.001 -0.032 0.002 -0.021 0.003 
M+2 0.290 0.040 0.376 0.023 0.199 0.011 0.364 0.044 0.119 0.003 0.172 0.001 0.110 0.001 0.172 0.004 
M+3 0.011 0.008 -0.016 0.010 0.101 0.007 -0.006 0.028 0.020 0.000 -0.005 0.000 0.012 0.002 -0.007 0.006 
ALA 260                 
M+0 0.606 0.004 0.577 0.002 0.607 0.002 0.584 0.001 0.904 0.002 0.858 0.002 0.918 0.001 0.880 0.004 
M+1 0.011 0.002 0.017 0.001 0.013 0.001 0.018 0.001 -0.016 0.001 -0.009 0.001 -0.016 0.001 -0.015 0.001 
M+2 0.390 0.004 0.409 0.001 0.390 0.002 0.404 0.002 0.115 0.002 0.152 0.001 0.101 0.001 0.138 0.003 
M+3 -0.007 0.001 -0.003 0.002 -0.009 0.002 -0.006 0.001 -0.004 0.001 -0.001 0.001 -0.003 0.000 -0.002 0.001 
LAC 261                 
M+0 0.585 0.003 0.549 0.009 0.590 0.002 0.571 0.004 0.585 0.011 0.549 0.011 0.892 0.002 0.810 0.007 
M+1 0.009 0.001 0.016 0.003 0.010 0.001 0.014 0.002 0.009 0.011 0.016 0.011 -0.006 0.001 0.008 0.003 
M+2 0.415 0.002 0.438 0.008 0.409 0.002 0.421 0.004 0.415 0.011 0.438 0.011 0.116 0.001 0.183 0.004 
M+3 -0.009 0.001 -0.003 0.003 -0.009 0.001 -0.006 0.001 -0.009 0.011 -0.003 0.011 -0.003 0.000 -0.002 0.002 
FUM 287                 
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Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
M+0 0.907 0.010 0.836 0.004 0.909 0.013 0.856 0.007 0.920 0.017 0.942 0.005 0.930 0.007 0.916 0.022 
M+1 -0.007 0.006 0.026 0.007 0.007 0.004 0.033 0.005 0.012 0.008 -0.004 0.014 -0.003 0.014 0.005 0.010 
M+2 0.063 0.005 0.105 0.004 0.068 0.002 0.084 0.003 0.039 0.007 0.054 0.004 0.035 0.004 0.047 0.007 
M+3 0.017 0.003 0.020 0.003 0.014 0.006 0.018 0.002 0.014 0.004 0.014 0.002 0.021 0.005 0.013 0.002 
M+4 0.021 0.005 0.013 0.004 0.003 0.009 0.008 0.005 0.016 0.012 -0.006 0.006 0.017 0.015 0.019 0.006 
SUC 289                 
M+0 0.966 0.012 0.925 0.006 0.975 0.028 0.939 0.003 1.003 0.002 0.958 0.014 1.017 0.007 0.997 0.010 
M+1 0.003 0.006 0.010 0.004 -0.015 0.008 -0.008 0.003 -0.016 0.002 0.012 0.005 -0.023 0.002 -0.015 0.005 
M+2 0.024 0.003 0.060 0.004 0.031 0.013 0.064 0.002 0.007 0.003 0.032 0.007 0.006 0.003 0.027 0.003 
M+3 -0.001 0.003 0.005 0.002 0.001 0.008 0.008 0.003 -0.002 0.002 -0.002 0.003 -0.008 0.006 -0.009 0.008 
M+4 0.008 0.002 -0.001 0.005 0.007 0.006 -0.002 0.002 0.007 0.003 0.000 0.004 0.008 0.002 0.001 0.003 
AKG 346                 
M+0 0.821 0.022 0.740 0.023 0.784 0.018 0.687 0.042 0.919 0.015 0.889 0.016 0.869 0.029 0.879 0.026 
M+1 0.046 0.010 0.053 0.014 0.071 0.022 0.082 0.015 -0.002 0.008 0.022 0.008 0.050 0.011 0.036 0.016 
M+2 0.092 0.014 0.140 0.009 0.106 0.015 0.139 0.008 0.063 0.014 0.080 0.003 0.044 0.012 0.056 0.004 
M+3 0.015 0.008 0.031 0.011 -0.003 0.030 0.037 0.015 0.016 0.006 0.005 0.005 0.010 0.004 0.009 0.013 
M+4 0.013 0.005 0.015 0.004 0.052 0.010 0.027 0.011 -0.012 0.005 0.001 0.003 -0.001 0.012 0.007 0.005 
M+5 0.013 0.021 0.021 0.003 -0.010 0.007 0.027 0.022 0.015 0.008 0.004 0.004 0.028 0.017 0.014 0.006 
ASP 418                 
M+0 0.812 0.005 0.750 0.010 0.787 0.011 0.726 0.004 0.842 0.021 0.822 0.024 0.815 0.004 0.835 0.023 
M+1 0.139 0.004 0.132 0.008 0.156 0.007 0.142 0.002 0.131 0.011 0.134 0.013 0.154 0.006 0.125 0.012 
M+2 0.047 0.003 0.089 0.005 0.045 0.008 0.100 0.004 0.021 0.008 0.035 0.005 0.026 0.003 0.042 0.010 
M+3 0.005 0.001 0.030 0.003 0.011 0.004 0.027 0.005 0.004 0.008 0.004 0.007 0.004 0.002 0.000 0.005 
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Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
M+4 -0.003 0.003 -0.001 0.002 0.001 0.004 0.005 0.002 0.002 0.004 0.005 0.007 0.001 0.002 -0.002 0.004 
MAL 419                 
M+0 0.817 0.002 0.713 0.012 0.808 0.015 0.718 0.003 0.874 0.003 0.829 0.012 0.860 0.005 0.839 0.012 
M+1 0.116 0.002 0.136 0.008 0.125 0.008 0.151 0.007 0.104 0.007 0.109 0.008 0.120 0.006 0.117 0.009 
M+2 0.054 0.002 0.119 0.004 0.063 0.004 0.107 0.009 0.025 0.005 0.053 0.004 0.019 0.002 0.038 0.004 
M+3 0.014 0.001 0.030 0.005 0.014 0.004 0.034 0.004 0.000 0.002 0.010 0.002 0.004 0.001 0.006 0.002 
M+4 0.000 0.001 0.002 0.002 -0.009 0.010 -0.010 0.013 -0.003 0.004 0.000 0.001 -0.004 0.004 0.000 0.001 
GLU 431                 
M+0 0.866 0.002 0.763 0.015 0.850 0.020 0.754 0.004 0.896 0.008 0.861 0.014 0.885 0.003 0.870 0.011 
M+1 0.067 0.001 0.064 0.009 0.081 0.009 0.075 0.004 0.077 0.009 0.059 0.011 0.088 0.002 0.068 0.008 
M+2 0.055 0.001 0.135 0.003 0.055 0.009 0.133 0.002 0.023 0.004 0.069 0.004 0.024 0.001 0.053 0.003 
M+3 0.008 0.001 0.023 0.004 0.009 0.008 0.024 0.002 0.005 0.001 0.009 0.002 0.004 0.001 0.009 0.002 
M+4 0.003 0.001 0.013 0.002 0.006 0.005 0.013 0.001 0.000 0.001 0.002 0.001 0.000 0.001 0.001 0.001 
M+5 0.000 0.000 0.002 0.001 0.000 0.003 0.002 0.000 -0.001 0.000 0.000 0.001 0.000 0.000 -0.001 0.000 
GLN 432                 
M+0 0.884 0.007 0.905 0.018 0.880 0.006 0.891 0.005 0.865 0.014 0.922 0.008 0.879 0.004 0.912 0.009 
M+1 0.120 0.005 0.097 0.014 0.128 0.006 0.112 0.006 0.145 0.013 0.082 0.007 0.129 0.004 0.089 0.006 
M+2 -0.002 0.004 -0.004 0.005 -0.006 0.002 -0.004 0.002 -0.014 0.005 -0.003 0.003 -0.006 0.002 -0.001 0.003 
M+3 -0.002 0.001 0.000 0.003 -0.002 0.001 -0.001 0.001 0.003 0.002 0.000 0.002 -0.001 0.001 0.000 0.002 
M+4 0.000 0.001 0.001 0.002 -0.001 0.000 0.001 0.000 0.001 0.001 0.000 0.001 -0.002 0.002 0.000 0.001 
M+5 0.000 0.001 0.000 0.001 0.000 0.001 0.000 0.000 0.001 0.001 -0.001 0.001 0.001 0.001 -0.001 0.001 
CIT 591                 
M+0 0.495 0.005 0.510 0.031 0.473 0.022 0.457 0.005 0.724 0.019 0.719 0.028 0.692 0.016 0.717 0.017 
 210 
Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
M+1 0.087 0.012 0.059 0.021 0.097 0.020 0.096 0.006 0.060 0.020 0.031 0.016 0.061 0.011 0.058 0.012 
M+2 0.219 0.021 0.296 0.008 0.227 0.013 0.283 0.010 0.147 0.016 0.189 0.012 0.133 0.013 0.174 0.009 
M+3 0.129 0.011 0.045 0.067 0.121 0.038 0.110 0.009 0.034 0.008 0.047 0.008 0.062 0.011 0.046 0.013 
M+4 0.018 0.007 0.075 0.036 0.049 0.023 0.036 0.004 0.015 0.005 0.000 0.003 -0.002 0.019 -0.004 0.016 
M+5 0.026 0.017 0.004 0.025 0.012 0.024 0.024 0.002 0.017 0.010 0.007 0.007 0.038 0.018 0.016 0.009 
M+6 0.026 0.010 0.011 0.015 0.021 0.038 -0.006 0.002 0.003 0.007 0.008 0.017 0.015 0.010 -0.007 0.011 
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Table N2. Measured intracellular MIDs from the [U-13C] glutamine tracer for K3 iPSCs for the Control, Low Glucose, High 
Lactate, and Low Glucose + High Lactate conditions with mean and standard errors. MIDs shown below have been corrected for 
natural abundance.  
 
Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
PYR 174                 
M+0 1.005 0.006 1.002 0.020 1.027 0.009 1.028 0.018 1.026 0.005 1.040 0.003 1.037 0.004 1.043 0.005 
M+1 -0.023 0.010 -0.029 0.011 -0.033 0.002 -0.040 0.006 -0.036 0.003 -0.039 0.001 -0.035 0.001 -0.041 0.002 
M+2 0.003 0.002 0.011 0.003 -0.006 0.008 -0.006 0.010 0.003 0.001 -0.005 0.001 -0.004 0.001 -0.008 0.003 
M+3 0.015 0.011 0.017 0.011 0.012 0.004 0.018 0.004 0.007 0.002 0.004 0.003 0.002 0.002 0.006 0.001 
ALA 260                 
M+0 1.006 0.001 0.989 0.002 1.006 0.001 0.989 0.001 1.026 0.010 1.011 0.002 1.018 0.000 1.011 0.001 
M+1 -0.028 0.001 -0.018 0.002 -0.023 0.002 -0.022 0.001 -0.037 0.012 -0.025 0.001 -0.023 0.001 -0.025 0.001 
M+2 0.003 0.002 0.005 0.001 0.001 0.002 0.006 0.001 0.002 0.003 0.002 0.001 -0.001 0.001 0.003 0.001 
M+3 0.019 0.001 0.025 0.001 0.016 0.001 0.026 0.001 0.009 0.001 0.011 0.000 0.007 0.001 0.010 0.000 
LAC 261                 
M+0 1.016 0.001 1.010 0.001 1.020 0.002 1.013 0.001 1.014 0.003 0.974 0.004 1.000 0.008 0.977 0.004 
M+1 -0.029 0.000 -0.027 0.001 -0.029 0.002 -0.027 0.001 -0.022 0.001 0.006 0.002 -0.008 0.003 0.006 0.003 
M+2 0.004 0.000 0.005 0.000 0.002 0.001 0.004 0.001 0.007 0.001 0.018 0.001 0.014 0.002 0.017 0.002 
M+3 0.010 0.001 0.012 0.000 0.007 0.000 0.011 0.000 0.001 0.000 0.001 0.001 -0.007 0.006 0.001 0.001 
FUM 287                 
M+0 0.355 0.012 0.320 0.015 0.423 0.028 0.327 0.008 0.327 0.009 0.269 0.008 0.386 0.012 0.302 0.012 
M+1 0.019 0.006 0.059 0.007 0.022 0.011 0.054 0.003 0.034 0.006 0.099 0.002 0.041 0.006 0.098 0.004 
M+2 0.071 0.003 0.136 0.002 0.062 0.004 0.145 0.004 0.108 0.004 0.183 0.008 0.117 0.002 0.180 0.003 
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Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
M+3 0.178 0.007 0.106 0.005 0.149 0.009 0.097 0.004 0.133 0.003 0.091 0.004 0.107 0.005 0.075 0.007 
M+4 0.378 0.018 0.379 0.012 0.345 0.026 0.377 0.005 0.399 0.015 0.357 0.001 0.349 0.009 0.346 0.013 
SUC 289                 
M+0 0.506 0.013 0.550 0.018 0.293 0.012 0.268 0.014 0.203 0.009 0.199 0.005 0.213 0.002 0.223 0.010 
M+1 -0.008 0.005 0.031 0.007 0.006 0.006 0.068 0.004 0.035 0.004 0.126 0.004 0.050 0.006 0.110 0.008 
M+2 0.060 0.002 0.113 0.006 0.088 0.002 0.172 0.003 0.154 0.001 0.212 0.005 0.156 0.003 0.205 0.004 
M+3 0.022 0.002 0.016 0.004 0.039 0.001 0.026 0.005 0.028 0.002 0.016 0.003 0.029 0.004 0.025 0.001 
M+4 0.420 0.013 0.290 0.013 0.574 0.017 0.466 0.006 0.581 0.010 0.447 0.006 0.552 0.008 0.437 0.009 
AKG 346                 
M+0 0.211 0.005 0.187 0.006 0.193 0.005 0.166 0.006 0.135 0.004 0.149 0.002 0.161 0.003 0.166 0.011 
M+1 0.016 0.003 0.055 0.002 0.035 0.004 0.064 0.006 0.035 0.002 0.095 0.004 0.046 0.002 0.087 0.004 
M+2 0.050 0.003 0.074 0.003 0.034 0.011 0.062 0.006 0.043 0.001 0.079 0.002 0.047 0.005 0.078 0.006 
M+3 0.089 0.003 0.159 0.008 0.077 0.007 0.180 0.010 0.137 0.005 0.204 0.004 0.152 0.003 0.185 0.004 
M+4 0.058 0.010 0.058 0.004 0.076 0.010 0.048 0.004 0.061 0.003 0.044 0.004 0.057 0.005 0.056 0.003 
M+5 0.576 0.023 0.468 0.009 0.586 0.019 0.481 0.007 0.590 0.004 0.430 0.005 0.539 0.005 0.429 0.011 
ASP 418                 
M+0 0.309 0.005 0.286 0.006 0.287 0.005 0.225 0.002 0.271 0.003 0.290 0.010 0.329 0.005 0.292 0.006 
M+1 0.047 0.007 0.105 0.004 0.063 0.004 0.113 0.001 0.086 0.002 0.145 0.005 0.098 0.010 0.150 0.007 
M+2 0.082 0.005 0.147 0.003 0.083 0.005 0.164 0.005 0.115 0.004 0.161 0.001 0.117 0.005 0.147 0.006 
M+3 0.183 0.004 0.132 0.008 0.206 0.006 0.137 0.002 0.161 0.002 0.114 0.008 0.128 0.003 0.127 0.004 
M+4 0.379 0.009 0.329 0.009 0.361 0.007 0.361 0.006 0.369 0.004 0.290 0.013 0.329 0.013 0.283 0.008 
MAL 419                 
M+0 0.212 0.002 0.182 0.001 0.222 0.004 0.178 0.001 0.163 0.003 0.175 0.000 0.171 0.002 0.177 0.002 
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Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
M+1 0.039 0.002 0.113 0.006 0.047 0.002 0.115 0.001 0.067 0.002 0.156 0.003 0.085 0.004 0.151 0.002 
M+2 0.099 0.002 0.172 0.004 0.092 0.001 0.180 0.002 0.143 0.003 0.200 0.001 0.148 0.003 0.199 0.002 
M+3 0.212 0.001 0.142 0.002 0.215 0.001 0.133 0.003 0.182 0.001 0.125 0.008 0.175 0.003 0.126 0.002 
M+4 0.439 0.002 0.391 0.009 0.425 0.004 0.394 0.004 0.445 0.006 0.344 0.009 0.421 0.008 0.347 0.006 
GLU 431                 
M+0 0.126 0.001 0.130 0.001 0.125 0.001 0.128 0.001 0.104 0.001 0.134 0.001 0.118 0.001 0.132 0.000 
M+1 0.016 0.001 0.064 0.004 0.019 0.001 0.064 0.001 0.037 0.001 0.100 0.003 0.046 0.001 0.092 0.001 
M+2 0.032 0.001 0.070 0.004 0.029 0.002 0.069 0.001 0.051 0.001 0.087 0.003 0.058 0.002 0.085 0.001 
M+3 0.092 0.002 0.179 0.003 0.082 0.003 0.177 0.002 0.136 0.002 0.196 0.001 0.153 0.002 0.188 0.002 
M+4 0.081 0.001 0.067 0.005 0.106 0.003 0.071 0.001 0.106 0.004 0.064 0.006 0.097 0.003 0.073 0.003 
M+5 0.654 0.002 0.491 0.013 0.640 0.008 0.491 0.003 0.565 0.005 0.418 0.010 0.528 0.007 0.430 0.004 
GLN 432                 
M+0 0.013 0.001 0.015 0.002 0.011 0.001 0.010 0.003 0.008 0.002 0.013 0.001 0.007 0.000 0.014 0.000 
M+1 0.003 0.001 0.003 0.001 0.003 0.001 0.003 0.001 0.003 0.001 0.004 0.001 0.003 0.001 0.005 0.000 
M+2 0.001 0.001 0.003 0.000 0.001 0.001 0.002 0.000 0.001 0.001 0.005 0.000 0.003 0.002 0.005 0.000 
M+3 0.008 0.001 0.012 0.001 0.009 0.001 0.013 0.001 0.011 0.002 0.013 0.005 0.011 0.001 0.017 0.000 
M+4 0.138 0.010 0.147 0.010 0.162 0.002 0.166 0.003 0.161 0.001 0.159 0.006 0.169 0.004 0.156 0.002 
M+5 0.837 0.011 0.821 0.014 0.815 0.005 0.806 0.007 0.816 0.005 0.806 0.002 0.807 0.005 0.804 0.002 
CIT 591                 
M+0 0.239 0.007 0.164 0.009 0.211 0.017 0.139 0.016 0.144 0.005 0.166 0.007 0.175 0.011 0.166 0.003 
M+1 0.081 0.009 0.13 0.007 0.106 0.019 0.138 0.01 0.106 0.009 0.143 0.013 0.103 0.006 0.158 0.01 
M+2 0.113 0.005 0.141 0.004 0.082 0.013 0.152 0.004 0.115 0.006 0.176 0.007 0.12 0.012 0.159 0.008 
M+3 0.165 0.008 0.169 0.004 0.204 0.011 0.182 0.005 0.177 0.005 0.189 0.014 0.161 0.017 0.185 0.005 
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Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
M+4 0.2 0.007 0.241 0.009 0.181 0.08 0.272 0.012 0.262 0.023 0.207 0.012 0.244 0.017 0.218 0.005 
M+5 0.144 0.009 0.127 0.005 0.173 0.045 0.111 0.007 0.163 0.017 0.108 0.009 0.133 0.017 0.107 0.008 
M+6 0.058 0.007 0.028 0.003 0.043 0.018 0.007 0.004 0.034 0.011 0.011 0.006 0.065 0.008 0.007 0.008 
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Table N3. Measured intracellular MIDs from the [U-13C] lactate tracer for K3 iPSCs for the High Lactate and Low Glucose + 
High Lactate conditions with mean and standard errors. MIDs shown below have been corrected for natural abundance.  
 
Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
PYR 174                 
M+0 - - - - - - - - 0.668 0.011 0.815 n/a 0.652 0.013 0.639 0.003 
M+1 - - - - - - - - -0.010 0.010 -0.019 n/a -0.009 0.004 -0.012 0.004 
M+2 - - - - - - - - 0.032 0.014 0.001 n/a 0.027 0.027 0.009 0.002 
M+3 - - - - - - - - 0.310 0.028 0.203 n/a 0.331 0.042 0.364 0.008 
ALA 260                 
M+0 - - - - - - - - 0.451 0.003 0.448 0.005 0.426 0.000 0.388 0.002 
M+1 - - - - - - - - -0.010 0.001 -0.007 0.002 -0.007 0.001 -0.004 0.001 
M+2 - - - - - - - - 0.011 0.001 0.012 0.001 0.012 0.001 0.015 0.001 
M+3 - - - - - - - - 0.548 0.003 0.548 0.005 0.570 0.000 0.601 0.002 
LAC 261                 
M+0 - - - - - - - - 0.398 0.055 0.454 0.064 0.423 0.004 0.440 0.004 
M+1 - - - - - - - - -0.008 0.019 -0.010 0.021 -0.010 0.002 -0.009 0.001 
M+2 - - - - - - - - 0.011 0.006 0.010 0.007 0.010 0.001 0.010 0.000 
M+3 - - - - - - - - 0.600 0.070 0.546 0.080 0.577 0.006 0.559 0.004 
FUM 287                 
M+0 - - - - - - - - 0.823 0.006 0.726 0.021 0.813 0.009 0.730 0.003 
M+1 - - - - - - - - 0.007 0.008 0.046 0.018 0.018 0.009 0.037 0.004 
M+2 - - - - - - - - 0.115 0.006 0.132 0.007 0.109 0.007 0.133 0.003 
M+3 - - - - - - - - 0.038 0.005 0.075 0.006 0.039 0.005 0.075 0.003 
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Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
M+4 - - - - - - - - 0.018 0.004 0.021 0.009 0.021 0.011 0.024 0.006 
SUC 289                 
M+0 - - - - - - - - 0.902 0.007 0.884 0.014 0.881 0.028 0.861 0.025 
M+1 - - - - - - - - -0.010 0.002 0.000 0.008 0.000 0.008 0.007 0.007 
M+2 - - - - - - - - 0.088 0.005 0.070 0.005 0.103 0.015 0.077 0.013 
M+3 - - - - - - - - 0.016 0.004 0.033 0.005 0.014 0.006 0.041 0.008 
M+4 - - - - - - - - 0.004 0.002 0.013 0.003 0.002 0.011 0.014 0.006 
AKG 346                 
M+0 - - - - - - - - 0.683 0.014 0.548 0.006 0.730 0.011 0.491 0.015 
M+1 - - - - - - - - 0.054 0.004 0.063 0.003 0.042 0.011 0.075 0.005 
M+2 - - - - - - - - 0.144 0.002 0.224 0.006 0.145 0.012 0.253 0.008 
M+3 - - - - - - - - 0.034 0.007 0.071 0.004 0.041 0.010 0.080 0.005 
M+4 - - - - - - - - 0.044 0.005 0.066 0.006 0.029 0.005 0.079 0.003 
M+5 - - - - - - - - 0.041 0.012 0.028 0.003 0.012 0.003 0.022 0.017 
ASP 418                 
M+0 - - - - - - - - 0.709 0.005 0.555 0.015 0.678 0.003 0.555 0.015 
M+1 - - - - - - - - 0.126 0.012 0.172 0.009 0.143 0.004 0.172 0.009 
M+2 - - - - - - - - 0.131 0.006 0.153 0.005 0.119 0.004 0.153 0.005 
M+3 - - - - - - - - 0.041 0.004 0.092 0.006 0.054 0.004 0.092 0.006 
M+4 - - - - - - - - -0.006 0.014 0.028 0.006 0.005 0.002 0.028 0.006 
MAL 419                 
M+0 - - - - - - - - 0.697 0.003 0.494 0.005 0.669 0.005 0.468 0.016 
M+1 - - - - - - - - 0.109 0.007 0.174 0.005 0.132 0.004 0.156 0.012 
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Condition Control Low Glucose High Lactate Low Glucose + High Lactate 
 24-h 48-h 24-h 48-h 24-h 48-h 24-h 48-h 
 MID SE MID SE MID SE MID SE MID SE MID SE MID SE MID SE 
M+2 - - - - - - - - 0.135 0.003 0.183 0.003 0.131 0.003 0.202 0.008 
M+3 - - - - - - - - 0.052 0.002 0.118 0.002 0.058 0.003 0.136 0.005 
M+4 - - - - - - - - 0.006 0.001 0.031 0.002 0.010 0.002 0.039 0.003 
GLU 431                 
M+0 - - - - - - - - 0.744 0.012 0.553 0.004 0.729 0.005 0.504 0.004 
M+1 - - - - - - - - 0.058 0.012 0.092 0.003 0.068 0.004 0.069 0.003 
M+2 - - - - - - - - 0.147 0.005 0.204 0.002 0.142 0.003 0.234 0.002 
M+3 - - - - - - - - 0.030 0.003 0.080 0.003 0.036 0.002 0.090 0.001 
M+4 - - - - - - - - 0.017 0.002 0.054 0.002 0.020 0.002 0.076 0.001 
M+5 - - - - - - - - 0.004 0.001 0.017 0.000 0.004 0.001 0.026 0.001 
CIT 591                 
M+0 - - - - - - - - 0.371 0.017 0.299 0.006 0.384 0.015 0.244 0.007 
M+1 - - - - - - - - 0.086 0.016 0.086 0.009 0.083 0.013 0.072 0.004 
M+2 - - - - - - - - 0.295 0.009 0.257 0.012 0.290 0.008 0.280 0.002 
M+3 - - - - - - - - 0.144 0.012 0.176 0.013 0.148 0.010 0.187 0.006 
M+4 - - - - - - - - 0.064 0.009 0.085 0.007 0.056 0.012 0.123 0.004 
M+5 - - - - - - - - 0.054 0.008 0.073 0.010 0.035 0.010 0.070 0.005 
M+6 - - - - - - - - -0.014 0.027 0.026 0.005 0.004 0.008 0.025 0.004 
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Appendix O 
 
Metabolite isotope labeling distributions from [1,2-13C] glucose, [U-13C] glutamine, and 
[U-13C] lactate for K3 iPSCs 
 
 
 
Figure O1. Metabolite isotope labeling distribution from [1,2-13C] glucose for K3 iPSC 
cultures for Control, Low Glucose, High Lactate, and Low Glucose + High Lactate 
conditions at 48-h. MIDs shown below have been corrected for natural abundance. 
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Figure O2. Metabolite isotope labeling distribution from [U-13C] glutamine for K3 iPSC 
cultures for Control, Low Glucose, High Lactate, and Low Glucose + High Lactate 
conditions at 48-h. MIDs shown below have been corrected for natural abundance. 
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Figure O3. Metabolite isotope labeling distribution from [U-13C] lactate for K3 iPSC 
cultures for High Lactate and Low-Glucose + High Lactate conditions at 48-h. MIDs 
shown below have been corrected for natural abundance. 
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Appendix P 
 
Metabolic flux analysis results for K3 iPSCs grown in Control, Low Glucose, High 
Lactate, and Low Glucose + High Lactate cultures 
 
Table P1. Metabolic flux analysis results for K3 iPSC Control cultures using [1,2-13C] 
glucose and [U-13C] glutamine. The fluxes are shown with 95% confidence intervals. The 
sum of squared residuals (SSR) was 81.4 with an expected range of 45.4 to 90.3. 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Glc.x -> Glc 1.05E+03 9.56E+02 1.15E+03 
Glc -> Pyr.c + Pyr.c 1.05E+03 9.50E+02 1.14E+03 
Pyr.c <-> Lac.c 2.11E+03 1.92E+03 2.30E+03 
Pyr.c <-> Lac.c 1.00E+07 8111.50 Inf 
Pyr.m -> CO2 + AcCoA.m 115.07 71.59 171.81 
AcCoA.m + OAA.m -> Cit.m 115.07 71.59 171.81 
Cit.m <-> AKG.m + CO2 23.96 12.67 57.41 
Cit.m <-> AKG.m + CO2 88.34 53.92 149.00 
AKG.m -> CO2 + Suc.m 111.73 76.25 158.98 
Suc.m <-> Fum.m 111.73 76.25 158.98 
Suc.m <-> Fum.m 8.55 0.00 Inf 
Fum.m <-> Mal.m 111.73 76.25 158.98 
Fum.m <-> Mal.m 1.97E+06 0.00E+00 1.97E+06 
Mal.m <-> OAA.m 78.68 45.13 127.83 
Mal.m <-> OAA.m 0.00 0.00 21.39 
Gln <-> Glu 128.45 98.09 158.74 
Gln <-> Glu 0.00 0.00 Inf 
Glu <-> AKG.m 87.78 57.18 118.30 
Glu <-> AKG.m 804.02 273.35 Inf 
Ser -> Pyr.c 21.70 10.43 32.98 
Ser -> Gly + MEETHF 6.36 3.70 9.02 
Gln.x -> Gln 132.20 101.84 162.48 
Ser.x -> Ser 33.30 23.13 43.49 
Ala -> Ala.x 33.33 29.22 37.45 
Pyr.x -> Pyr.c 67.55 62.45 72.65 
Glu -> Glu.x 36.19 32.86 39.52 
Lac.c -> Lac.x 2.11E+03 1.92E+03 2.30E+03 
Asp.x -> Asp 0.40 0.07 6.00 
Pyr.c <-> Pyr.m 71.45 31.61 115.05 
Pyr.c <-> Pyr.m 1.00E+07 2.70E+03 Inf 
Pyr.m + CO2 -> OAA.m 36.39 24.62 50.40 
Mal.m -> Pyr.m + CO2 120.44 79.02 163.43 
Pyr.m <-> Ala 40.44 35.36 45.52 
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Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Pyr.m <-> Ala 1.09E+03 0.00 1.93E+06 
Cit.m -> Cit.c 91.11 24.92 147.86 
Cit.c -> OAA.c + AcCoA.c 91.11 24.92 147.86 
AcCoA.c -> Lipids 27.00 15.24 38.76 
OAA.c <-> Asp 4.11 -1.67 5.97 
OAA.c <-> Asp 0.00 0.00 108.98 
OAA.c <-> Mal.c 87.00 20.76 143.80 
OAA.c <-> Mal.c 5.37E+03 0.00 Inf 
Mal.c <-> Mal.m 87.40 21.16 144.18 
Mal.c <-> Mal.m 2.46E+03 34.55 Inf 
Mal.c <-> Fum.c -0.39 -1.37 0.58 
Mal.c <-> Fum.c 34.95 0.00 Inf 
Asp <-> Fum.c 0.39 -0.58 1.37 
Asp <-> Fum.c 0.00 0.00 Inf 
0.19*Ala + 0.11*Asp + 0.1*Gln + 
0.12*Glu + 0.17*Gly + 0.14*Ser + 
0.16*Glc -> Biomass 37.40 21.76 53.05 
Lac.c <-> Lac.t + dummyL 0.00 0.00 0.00 
Lac.c <-> Lac.t + dummyL 386.56 252.94 540.90 
AcCoA.c -> sink 64.11 0.00 121.82 
    
Compartmentalization/Mixing Reactions 
0*Cit.c -> Cit.p 31.14 0.00 100.00 
0*Cit.m -> Cit.p 68.86 0.00 100.00 
Cit.p -> sink 100.00 100.00 100.00 
0*Mal.c -> Mal.p 0.00 0.00 100.00 
0*Mal.m -> Mal.p 100.00 0.00 100.00 
Mal.p -> sink 100.00 100.00 100.00 
0*Fum.c -> Fum.p 99.98 0.00 100.00 
0*Fum.m -> Fum.p 0.02 0.00 100.00 
Fum.p -> sink 100.00 100.00 100.00 
    
Dilution Reactions 
0*Suc.m -> Suc.d 0.63 0.58 0.68 
0*Suc.u -> Suc.d 0.37 0.32 0.42 
Suc.d -> sink 1.00 1.00 1.00 
0*Fum.e -> Fum.d 0.87 0.81 1.00 
0*Fum.u -> Fum.d 0.13 0.00 0.19 
Fum.d -> sink 1.00 1.00 1.00 
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Table P2. Metabolic flux analysis results for K3 iPSC Low Glucose cultures using [1,2-
13C] glucose and [U-13C] glutamine. The fluxes are shown with 95% confidence intervals. 
The sum of squared residuals (SSR) was 73.2 with an expected range of 34.0 to 73.8. 
 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Glc.x -> Glc 993.85 931.33 1056.90 
Glc -> Pyr.c + Pyr.c 987.51 925.16 1050.40 
Pyr.c <-> Lac.c 2.00E+03 1.88E+03 2.12E+03 
Pyr.c <-> Lac.c 1.00E+07 3.35E+03 Inf 
Pyr.m -> CO2 + AcCoA.m 124.04 59.25 183.61 
AcCoA.m + OAA.m -> Cit.m 124.04 59.25 183.61 
Cit.m <-> AKG.m + CO2 24.47 -2.81 69.30 
Cit.m <-> AKG.m + CO2 128.93 60.22 282.62 
AKG.m -> CO2 + Suc.m 130.38 107.19 180.33 
Suc.m <-> Fum.m 130.38 107.19 180.33 
Suc.m <-> Fum.m 26.63 0.00 2.58E+04 
Fum.m <-> Mal.m 130.38 107.19 180.33 
Fum.m <-> Mal.m 1.05E+03 0.00 Inf 
Mal.m <-> OAA.m 76.75 31.78 134.49 
Mal.m <-> OAA.m 0.00 0.00 25.41 
Gln <-> Glu 143.09 126.08 160.18 
Gln <-> Glu 1.28E+06 0.00 Inf 
Glu <-> AKG.m 105.91 88.51 123.37 
Glu <-> AKG.m 2.76E+06 0.00 Inf 
Ser -> Pyr.c 11.16 2.45 19.87 
Ser -> Gly + MEETHF 6.73 4.08 9.39 
Gln.x -> Gln 147.05 130.08 164.10 
Ser.x -> Ser 23.44 16.19 30.69 
Ala -> Ala.x 32.26 29.32 35.20 
Pyr.x -> Pyr.c 75.19 71.28 79.11 
Glu -> Glu.x 32.43 30.08 34.78 
Lac.c -> Lac.x 2.00E+03 1.88E+03 2.12E+03 
Asp.x -> Asp 0.44 0.00 7.71 
Pyr.c <-> Pyr.m 61.84 -2.39 117.55 
Pyr.c <-> Pyr.m 1.00E+07 7.46E+03 Inf 
Pyr.m + CO2 -> OAA.m 47.29 24.81 58.90 
Mal.m -> Pyr.m + CO2 149.28 115.05 175.57 
Pyr.m <-> Ala 39.79 35.61 43.96 
Pyr.m <-> Ala 0.06 0.00 Inf 
Cit.m -> Cit.c 99.57 21.18 162.92 
Cit.c -> OAA.c + AcCoA.c 99.57 21.18 162.92 
AcCoA.c -> Lipids 27.00 15.24 38.76 
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Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
OAA.c <-> Asp 7.42 0.03 9.22 
OAA.c <-> Asp 0.00 0.00 Inf 
OAA.c <-> Mal.c 92.15 14.49 155.47 
OAA.c <-> Mal.c 892.75 0.00 Inf 
Mal.c <-> Mal.m 95.65 62.54 158.97 
Mal.c <-> Mal.m 8.49E+05 26.41 Inf 
Mal.c <-> Fum.c -3.50 -3.89 -3.11 
Mal.c <-> Fum.c 1.02E+04 0.00 Inf 
Asp <-> Fum.c 3.50 3.11 3.89 
Asp <-> Fum.c 0.00 0.00 Inf 
0.19*Ala + 0.11*Asp + 0.1*Gln + 
0.12*Glu + 0.17*Gly + 0.14*Ser + 
0.16*Glc -> Biomass 39.61 23.99 55.22 
Lac.c <-> Lac.t + dummyL 0.00 0.00 0.00 
Lac.c <-> Lac.t + dummyL 303.56 180.29 444.07 
AcCoA.c -> sink 72.57 0.00 136.62 
    
Compartmentalization/Mixing Reactions 
0*Cit.c -> Cit.p 49.04 0.00 100.00 
0*Cit.m -> Cit.p 50.96 0.00 100.00 
Cit.p -> sink 100.00 100.00 100.00 
0*Mal.c -> Mal.p 0.00 0.00 100.00 
0*Mal.m -> Mal.p 100.00 0.00 100.00 
Mal.p -> sink 100.00 100.00 100.00 
0*Fum.c -> Fum.p 46.55 0.00 100.00 
0*Fum.m -> Fum.p 53.45 0.00 100.00 
Fum.p -> sink 100.00 100.00 100.00 
    
Dilution Reactions 
0*Suc.m -> Suc.d 0.89 0.83 0.95 
0*Suc.u -> Suc.d 0.11 0.05 0.17 
Suc.d -> sink 1.00 1.00 1.00 
0*Fum.e -> Fum.d 0.77 0.70 0.90 
0*Fum.u -> Fum.d 0.23 0.10 0.30 
Fum.d -> sink 1.00 1.00 1.00 
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Table P3. Metabolic flux analysis results for K3 iPSC High Lactate cultures using [1,2-
13C] glucose, [U-13C] glutamine, and [U-13C] lactate. The fluxes are shown with 95% 
confidence intervals. The sum of squared residuals (SSR) was 77.8 with an expected range 
of 43.8 to 88.0. 
 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Glc.x -> Glc 873.54 803.94 943.81 
Glc -> Pyr.c + Pyr.c 867.80 798.41 937.87 
Pyr.c <-> Lac.c 1.69E+03 1.56E+03 1.83E+03 
Pyr.c <-> Lac.c 1.45E+04 7.78E+03 6.97E+04 
Pyr.m -> CO2 + AcCoA.m 132.10 94.74 192.54 
AcCoA.m + OAA.m -> Cit.m 132.10 94.74 192.54 
Cit.m <-> AKG.m + CO2 25.52 16.43 36.90 
Cit.m <-> AKG.m + CO2 52.81 37.80 71.92 
AKG.m -> CO2 + Suc.m 96.27 72.98 121.27 
Suc.m <-> Fum.m 96.27 72.98 121.27 
Suc.m <-> Fum.m 14.67 0.00 72.77 
Fum.m <-> Mal.m 96.27 72.98 121.27 
Fum.m <-> Mal.m 539.46 0.00 Inf 
Mal.m <-> OAA.m 117.70 80.90 174.70 
Mal.m <-> OAA.m 0.00 0.00 336.82 
Gln <-> Glu 103.35 84.51 122.19 
Gln <-> Glu 5.38E+06 0.00 Inf 
Glu <-> AKG.m 70.75 51.47 90.03 
Glu <-> AKG.m 1.00E+07 0.00 Inf 
Ser -> Pyr.c 17.31 8.10 26.53 
Ser -> Gly + MEETHF 6.10 3.44 8.76 
Gln.x -> Gln 106.94 88.16 125.71 
Ser.x -> Ser 28.43 20.60 36.27 
Ala -> Ala.x 28.81 21.95 35.66 
Pyr.x -> Pyr.c 38.95 31.90 46.00 
Glu -> Glu.x 28.30 25.55 31.04 
Lac.c -> Lac.x 1.69E+03 1.56E+03 1.83E+03 
Asp.x -> Asp 3.19 0.63 15.85 
Pyr.c <-> Pyr.m 97.74 62.57 153.99 
Pyr.c <-> Pyr.m 3.43E+03 1.12E+03 Inf 
Pyr.m + CO2 -> OAA.m 14.40 3.90 22.87 
Mal.m -> Pyr.m + CO2 84.39 61.05 108.11 
Pyr.m <-> Ala 35.62 28.15 43.10 
Pyr.m <-> Ala 0.01 0.00 Inf 
Cit.m -> Cit.c 106.58 68.16 168.47 
Cit.c -> OAA.c + AcCoA.c 106.58 68.16 168.47 
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Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
AcCoA.c -> Lipids 27.00 15.24 38.76 
OAA.c <-> Asp 0.46 -12.35 4.32 
OAA.c <-> Asp 13.58 0.00 212.40 
OAA.c <-> Mal.c 106.12 53.78 167.14 
OAA.c <-> Mal.c 2.44E+03 0.00 Inf 
Mal.c <-> Mal.m 105.82 65.46 166.84 
Mal.c <-> Mal.m 1.00E+07 76.76 Inf 
Mal.c <-> Fum.c 0.30 -0.48 1.08 
Mal.c <-> Fum.c 1.00E+07 0.00 Inf 
Asp <-> Fum.c -0.30 -1.08 0.48 
Asp <-> Fum.c 6.67 0.00 164.82 
0.19*Ala + 0.11*Asp + 0.1*Gln + 
0.12*Glu + 0.17*Gly + 0.14*Ser + 
0.16*Glc -> Biomass 35.88 20.21 51.54 
Lac.c <-> Lac.t + dummyL 0.00 0.00 0.00 
Lac.c <-> Lac.t + dummyL 4.20E+03 3.26E+03 5.63E+03 
AcCoA.c -> sink 79.58 39.04 142.31 
    
Compartmentalization/Mixing Reactions 
0*Cit.c -> Cit.p 7.58 0.00 100.00 
0*Cit.m -> Cit.p 92.42 0.00 100.00 
Cit.p -> sink 100.00 100.00 100.00 
0*Mal.c -> Mal.p 0.00 0.00 100.00 
0*Mal.m -> Mal.p 100.00 0.00 100.00 
Mal.p -> sink 100.00 100.00 100.00 
0*Fum.c -> Fum.p 0.00 0.00 100.00 
0*Fum.m -> Fum.p 100.00 0.00 100.00 
Fum.p -> sink 100.00 100.00 100.00 
    
Dilution Reactions 
0*Suc.m -> Suc.d 0.90 0.86 0.95 
0*Suc.u -> Suc.d 0.10 0.05 0.14 
Suc.d -> sink 1.00 1.00 1.00 
0*Fum.e -> Fum.d 0.81 0.76 0.88 
0*Fum.u -> Fum.d 0.19 0.12 0.24 
Fum.d -> sink 1.00 1.00 1.00 
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Table P4. Metabolic flux analysis results for K3 iPSC Low Glucose + High Lactate 
cultures using [1,2-13C] glucose, [U-13C] glutamine, and [U-13C] lactate. The fluxes are 
shown with 95% confidence intervals. The sum of squared residuals (SSR) was 88.2 with 
an expected range of 45.4 to 90.3. 
 
Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
Glc.x -> Glc 859.77 801.34 918.22 
Glc -> Pyr.c + Pyr.c 853.80 795.45 912.14 
Pyr.c <-> Lac.c 1.65E+03 1.54E+03 1.76E+03 
Pyr.c <-> Lac.c 5.32E+04 1.87E+04 Inf 
Pyr.m -> CO2 + AcCoA.m 172.07 115.11 250.93 
AcCoA.m + OAA.m -> Cit.m 172.07 115.11 250.93 
Cit.m <-> AKG.m + CO2 42.64 30.78 63.71 
Cit.m <-> AKG.m + CO2 68.43 47.41 94.00 
AKG.m -> CO2 + Suc.m 124.63 98.64 156.35 
Suc.m <-> Fum.m 124.63 98.64 156.35 
Suc.m <-> Fum.m 218.94 0.00 Inf 
Fum.m <-> Mal.m 124.63 98.64 156.35 
Fum.m <-> Mal.m 26.69 0.00 260.04 
Mal.m <-> OAA.m 149.84 106.50 225.93 
Mal.m <-> OAA.m 0.00 0.00 149.33 
Gln <-> Glu 115.88 97.58 134.59 
Gln <-> Glu 2.26E+05 0.00 Inf 
Glu <-> AKG.m 81.98 63.18 101.20 
Glu <-> AKG.m 2.91E+06 1.08E+03 Inf 
Ser -> Pyr.c 34.59 12.49 56.71 
Ser -> Gly + MEETHF 6.34 3.68 8.99 
Gln.x -> Gln 119.61 101.37 138.25 
Ser.x -> Ser 46.15 24.54 67.76 
Ala -> Ala.x 27.89 21.81 33.96 
Pyr.x -> Pyr.c 36.49 31.40 41.59 
Glu -> Glu.x 29.42 26.28 32.55 
Lac.c -> Lac.x 1.65E+03 1.54E+03 1.76E+03 
Asp.x -> Asp 1.12 0.59 12.00 
Pyr.c <-> Pyr.m 128.05 75.86 200.26 
Pyr.c <-> Pyr.m 3.63E+06 2.89E+03 Inf 
Pyr.m + CO2 -> OAA.m 22.23 12.79 28.77 
Mal.m -> Pyr.m + CO2 101.23 77.82 125.30 
Pyr.m <-> Ala 34.98 28.21 41.73 
Pyr.m <-> Ala 0.32 0.00 Inf 
Cit.m -> Cit.c 129.43 61.48 208.48 
Cit.c -> OAA.c + AcCoA.c 129.43 61.48 208.48 
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Reaction Flux 95% Confidence Interval 
  nmol/106 cells/h Lower Bound Upper Bound 
AcCoA.c -> Lipids 27.00 15.24 38.76 
OAA.c <-> Asp 4.77 -6.31 6.93 
OAA.c <-> Asp 0.00 0.00 68.82 
OAA.c <-> Mal.c 124.66 56.64 203.77 
OAA.c <-> Mal.c 1.27E+06 0.00 Inf 
Mal.c <-> Mal.m 126.45 58.41 205.55 
Mal.c <-> Mal.m 6.88E+05 102.01 Inf 
Mal.c <-> Fum.c -1.78 -3.74 0.16 
Mal.c <-> Fum.c 6.42E+03 0.00 Inf 
Asp <-> Fum.c 1.78 -0.16 3.74 
Asp <-> Fum.c 0.00 0.00 Inf 
0.19*Ala + 0.11*Asp + 0.1*Gln + 
0.12*Glu + 0.17*Gly + 0.14*Ser + 
0.16*Glc -> Biomass 37.31 21.63 52.91 
Lac.c <-> Lac.t + dummyL 0.00 0.00 0.00 
Lac.c <-> Lac.t + dummyL 3.15E+03 2.79E+03 3.57E+03 
AcCoA.c -> sink 102.43 33.42 182.09 
    
Compartmentalization/Mixing Reactions 
0*Cit.c -> Cit.p 10.19 0.00 100.00 
0*Cit.m -> Cit.p 89.81 0.00 100.00 
Cit.p -> sink 100.00 100.00 100.00 
0*Mal.c -> Mal.p 100.00 0.00 100.00 
0*Mal.m -> Mal.p 0.00 0.00 100.00 
Mal.p -> sink 100.00 100.00 100.00 
0*Fum.c -> Fum.p 78.19 28.41 100.00 
0*Fum.m -> Fum.p 21.81 0.00 71.59 
Fum.p -> sink 100.00 100.00 100.00 
    
Dilution Reactions 
0*Suc.m -> Suc.d 0.92 0.87 0.97 
0*Suc.u -> Suc.d 0.08 0.03 0.13 
Suc.d -> sink 1.00 1.00 1.00 
0*Fum.e -> Fum.d 0.75 0.70 1.00 
0*Fum.u -> Fum.d 0.25 0.00 0.30 
Fum.d -> sink 1.00 1.00 1.00 
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Appendix Q 
 
Measured and simulated MIDs from 13C-MFA simulations for K3 iPSC cultures 
 
 
Figure Q1. Measured and simulated MIDs for intracellular metabolites for K3 iPSC 
Control cultures. MIDs shown below have been corrected for natural abundance. 
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Figure Q2. Measured and simulated MIDs for intracellular metabolites for K3 iPSC Low 
Glucose cultures. MIDs shown below have been corrected for natural abundance. 
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Figure Q3. Measured and simulated MIDs for intracellular metabolites for K3 iPSC 
High Lactate cultures. MIDs shown below have been corrected for natural abundance. 
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Figure Q4. Measured and simulated MIDs for intracellular metabolites for K3 iPSC Low 
Glucose + High Lactate cultures. MIDs shown below have been corrected for natural 
abundance.  
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